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Gene expression is influenced by precise epigenetic mechanisms. In the context of 
pregnancy proper placental development and pregnancy outcome are dependent upon 
these mechanisms. These are poorly understood in the placenta and historically have not 
been investigated. In many biomedical research fields epigenetic modifications such as 
DNA methylation have been proven to be an effective biomarker. However, this has yet 
to be shown in the reproduction research field. 
The overall aim of this thesis was to investigate new epigenetic mechanisms in placental 
development and to identify novel biomarkers for phenotype prediction. This thesis 
firstly focuses on sex-biased gene expression in multiple human tissues to identify targets 
of sexual dimorphism. Secondly, it investigates novel transcripts in the placenta and 
finally focuses on using DNA methylation as a biomarker. 
Firstly, the research has identified potential new gene targets and mechanisms which may 
explain sexual dimorphism in many phenotypic traits and diseases. These results suggest 
that sex-biased gene expression is dynamic and tissue specific. It also highlights the need 
to consider sex as a biological variable in biomedical research and to address the lack of 
female representation in many studies. 
Secondly, by performing a de novo transcript analysis on the placenta this thesis has 
identified new non-coding RNAs. These placental transcripts were also found to be 
specific to the placenta and were differentially expressed across gestation and in 
preeclampsia compared to uncomplicated pregnancies. This suggests these transcripts 
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may be involved in placental development and may have roles in the pathogenesis of 
preeclampsia. Identifying novel placenta specific transcripts has uncovered new research 
opportunities involving the placenta. There are potentially hundreds of other unannotated 
transcripts in the placenta which may have roles in placental development and may be 
crucial to a successful pregnancy outcome.  
Thirdly, using DNA methylation as a biomarker has led to the development of two key 
prediction models. The first one used the level of methylation at 62 cytosine-phosphate-
guanosine (CpG) sites to determine the gestational age of a placenta. This computational 
tool was also used to identify placental aging in placentas from women with early onset 
preeclampsia. This tool points to potential mechanisms underpinning placental aging 
which may have an impact on pregnancy complications. The second prediction tool has 
identified 84 methylated sites in the methylome of maternal circulating leukocytes which 
can distinguish five pregnancy outcomes. This tool has potential clinical application to 
identify women at risk of a pregnancy complication. This would enable clinicians to 
intervene and potentially prevent or reduce morbidity and mortality for mother and child. 
In summary, this thesis has focused on sex differences in gene expression and DNA 
methylation in placental development. It has also shown that DNA methylation has 
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1.1 The epigenetic landscape of the developing placenta is essential to a 
successful pregnancy outcome 
 
The placenta comprises an important part of the conceptus but is only present for a short 
period of time, where term is defined as 37-41 weeks’ gestation. Despite its short life it has 
the substantial task of providing for the needs of the growing fetus. It protects the fetus 
from the maternal immune system, acts as interface for the exchange of nutrients, gases 
and wastes between the mother and fetus, and orchestrates maternal adaptation to 
pregnancy. The placenta itself undergoes drastic changes during development which are 
essential for a successful pregnancy outcome. 
In order for the placenta to undergo dynamic change across gestation to facilitate the needs 
of the developing fetus, there must be tightly controlled mechanisms at the genomic level. 
Alterations in the mechanisms controlling placental transcription during development have 
been implicated in pregnancy complications such as preeclampsia and intrauterine growth 
restriction [1]. Many defects in placental function may stem from early on in gestation 
during trophoblast invasion of the maternal vasculature. Impaired implantation and 
placentation during the early stages of development can increase risk for pregnancy 
complications such as miscarriage, preeclampsia, preterm birth and intrauterine growth 
restriction [2]. Despite the knowledge of the link between placental development and 
pregnancy complications, the placenta remains the most poorly understood organ in the 
human body [3].  
The placenta originates from the conceptus and is therefore genetically identical to the 
fetus. Placental development is directed by the fetal genome but there are a number of 
factors that tightly regulate transcription such as the epigenetic landscape. For example, 
DNA methylation has been extensively studied in the placenta in terms of genomic 
imprinting, which is essential for placental and fetal development. Furthermore, alterations 
in placental DNA methylation levels have been shown to associate with pregnancy 
complications [4]. Despite increasing literature, the precise mechanisms by which 
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epigenetics and transcription interact with one another and how these interactions relate to 
pregnancy success remains to be elucidated. 
1.2 The developing placental transcriptome  
 
The massive amount of high resolution gene expression data that is generated by next 
generation sequencing (NGS) enables the identification of previously unannotated 
transcripts in the human genome [5, 6]. These analyses are essential to identifying new 
biological pathways which could potentially play a role in various diseases. There have 
been a number of RNA sequencing studies that have focused on the placenta [7-9], 
however these have focused on the term placenta and therefore the first trimester placenta 
remains an enigma. In addition, most studies have been confined to group comparisons and 
have not dived deeper into transcriptomic analysis of the placenta.  
Thus far, gene expression analyses have been carried out on the first trimester placenta 
using gene expression microarrays [10, 11]. These microarray experiments rely on a priori 
transcript information and hence, cannot identify novel transcriptional events. In other 
areas of genomic research, studies have been identifying novel transcripts and determining 
their association in a range of diseases including cancers [12, 13] and neurological 
disorders [14]. Detecting novel transcripts in a tissue-specific manner enables the 
identification of new biological pathways and deeper understanding of the transcriptome 
environment. Such studies are essential to improve understanding of the role of gene 
expression in the development of the placenta in health and disease. Although large scale 
analyses have focused on novel transcripts in a range of human tissues [15], no such study 
has conducted these type of analyses in the placenta. In this thesis, RNA-seq will be used 
to perform a de novo transcript analysis on placental tissue to fill this gap in our 
knowledge. 
1.3 The importance of considering sex as a biological variable  
 
Many biomedical researchers avoid the use of female mammals in experimental 
manipulations. There is a common assumption that results from males can be directly 
applied to females. However, since sex differences in body metabolism are well known 
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[16, 17] research should conduct experiments on both sexes. One of the misconceptions of 
females not being used in biomedical research is that their hormonal cycles may be a 
confounding factor [18, 19]. However, some studies have shown that females can still give 
consistent results comparable to males [20, 21]. Despite this, there is a bias of using males 
in 8 out of 10 biological disciplines [22]. Conducting research only on male subjects can 
have implications for women’s health. Since there are sex differences in the absorption and 
metabolism of drugs [23], it is potentially unknown how a drug may behave specifically in 
females since the research was conducted only on males. 
Sex differences in physiology and pathology are well known, however it is unknown how 
these differences arise. Sexually dimorphic traits can be contributed by sex chromosomes, 
sex hormones and reproductive factors, but may extend beyond these factors. Despite 
sharing similar genomes, differences in gene regulation between sexes may be an 
underlying mechanism in many sexually dimorphic traits. Previous studies have reported 
sex biased gene expression in the human brain [24-28], pancreas [29], heart [30], placenta 
[31] and the liver [32]. One major difference between males and females is the presence of 
the sex chromosomes (XX in females and XY in males) that contribute a large proportion 
of the total number of sex biased genes within a tissue. Genes located on the Y 
chromosome, which females don’t have, are not considered to be differentially expressed 
between sexes. However, Y chromosome genes may have an important role in the male 
phenotype in a range of tissues. To compensate for gene dosage in mammalian female 
somatic cells, one X chromosome is randomly inactivated by the long non-coding RNA, 
XIST, in a process referred to as X chromosome inactivation (XCI). In humans, up to 15% 
of genes escape XCI, unlike in mice where there is relatively no escape of XCI [33, 34]. 
Sex biased gene expression can extend beyond the X chromosome and into genes located 
on autosomes. These differences may contribute to sex differences in the prevalence of 
certain diseases and disorders.  
Sex differences in autosomal gene expression and non-reproductive factors have been 
shown to be associated with brain disorders such as multiple sclerosis (MS) [35, 36] and 
epilepsy [37]. Furthermore, genes that encode for pro-inflammatory factors such as heat 
shock proteins (HSPs) have been shown to be upregulated in female brains compared to 
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males [38]. In addition to other organs, isolated systolic hypertension can be up to 14% 
more prevalent in females compared to males [39]. Sex biased gene expression may result 
in sex differences in how many prescribed medications are absorbed and metabolized [40]. 
Not taking these factors into consideration may have devastating consequences for females 
and it may also be the reason why females are 1.5 times more likely to have an adverse 
reaction to a prescription drug compared to males [41]. Therefore, studying sex differences 
in gene expression, if the true extent of sex differences can be elucidated, may help 
identify possible mechanisms for sexually dimorphic traits. In this thesis I will make use of 
publicly available data to investigate sex differences in gene expression and DNA 
methylation.  
1.4 Machine learning applications in epigenetic studies  
 
Advances in technology in the past decade has substantially reduced the time and cost of 
sequencing a human genome. The cost has reduced from $3 billion to currently $1000 
[42]. This has created a wealth of data in which to conduct large scale genomic studies. 
However, our ability to identify meaningful patterns in data has proven to be difficult. 
Genomic data such as DNA methylation data suffers from the problem of high 
dimensionality [43]. This can result in high computational costs when analysing data with 
potentially millions of variables.  
Machine learning comprises techniques in which computer algorithms can be used to 
identify meaningful results from large sets of data [43]. In the field of genomics machine 
learning can be used to identify potential biomarkers and possible biological mechanisms. 
The methods used in machine learning can be divided into two main categories, 
unsupervised and supervised learning [44]. Unsupervised techniques summarise the data 
such that an overview of the data can be interpreted. By contrast, supervised learning 
constructs models using the data to predict an outcome. Supervised learning can be used 
with epigenetic data to construct models which can be used as either prognostic or 
diagnostic tools. These methods have been widely used in cancer prognosis and 
diagnostics [45, 46]. However, these methods are gaining traction in other applications in 
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clinical research and can potentially be used with epigenetic data for the prediction of a 
wide variety of diseases. 
1.5 DNA methylation can be used as biomarkers for pregnancy 
complications 
 
A biomarker is a factor that can be measured to give a prediction of either a normal 
biological or pathogenic process [47]. Many complex, pleiotropic human traits and disease 
states are the result of a mixture of both genetic and environmental factors and as such, 
biomarkers should reflect each so that they provide accurate prediction. Epigenetic 
modifications, influence gene expression but do not alter the DNA sequence [48], they are 
relatively stable [49] and reflective of both genetic and environmental factors, making 
them ideal biomarkers for identifying diseased states.  
Epigenetic modifications include DNA methylation which is the addition of a methyl 
group to a cytosine residue. In the human genome, DNA methylation occurs 
predominantly at cytosine-phosphate-guanine (CpG) dinucleotides [50]. Most epigenetic 
studies in humans have focused on CpG methylation through the use of microarrays or 
sequencing based methods. Currently, pregnancy research has focused on epigenome-wide 
studies which have identified DNA methylation differences in pregnancy complications 
[4]. While multiple studies have focused on individual sites [51-53], differentially 
methylated regions [54] or trait association [55] few studies have investigated the use of 
stable methylated sites that could be biomarkers and act as diagnostic tools. Currently, no 
epigenetic biomarkers exist for the prediction of pregnancy complications. Furthermore, 
previous studies have focused on microarray technology which only captures a limited 
number of CpG sites in the genome. However, with the increased resolution of epigenomic 
markers generated by NGS technology, there is the potential for using such data for 
biomarker discovery in pregnancy research. Furthermore, NGS technology is capable of 
capturing more markers as opposed to  microarray technology and therefore can be used to 






The aim of this thesis was to investigate the epigenetic dysregulation in pregnancy 
complications. In addition, it also focused on the epigenetic landscape during normal 
placental development. The analysis presented here in this thesis was primarily conducted 
using DNA methylation data. However, gene expression data was also generated to gain a 
further understanding of the placental transcriptome. Gene expression data was also used 
in other human tissues to build a comprehensive resource of sex biased gene expression. 
Furthermore, many of the bioinformatic methods did not exist prior to this thesis and to my 
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2 Literature Review 
Abstract  
Pregnancy complications can cause perinatal and lifelong health problems for the child. 
Prediction of complications and interventions that prevent them could significantly 
improve the future quality of life for the child. Prediction of pregnancy complications prior 
to the onset of disease is a major challenge for clinicians and researchers as there are 
currently no accurate predictors. Non-invasive biomarkers are promising candidates for the 
prediction of pregnancy complications due to their easy accessibility. Previous studies 
have focused on differences in profiles of placental DNA methylation in uncomplicated 
and complicated pregnancies, showing that identified methylated sites may be potential 
biomarkers. In addition, these studies have also focused on expression profiles of non-
coding RNAs (ncRNA) in maternal blood and the placenta. These studies have identified 
biological mechanisms where ncRNAs have a role in the development of certain 
pregnancy complications. Furthermore, specific ncRNAs have been shown to be present in 
maternal plasma depending on pregnancy outcome. This review focuses on DNA 
methylation and ncRNAs as biomarkers of pregnancy complications. It also focuses on the 
roles of epigenetic modifications in the development of the placenta and how they relate to 
the onset of pregnancy complications. Finally, it will also describe recent work relating to 
the use of epigenetic modifications as biomarkers in pregnancy.  
2.1 Introduction 
 
Pregnancy is a physiological state where the mother’s body faces significant challenges. In 
order for a successful pregnancy outcome, maternal physiological adaptations include 
insulin resistance, increased cardiac output and increased glomerular filtration rate [1]. 
Despite the adaptability of a woman’s body in pregnancy, complications can arise. 
Pregnancy complications including preeclampsia (PE), which is characterised by high 
maternal blood pressure and proteinuria, preterm birth (PTB), when the baby is born prior 
to 37 weeks’ gestation, intrauterine growth restriction (IUGR), when birthweight is < 5th 
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centile and gestational diabetes mellitus (GDM), affect up to 1 in 4 pregnancies [1]. These 
pregnancy complications can be life threatening to the growing fetus and mother but also 
impact the lifelong health of the child. Pregnancy complications can result from defective 
early placental morphogenesis which impacts placental function and, thereby, the health of 
both the mother and fetus later in gestation [1]. Genetic and environmental factors 
contribute to pregnancy success. These impact epigenetic modifications in the placenta, 
fetus and maternal tissues which may have a profound impact on fetal development and 
pregnancy outcome [2]. 
 
An increasing number of studies have demonstrated that aberrant epigenetic modifications 
may be the underlying mechanism in many diseases such as some cancers, cardiovascular 
and autoimmune diseases and pregnancy complications [3, 4]. One of the most commonly 
studied epigenetic modifications, DNA methylation, has increasing prominence as a 
biomarker in many biomedical research fields. DNA methylation has been used as a 
biomarker in diagnosis and prognosis in many types of cancers [5]. In addition, non-coding 
RNAs (ncRNAs) also have great promise as biomarkers and have been used in cancer 
diagnostics [6]. A biomarker is any biological measure that can be used to predict the risk 
of a pathological condition occurring [7]. Generally, peripheral fluids such as blood and 
saliva are ideal, as they have been widely used in studies as a non-invasive method for 
disease prediction [8, 9]. For example, DNA methylation levels at specific sites in the 
peripheral blood have been shown to be associated with colorectal cancer [10]. 
Furthermore, detection of a biomarker must not only be reproducible but provide high 
sensitivity and specificity for accurate prediction. 
 
Currently, cancer related applications of epigenetic modifications as biomarkers, dominate 
research. However, there is the potential for using epigenetic modifications, including 
DNA methylation and ncRNAs as biomarkers of monitoring pregnancy development and 
outcome. In this review, we highlight studies that have identified key epigenetic 
biomarkers of pregnancy development and outcome. We also discuss possible biological 
functions of the epigenetic modifications in the context of fetal development. 
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2.2 Epigenetics  
 
Epigenetics can be defined as the study of heritable modifications that alter gene 
expression without changing the underlying DNA sequence [11, 12]. Epigenetics covers a 
broad range of modifications that occur to the underlying DNA sequence without changing 
the genetic code. We will confine our review to DNA methylation and ncRNAs. The form 
of DNA methylation discussed will specifically be the addition of a methyl group (CH3) to 
a cytosine residue. However, it is acknowledged that there are other forms of DNA 
methylation that exist [13]. DNA methylation is maintained by DNA methyltransferases 
(DNMT1, DNMT3A and DNMT3B) which generally act to repress gene expression 
through the addition of methyl groups within promoter regions [14]. On the other hand 
ncRNAs, which were originally thought to be non-functional junk, also feature in 
transcriptional regulation [15]. The length of ncRNAs is used to define their class. The first 
class is short ncRNAs (20-200 nt) and the other class, which makes up 80% of ncRNAs, is 
long non-coding RNAs (lncRNAs) (200nt – 1kb) [6, 16, 17]. Placental development is 
dependent upon ncRNA expression and genomic imprinting. Imprinted genes are 
expressed in a parent of origin fashion and are epigenetically silenced by DNA 
methylation, histone modifications or lncRNAs [18, 19].  
 
Despite epigenetic modifications having great promise as biomarkers, there is little 
knowledge on the molecular mechanisms by which chosen markers act. . DNA 
methylation is well known for its role in regulating gene expression levels [20]. DNA 
methylation at cytosine-phosphate-guanosine (CpG) sites nearby the transcription start site 
of genes commonly represses gene expression [21] by preventing binding of transcription 
regulatory factors which would otherwise increase expression. However, DNA methylation 
has also been shown to act over long range distances through chromatin remodelling [21], 
increasing the complexity of regulation of gene expression levels. Moreover, DNA 
methylation is not the only epigenetic regulator of gene expression. The expression of 
ncRNAs can also influence gene expression by recruiting transcription factors or mediating 
heterochromatin assembly [22]. The regulation of gene expression is mediated by different 
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epigenetic factors which act together [23]. However, many of the precise mechanisms 
remain to be elucidated but they may uncover novel targets for a range of future research 
questions. 
2.3 Epigenetic modifications in placental development  
 
The placenta still remains the most poorly understood organ in the human body [24]. 
Although the placenta only exists for a short period of time, it has the substantial task of 
providing protection from the maternal immune system and nutrient, gaseous and waste 
exchange for the growing fetus among other functions [1, 25]. Implantation of the 
blastocyst into the decidua initiates the differentiation of various trophoblast cell types 
which later form the epithelial populations in the placenta. Implantation and early placental 
morphogenesis are mediated by extravillous cytotrophoblast invasion of the decidua and its 
vasculature, which uses mechanisms similar to tumour metastasis [26]. Improper 
implantation and placental morphogenesis during the early stages of development can lead 
to an increased risk of pregnancy complications such as miscarriage, PE, PTB and fetal 
growth restriction (FGR) [1, 25].   
 
Studies have shown that epigenetic modifications such as DNA methylation [27, 28] and 
ncRNAs [29] undergo rapid changes during placental development. Global levels of DNA 
methylation in the placenta increase during gestation which are associated with gene 
expression levels [28]. This has been observed using the Illumina Infinium 
HumanMethylation27 BeadChip which assesses DNA methylation at 27,000 CpG sites. 
The level of methylation was averaged across these sites to show that a significant increase 
in the level of DNA methylation from first, second and third trimester [28]. This suggests 
that DNA methylation is required for proper placental development. 
 
MicroRNAs (miRNAs) (~22nt) also regulate placental development. For example, specific 
miRNAs have been found to be associated with enhancing or downregulating trophoblast 
proliferation. Trophoblast proliferation is tightly controlled throughout gestation. 
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Proliferation is dependent upon the expression of specific miRNAs which activate 
downstream targets, thereby increasing cell growth. Several miRNAs, including miR-376c 
[30] and miR-195 [31] enhance proliferation and trophoblast invasion during early 
gestation by downregulating nodal signalling and inhibiting transforming growth factor-β. 
Other miRNAs such as miR-675 [32], miR-155 [33] and miR-29b [34] inhibit trophoblast 
invasion by downregulating angiogenic factors which would otherwise increase cell 
proliferation. There are more than 500 known miRNAs expressed in the placenta [35], 
many of which are specific to pregnancy. Despite the known changes of DNA methylation 
and ncRNA expression during placental development only a limited number of CpG sites 
and ncRNAs have been analysed. Hence, further research is required to understand the full 
impact of DNA methylation and ncRNA expression during placental development.  
2.4 Placental DNA methylation 
 
DNA methylation occurs when a methyl group is added to a cytosine residue at the C5 
position of a pyrimidine ring or to an adenine at the N6 position of a purine ring [36]. 
Cytosine and adenine methylation occur in bacteria as a defence mechanism [37]. 
However, in mammals most research investigating DNA methylation is focused on 
cytosine methylation [36]. DNA methylation is mediated by DNA methyltransferases 
(DNMTs) along with S-adenosylmethionine which is the universal methyl donor [12, 38]. 
Traditionally, DNA methylation is well known for its role at promoters and enhancers in 
regulating gene expression [39].   
The placenta is unique compared to other tissues, with the exception of cancer tissues [40, 
41] and a human fetal fibroblast cell line (IMR90) [42] in that it has low levels of genome 
wide cytosine methylation [27, 43]. Despite low levels of DNA methylation in this tissue, 
it has been observed that levels of DNA methylation increase during gestation [28, 44]. 
Furthermore, this hypomethylation is not consistent across the genome but rather occurs in 
large domains (> 100kb) [27]. These large domains, which are referred to as partially 
methylated domains (PMDs), cover approximately 40% of the genome and are specific to 
the placenta [27]. Genes within PMDs are typically repressed and this is maintained 
throughout gestation [27]. In addition, PMDs have only been investigated in placentas 
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from uncomplicated pregnancies. It still remains to be determined if PMDs are disrupted in 
pregnancy complications. 
 
In addition, the placenta has a variety of cell types with their own distinct patterns of 
methylation. This has been demonstrated using DNA methylation profiles of 
cytotrophoblasts and fibroblasts analysed by Illumina Infinium Human Methylation 27K 
BeadChip Array [45]. The cytotrophoblasts and fibroblasts were found to cluster 
separately by hierarchical clustering which highlights distinct cell type methylation 
patterns in the placenta [28].  Moreover, novel ncRNAs have been found to be in 
trophoblast subpopulations and differentially expressed in placentas from preeclamptic 
pregnancies [46]. This research highlights distinct DNA methylation and gene expression 
profiles in different placental cell types. Future work should focus on capturing the 
complete DNA methylation and gene expression profiles of trophoblast subpopulations in 
the placenta which may uncover targets critical for placental development.  
2.5 Non-coding RNA expression in the placenta 
 
It is currently estimated that only 2% of all genomic transcripts have protein coding 
capability [6, 47]. The remaining genomic transcripts are classified as ncRNAs and fall 
into either one of two main classes depending on their length as previously described 
above. lncRNAs play an important role in placental development. One of the first lncRNAs 
to be discovered, H19, is an imprinted gene that is essential to placental development. H19 
is situated on chromosome 11 and is expressed by the maternal allele. It also shares cis-
regulatory elements with IGF2 which encodes an insulin-like growth factor. Mutations 
within the H19-IGF2 locus have implications in placental development and are associated 
with pregnancy complications [48]. For example, altered epigenetic regulation of H19 and 
IGF2 are associated with PE [49]. Expression of ncRNAs are important for proper 
placental development. The complete landscape of ncRNA expression in the placenta 
remains unknown. There are potentially thousands of undiscovered ncRNAs expressed in 
the placenta. Moreover, the precise mechanisms by which these ncRNAs act remains to be 
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determined.  Further research is needed to identify potentially novel transcripts and their 
targets within the placenta, advancing our knowledge.  
2.6 Lifelong effects of perinatal exposures in utero 
 
In utero exposures play a critical role in perinatal and childhood development. These 
effects can potentially have long lasting effects on the health of the child into adulthood. 
Studies have identified epigenetic changes in relation to in utero exposures such as 
maternal smoking [50-53]. Although it is well known that smoking impacts on DNA 
methylation profiles [54], it is unclear what the long lasting effects are on the developing 
fetal epigenome. It has also been shown that if the mother ceases smoking prior to 18 
weeks gestation that there is evidence in DNA methylation profiles of cord blood [50]. 
However, smoking is not the only environmental exposure to impact on DNA methylation. 
Levels of micronutrients in maternal plasma have also been shown to impact the fetal 
epigenome [55]. Folate, which is involved in the production of S-adenosylmethionine, is 
vital for fetal development. One study has shown that levels of maternal plasma folate are 
associated with DNA methylation in cord blood at 443 CpG sites which are related to 320 
genes [55]. These genes are involved in embryonic development and birth defects such as 
neural tube defects. In utero exposures can impact DNA methylation profiles, although it is 
not clear what is the precise mechanism.  
Unforeseen events, including natural disasters and famines can affect women and the 
developing fetus at an epigenetic level. One of the first studies to show this was “Project 
Ice Storm” [56], which assessed the DNA methylation profiles of blood samples from 
offspring at 13 years of age from women who experienced the 1998 Quebec ice storm. The 
researchers identified 1675 CpG sites that were associated with maternal stress [56]. Other 
natural disasters have been shown to impact on pregnancy complications [57]. These 
studies also strengthen the notion that perinatal exposures during in utero development can 





2.7 DNA methylation as a biomarker for pregnancy outcome  
 
Epigenetic dysregulation, including differential DNA methylation is associated with 
pregnancy complications [58]. Analysis of DNA methylation in relation to pregnancy 
outcome has been conducted in the placenta and cord blood extensively. Using microarray 
technology it has been shown that differential methylation occurs in placentas from PE 
[59-61], IUGR [62] and GDM [61, 63] in comparison to uncomplicated controls. In 
addition, studies have also identified the same regions to be differentially methylated in 
cord blood [64, 65]. These studies identify epigenetic mechanisms that are associated with 
pregnancy complications.  
Studies have also focused on assessing differential methylation in the maternal blood of 
women early in pregnancy to identify women at risk of pregnancy complications [66, 67]. 
In maternal peripheral blood, it has been found that hypomethylation occurs in genes 
related to cell morphology and cell cycle in women who develop GDM [66]. This study 
assessed DNA methylation using the Illumina HumanMethylation 27 BeadChip at 16 
weeks’ gestation and identified 27 target sites that may be novel biomarkers for the 
identification of women at risk of developing GDM. Furthermore, differences in DNA 
methylation profiles of women who developed PE, GDM, PTB or SGA compared to 
uncomplicated controls have been identified in a preliminary study using peripheral blood 
collected at 15 weeks’ gestation [67]. These differences in DNA methylation profiles are 
detectable well before the onset of any of the pregnancy complications. There have been 
several suggestions of using DNA methylation as a biomarker for pregnancy complications 
[68-70]. Furthermore, studies have also used miRNAs as biomarkers for the prediction of 
pregnancy outcomes in maternal blood (Table 2-1). These studies demonstrate the 













CpG: cytosine phosphate guanosine, GDM: gestational diabetes mellitus, PE: preeclampsia, miR: micro RNA.  
Reference Biomarker(s) Prognosis, diagnosis, assessment  
Tsochandaridis et al. 2015 [82] miR-144 Prognosis of PE 
Ge et al. 2015 [80] miR-141-3p and miR-200c-3p Fetal macrosomia  
Anton et al. 2013 [81] miR-210 Prognosis of PE 
Li et al. 2013 [34] miR-29a Prognosis of PE 
Zhao et al. 2011 [83]  miR-29a, miR-222 and miR-132 Prognosis of GDM 
Anderson et al. 2014 [70] 207 CpG sites Prognosis of PE 
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2.8 DNA methylation as a biomarker of gestational age 
 
Rapid development changes occur every week during gestation and these significantly 
impact neonatal mortality and morbidity [71]. The gold standard for measuring 
gestational age has typically been through ultrasound based methods [72]. Differential 
methylation has been observed at specific CpG sites at different gestational age time 
points in cord blood [73, 74]. Recently, using Illumina Infinium Human Methylation 27K 
and 450K BeadChip Arrays, DNA methylation has been used to predict gestational age 
from cord blood [75]. Gestational age can be calculated from the level of methylation at 
148 CpG sites from either cord blood or blood spot samples [75]. The importance of this 
study highlights aging mechanisms are associated with DNA methylation. 
2.9 Association of non-coding RNA expression with pregnancy 
complications 
 
Recently, it has been found that differential placental expression of ncRNAs occurs in PE 
[76] and PTB [77] compared to that in uncomplicated pregnancies. Pathway analyses of 
these differentially expressed ncRNAs in PE have been shown to be related to pregnancy, 
lipid metabolism and the immune response [76]. In addition, pathway analyses have 
shown upregulated ncRNA expression in PTB to be associated with inflammation [77]. 
The results from these studies indicate that PE and PTB are immune and metabolic 
conditions that are possibly driven by ncRNAs.  However, these studies have used 
microarray technology to assess the expression profiles, which only assess the expression 
of a limited number of genes.  
Sequencing-based methods have the ability to assess the expression of all expressed 
ncRNAs within a tissue and discover novel ncRNAs. One study has used high throughput 
sequencing of maternal blood at 16-19 weeks’ gestation, to identify 32 differentially 
expressed miRNAs from pregnant women who went on to have either GDM or 
uncomplicated pregnancies [78]. There are only a few studies that have used high 
throughput sequencing to identify biomarkers of pregnancy complications. However, this 
may change in the future due to the diminishing cost of high throughput sequencing. 
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Large sequencing studies and databases have been used to discover thousands of 
previously unannotated ncRNAs. In a recent study, using 25 independent studies of 
sequencing data from a variety of human tissues, it found 48,952 previously unannotated 
lncRNAs [79]. These novel lncRNAs are important as they can be potentially used in a 
broad range of applications. For example they can be used in biomarker development and 
studying the biological mechanisms in placental gene expression during development. 
Despite the size of studies such as these, little work has been conducted in the placenta. 
Future work should focus on ncRNA discovery in the placenta and the mechanisms by 
which ncRNAs regulate gene expression in placental development. 
2.10 Maternal circulating non-coding RNA 
 
Non-invasive biomarkers such as ncRNAs in maternal blood are becoming promising 
predictors of pregnancy complications. Studies have identified plasma miRNAs as 
potential biomarkers for predicting pregnancy outcomes. Expression of specific miRNAs 
during second trimester, such as miR-141-3p and miR-200c-3p in maternal blood have 
been shown to be candidate biomarkers for predicting fetal macrosomia [80]. Other 
miRNAs such as miR-210 have also been shown to be a biomarker for PE, which acts by 
inhibiting trophoblast invasion [81]. Inadequate trophoblast invasion results in reduced 
maternal spiral artery remodelling which can result in an increase of placental oxidative 
stress. miR-144 is an important regulator of hypoxia and has also been shown as a 
potential biomarker for PE [82]. These findings involving miR-210 and miR-144 show an 
important role in the pathogenesis in PE. They can potentially be used as biomarkers in 
the prediction of PE.  
2.11 Conclusions and recommendations  
 
Epigenetic modifications including DNA methylation are relatively stable within tissues 
and plasma. This makes epigenetic modifications ideal candidates for the prognosis and 
diagnosis for a range of diseases. Circulating ncRNAs within maternal plasma offer a 
non-invasive method to predict pregnancy complications. DNA methylation is also a 
strong candidate as a biomarker due to its stability. An epigenetic biomarker for 
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pregnancy complications would significantly improve the assessment and interventions 
for women at high risk. Targeted early interventions could reduce health burdens of 
pregnancy. Expression of protein coding genes varies across pregnancy and is influenced 
by multiple environmental factors. Specific epigenetic modifications are ideal as 
biomarkers as they can be used to distinguish health outcomes from varying 
environmental exposures.  
This review, has brought to attention the current research to identify epigenetic 
modifications as biomarkers of development and pregnancy outcome. It has focused 
primarily on DNA methylation profiles and expression of ncRNAs in maternal blood and 
the developing placenta. Most studies have used microarray technology in their 
biomarker discovery. However, future research using sequencing technology has the 
ability to identify potential novel and pregnancy specific biomarkers. These novel 
biomarkers may increase the sensitivity and specificity in the prediction of pregnancy 
complications. Successful development and progress of use of epigenetic modifications 
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3 Large scale gene expression meta-analysis reveals 
tissue-specific, sex-biased gene expression in humans 
BENJAMIN T MAYNE, TINA BIANCO-MIOTTO, SAM BUCKBERRY, JAMES 
BREEN, VICKI CLIFTON, CHERYL SHOUBRIDGE and CLAIRE T ROBERTS 
Abstract 
The severity and prevalence of many diseases are known to differ between the sexes. 
Organ specific sex-biased gene expression may underpin these and other sexually 
dimorphic traits. To further our understanding of sex differences in transcriptional 
regulation, we performed meta-analyses of sex biased gene expression in multiple human 
tissues. We analysed 22 publicly available human gene expression microarray data sets 
including over 2500 samples from 15 different tissues and 9 different organs. Briefly, by 
using an inverse-variance method we determined the effect size difference of gene 
expression between males and females. We found the greatest sex differences in gene 
expression in the brain, specifically in the anterior cingulate cortex, (1818 genes), 
followed by the heart (375 genes), kidney (224 genes), colon (218 genes) and thyroid 
(163 genes). More interestingly, we found different parts of the brain with varying 
numbers and identity of sex-biased genes, indicating that specific cortical regions may 
influence sexually dimorphic traits. The majority of sex-biased genes in other tissues 
such as the bladder, liver, lungs and pancreas were on the sex chromosomes or involved 
in sex hormone production. On average in each tissue, 32% of autosomal genes that were 
expressed in a sex-biased fashion contained androgen or estrogen hormone response 
elements. Interestingly, across all tissues, we found approximately two-thirds of 
autosomal genes that were sex-biased were not under direct influence of sex hormones. 
To our knowledge this is the largest analysis of sex-biased gene expression in human 
tissues to date. We identified many sex-biased genes that were not under the direct 
influence of sex chromosome genes or sex hormones. These may provide targets for 




3.1 Introduction   
 
Differences in both disease severity, prevalence, symptoms and age of onset vary greatly 
between males and females [1]. For example, cardiovascular disease is one of the leading 
causes of death, affecting up to 55% of females but only 44% of males in Europe [2]. Sex 
differences are also evident in the risk factors for cardiovascular disease, such as diabetes 
which increases the risk for cardiovascular disease 2-3 fold in males but 3-7 fold in 
females [3]. Sex differences have also been identified in the age of onset of brain diseases 
such as schizophrenia, where males develop symptoms between 18-25 years of age 
whereas females develop symptoms between 25-35 years [4]. Moreover, reported atonic 
seizures in epilepsy are more frequent in males compared to females (6.5% vs 1.7%) [5]. 
These sex differences in diseases may be the result of tissue-specific differential gene 
expression between males and females. In schizophrenia, genes relating to energy 
metabolism have been found to have altered expression in the prefrontal cortex of only 
males [6]. Therefore, gene expression may have a role in orchestrating sex differences in 
the prevalence of diseases. 
 
Many studies neglect to account for sample sex in the design and analysis of their 
experiments [7, 8]. Historically, females have been excluded from biomedical studies, 
due to the assumption that their hormonal cycles are a confounding factor in experimental 
manipulations [7, 9]. Despite females and males sharing highly similar genomes, there 
are numerous sex-specific traits in phenotype, physiology and pathology. Sexually 
dimorphic traits can be influenced by sex chromosome genes or sex hormones, but may 
extend beyond these influences. Sex differences may arise through alterations in 
autosomal gene regulation but the true extent of sex specific differential gene regulation 
is not fully known. Understanding these differences may dictate that future research 
should consider sex as a biological confounder [9]. Sex differences in many traits are 
often small and require large sample sizes for studies to be sufficiently powered. The 
substantial increase in the number of large publicly available genomic data sets could 
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assist in determining the true extent of sex-biased gene expression but to date there are no 
large-scale meta-analyses investigating this in adult human tissues. 
Previous studies have reported sex-biased gene expression in the human brain [10-14], 
pancreas [15], heart [16] and liver [17]. Most studies identify sex-biased genes as those 
located on the sex chromosomes and it is well known that these are a source of 
differentially expressed genes between the sexes [18]. In mammalian, female, somatic 
cells, one X chromosome is randomly inactivated by a process referred to as X 
chromosome inactivation (XCI) [18, 19]. In normal human XX females, up to 15% of 
genes on the X chromosome escape XCI, unlike the case in mice where very few escape 
inactivation [18, 19]. Escape from XCI results in a number of genes that are expressed 
more highly in females compared to males. In addition, autosomal genes have also been 
shown to be sex-biased in human tissues including the brain [10], heart [16] and placenta 
[20]. Furthermore, sex differences in the brain in diseases such as multiple sclerosis (MS) 
are related to autosomal genes and are not regulated by sex chromosome genes [21, 22]. 
These studies highlight the importance of investigating sex differences outside the 
context of reproductive and sex chromosome factors. In order to characterize the true 
extent of sex-biased gene expression in humans, we performed a large meta-analysis of 
publicly available microarray data. We limited our analysis to tissue samples from 
healthy individuals, reducing the possible effect that diseases may have on gene 
expression. Our analysis revealed consistencies in sex differences that are widespread in 
a range of human tissues. Furthermore, we have identified sex-biased genes that are 
disease-related, suggesting possible mechanisms for the associations of sex with an 
increased risk of certain diseases.  
3.2 Materials and methods 
3.2.1 Data collection 
 
Data sets were from different microarray platforms and therefore pre-processing was 
tailored to each platform. Briefly, data from Illumina platforms were pre-processed using 
Beadarray prior to quantile normalisation [23]. Data from Affymetrix platforms were pre-
processed and quantile normalised using the robust multiarray average (RMA) or 
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GeneChip-RMA (GC-RMA) where appropriate that is implemented in Simpleaffy [24]. 
Batch effects in data sets were corrected for using the ‘combat’ function in the SVA 
package [25]. Outliers were identified and removed using ArrayQualityMetrics by 
analysing MA plots [26].   
3.3 Sample sex identification 
 
To identify sample sex in each data set we used the massiR Bioconductor package [27]. 
This R package uses unsupervised clustering of probes that target Y chromosome genes 
to identify sample sex. In data sets where sample sex was supplied, we found an 
agreement in all predicted and supplied sample sex identification.  
3.3.1 Differential gene expression analysis 
 
Probes were re-annotated to Ensembl gene identifiers using biomaRt [28]. In tissues 
where only one data set was found to be useable, sex-biased gene expression was 
determined using the Empirical Bayes methods within limma [29]. For tissues that were 
present in >1 data set, differential gene expression analysis was performed using the 
metaGEM package (https://spiral.imperial.ac.uk/handle/10044/1/4217) and using the 
inverse–variance method as previously described [30]. For each probe, study specific 
effect sizes were calculated, by determining the mean and standard deviation for each 
probe which was corrected using Hedges’ g (accounts for the number of samples in each 
dataset). Z statistics were calculated for each gene identifier which was used to calculate 
a nominal p-value to give a corrected p-value (false discovery rate, FDR).  
3.3.2 Androgen and estrogen response elements  
 
To determine which genes contained androgen response elements (AREs), we firstly 
downloaded the coordinates of AREs from JASPAR [31, 32] and determined the 
positions within the genome in relation to genes and genomic locations. This was 
performed using the matchGenes function in the bumphunter Bioconductor package [33] 
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and UCSC hg19 annotation package [34]. For estrogen response elements (EREs) we 
used a previous study that lists genes that are targets of ERα [35]. 
3.3.3 Identifying enriched transcription factors  
 
Transcription factor binding sites within 10kb upstream/downstream of sex-biased genes 
were analysed using oPOSSUM-3 and the JASPAR vertebrate core profiles [31, 36]. We 
chose 10kb upstream/downstream of genes as this was the largest range the oPOSSUM-3 
would allow. Thus we sought to identify all possible transcription factor (TF) binding 
sites enriched within sex-biased genes. For each sex-biased gene in each tissue, the TF 
binding site motifs were searched with a conservation cut-off of 0.4, an 85% threshold for 
the matrix score and minimum specificity of 8 bits. The resulting TF analysis was limited 
to the most enriched TFs which were defined as those with the highest Fisher’s exact test 
and z score rankings.  
3.3.4 Gene ontology  
 
Gene ontology (GO) analysis was performed using all human genes in the Database for 
Annotation, Visualization and Integrated Discovery (DAVID ) v6.7 [37] and g:Profiler 
[38]. GO terms were considered significant if the corrected p-value (FDR) < 0.05. 
A more detailed account of the methodology is provided in Supplementary File 3-1. 
3.4 Results and Discussion  
3.4.1 Overview of publicly available microarray data  
 
Using the Gene Expression Omnibus (GEO) [39] and ArrayExpress [40] we identified 22 
microarray data sets containing a total of 2502 samples, in 15 different human tissues 
(Table 3-1). We excluded pooled samples and limited our analyses to data sets with >10 
samples to allow better determination of sample sex. To increase the number of useable 
data sets we used massiR [27] to identify and to verify the sample sex in all data sets. 
From the 22 chosen studies, 10 had sample sex metadata and within these we found 
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concordance with all the predicted and supplied sample sex information. Female samples 
(N = 803) made up 32% of all samples across all data sets (Table 3-1).
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Table 3-1: Gene expression data involving 15 healthy tissues.  
Each row corresponds to a data set where only healthy tissue was used within this 






































Bladder GSE13507 Affymetrix 256 68 68 48 20 
Brain GSE45642 Affymetrix 670 670 659 493 166 
Brain GSE11512 Affymetrix 80 44 44 29 15 
Brain GSE54572 Affymetrix 24 12 12 5 7 
Brain GSE36192 Illumina 911 911 911 622 289 
Brain  GSE44456 Affymetrix 39 39 39 28 11 
Colon GSE8671 Affymetrix 62 25 23 15 8 
Colon GSE41328 Affymetrix 20 10 10 8 2 
Heart GSE55231 Illumina 129 129 118 69 49 
Heart GSE26887 Affymetrix 24 24 23 19 4 
Heart GSE57338 Affymetrix 313 136 136 97 39 
Kidney GSE43974 Illumina 554 118 118 73 45 
Kidney GSE50892 Affymetrix 17 17 15 9 6 
Liver GSE61276 Illumina 106 50 48 22 26 
Liver GSE23649 Illumina 69 69 68 42 26 
Liver GSE38941 Affymetrix 27 10 10 4 6 
Lung GSE10072 Affymetrix 107 49 46 32 14 
Lung GSE18995 Affymetrix 35 35 34 15 19 
Lung GSE51024 Affymetrix 96 41 39 34 5 
Pancreas GSE15471 Affymetrix 78 36 35 19 16 
Thyroid  GSE33630 Affymetrix 105 45 35 10 25 
Thyroid  GSE65144 Affymetrix 25 13 12 7 5 
  Total 3747 2551 2502 1699 803 
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Sex differences in autosomal gene expression are typically small so in order to increase 
statistical robustness, we performed multiple testing corrections in three different 
analyses for each tissue. We determined the adjusted p-value implemented by Benjamini 
& Hochberg [41] for each autosomal gene where 1) all the chromosomes were included, 
2) the Y chromosome was excluded, and 3) both the X and Y chromosomes were 
excluded in the analysis (Table 3-2). In general, we observed a reduction in the number 
of autosomal genes that were significantly sex-biased when we removed sex 
chromosomes from the analysis. Since most genes located on the sex chromosomes had 
the smallest adjusted p-value, their removal from the analysis slightly increased the 
adjusted p-value for all other genes. Here we supply the adjusted p-values for all three 
analyses (Supplementary Table 3-1, 3-2, and 3-3) but discuss only autosomal genes that 
were significantly different in all three cases. Furthermore, the sample size in each tissue 
was not reflective of the total number of genes differentially expressed between males 
and females (Figure 3-1). For example, despite the frontal lobe of the cerebral cortex or 
frontal cortex (FC) and cerebellum (CB) data sets containing the greatest number of 
samples, with 455 and 553 samples, respectively, we detected only a small number of 
sex-biased genes compared to other tissues such as the anterior cingulate cortex (AnCg) 
and the heart which contained the greatest number of sex-biased genes with average 




Table 3-2: Total number of sex-biased genes in each tissue. 
Each column corresponds to the total number of genes that were differentially expressed between males and females in each analysis. 
 Organ/Tissue No. of Sex-biased 
Genes (All 
Chromosomes)  
No. of autosomal sex-
biased genes (Sex 
chromosomes included 
in analysis)  
No. of autosomal sex-
biased genes (Sex 
chromosomes 
removed) 
No. of autosomal sex-
biased genes (Y 
chromosome 
removed) 
Bladder 16 0 0 0 
Brain (Nucleus Accumbens) 264 239 216 244 
Brain (Amygdala) 17 6 0 0 
Brain (Cerebellum) 98 59 45 52 
Brain (Anterior Cingulate Cortex) 1818 1726 1690 1728 
Brain (Dorsolateral Prefrontal Cortex) 198 180 165 169 
Brain (Frontal Cortex) 45 10 27 7 
Brain (Hippocampus) 205 183 174 180 
Colon 218 199 162 190 
Heart 375 348 334 346 
Kidney 224 196 194 194 
Liver 32 21 16 28 
Lung 36 14 2 12 
Pancreas 22 0 0 0 






Figure 3-1: Total number of detectable sex-biased genes relative to the sample size in each tissue. 
A bubble plot of each tissue where the size of the bubble is proportional to the sample size of the tissue. Bubbles that are higher on the 
y-axis are tissues that demonstrate a higher number of detectable sex-biased genes. Nucleus accumbens (NC); amygdala (AMY); 
cerebellum (CB); anterior cingulate cortex (AnCg); dorsolateral frontal cortex (DLPFC); frontal cortex (FC); hippocampus (HC).   
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3.4.2 Sex-biased gene expression in the human brain  
 
Previous studies have found sex-biased gene expression in the human brain [11-14]. We 
identified 5 data sets for 7 brain regions and our analyses showed that each region had 
different numbers of differentially expressed genes (Table 3-1 and 3-2). Our findings 
were consistent with previous studies [11, 13, 14], whereby the most striking differences 
in gene expression between the sexes were sex chromosome genes. These comprised 
most of the sex-biased genes in the amygdala (65%) (AMY) and FC (78%). However, a 
large proportion of sex-biased genes were autosomal in the nucleus accumbens (91%) 
(NC), AnCg (95%), dorsolateral prefrontal cortex (91%) (DLPFC), CB (60%) and the 
hippocampus (89%) (HC). Of the 1690 autosomal sex-biased genes in AnCg, 65% were 
expressed more highly in males (Figure 3-2A, Supplementary Table 3-1, 3-2 and 3-3). 
Conversely, we observed a greater proportion of autosomal genes expressed more highly 
in females in the NC (75%), DLPFC (68%) and the HC (62%). We also found that each 
brain region was unique in its proportion of sex-biased genes, with as many sex-biased 





Figure 3-2: Sex differences in autosomal gene expression in the human brain. 
 (A) A volcano plot representing the autosomal genes that were sex-biased in the AnCg. Pink coloured dots represent genes that were 
significantly expressed more highly in females and blue coloured dots represent genes that were expressed more highly in males. (B) 
A four-way venn diagram showing the overlap of sex-biased autosomal gene expression in different regions of the human brain. Most 
genes that were found to be sex-biased in one region were not sex-biased in another region. The top GO terms that were enriched for 
sex-biased genes in (C) Nucleus accumbens (NC), (D) anterior cingulate cortex (AnCg) and (E) hippocampus (HC).  
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An increase in the expression of heat shock proteins (HSPs) has been shown to have 
protective roles in pro-inflammatory responses [42]. Consistent with a previous study 
[43], we found genes that encode for HSPs to have sex-biased expression in the human 
brain. Our analyses also identified genes that are involved in pro-inflammatory responses, 
such as those encoding interleukins, that are more highly expressed in females in NC, 
AnCg, DLPFC and HC tissues (Supplementary Table 3-1, 3-2 and 3-3). By contrast, 
genes expressed more highly in males within the brain were related to energy production 
and growth, including ATPase’s and insulin-like growth factors in the HC and NC, 
respectively, and GAPDH in the AnCg. We found sex-biased genes in the NC, AnCg and 
HC to be enriched for Gene Ontology (GO) as defined by DAVID v6.7 for terms relating 
to cellular functions, the immune response and energy production (Figure 3-2C, 2D, 2E, 
Supplementary Table 3-4). We also used g:Profiler [38] for a comparison of GO terms 
and found similar results to what was found by DAVID v6.7. For example, in the NC, 
AnCg and HC we found that the gene upregulated in females were enriched for those 
involved in the immune response (GO:0006955). Whereas, genes upregulated in males 
were found to be enriched for GO terms such as generation of precursor metabolites and 
energy (GO:0006091).  Overall, varying proportions and types of sex-biased genes were 
identified within different locations of the brain, suggesting that specific cortical regions 
may influence sexually dimorphic traits. As mentioned above, the AnCg contained the 
largest number of genes differentially expressed between males and females. The AnCg 
is one of the most recently evolved parts of the mammalian brain [44] and also has been 
shown to regulate behaviour and act in a sex-specific manner [45]. Furthermore, previous 
studies have identified sex differences in mood disorders and the AnCg is known to have 
a role in regulating mood [46, 47]. In mice, the AnCg has also been shown to have a 
critical role in sexual interest of males for females [48] and hence the large number of 
genes that were differentially expressed between sexes in the AnCg may assist in the 
explanation for sexual dimorphism in behaviour. 
 
Sex biased gene expression in the brain may potentially contribute to differences in 
certain neurological diseases between sexes, such as the previously mentioned epilepsy. 
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Sex differences in gene expression may mediate these differences in susceptibility or 
comprise part of the mechanistic pathways involved in their pathology. Previously, sex 
biased gene expression in the brain has been proposed to underlie the sex differences in 
schizophrenia [10] which has an incidence of 1.4:1 between males and females [49]. We 
found several genes that have been associated with brain disorders to be sex-biased 
within specific locations of the brain. For example in the AnCg, NOTCH3, a gene 
associated with hereditary stroke disorder [50], and ALDH3B1, a gene associated with 
schizophrenia [51], were more highly expressed in females than males. On the other 
hand, KCNH3, a gene associated with epilepsy [52], GABRB3, a gene associated with 
schizophrenia [53], epilepsy [54] and autism [55], SNCA, a gene associated with 
Parkinson’s disease [56], and RGS4, a gene associated with schizophrenia [57], were all 
expressed more highly in males. Recently, sex-biased gene expression has also been 
identified during developmental stages of the human brain [58]. Furthermore, genes 
associated with schizophrenia have been found to be upregulated in male brains as 
opposed to females across different developmental stages [58]. This demonstrates 
consistency in sex-biased genes within the human brain across different studies. Taken 
together, these findings suggest possible mechanisms by which sex-specific prevalence of 
brain disorders may occur. 
3.4.3 The heart and kidney show opposite trends in sex differences in gene 
expression  
 
Most of the heart gene expression data used in this study are from individuals with an 
average age of 47 years and we observed many sex differences in expression of genes 
associated with heart disease. It has been reported in elderly individuals (> 75 years), 
isolated systolic hypertension can be up to 14% more prevalent in females than males 
[59]. We found SCN10A, a gene associated with hypertrophic cardiomyopathy [60], and 
KCNE1, a gene associated with long-QT syndrome [61], to be expressed more highly in 
hearts from females. Interestingly, 62% of the 334 autosomal sex-biased genes in the 
heart were expressed more highly in females. The distribution of sex-biased genes across 
all chromosomes in the heart was similar to that in a previous study [16]. However, we 
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report a much smaller number of sex-biased genes in the heart (375 genes in 277 samples 
(Table 3-2, Supplementary Table 3-1) compared to 1800 genes in 102 samples in that 
study [16]).  
Conversely, compared to the heart, we found an opposite trend in the kidneys, with 72% 
of a total of 194 autosomal genes being expressed more highly in males. We also 
identified 6 genes located on chromosome 1 that were expressed more highly in females 
in the heart that were more abundantly expressed in males in the kidney (Figure 3-3). 
These genes are from the RNA U1 family (RNU1-1, RNU1-2, RNU1-3, RNU1-4, 
RNVU1-7 and RNU1-18) that includes genes that regulate transcription, elongation and 
pre-mRNA splicing events [62, 63]. It has been suggested that the expression of these 
genes is different between tissues to regulate organ specific alternative splicing events 
[63]. Sex differences in alternative splicing have also previously been detected in the 
brain, where it has been found to affect 2.5% of expressed genes [10]. Apart from RNA 






Figure 3-3: Sex-biased gene expression differences on chromosome 1 in the heart and kidney. 
Each dot represents a gene, blue dots are genes that were expressed more highly in males and pink dots are those expressed more 
highly in females. The ideogram of chromosome 1 was obtained from the National Centre for Biotechnology Information (NCBI). 
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3.4.4 Sex hormones and gene expression  
 
Many of the sex-biased genes we identified encode enzymes that are known to regulate 
the production of sex hormones. In the AnCg, three genes from the sulfotransferase 
family that regulates sulphate conjugation in estrogen precursors [64] (SULT2A1, 
SULT1B1 and SULT1C1) were expressed more highly in females. In addition, we also 
found STS (a gene involved in the production of estrogen precursors [65]) to be 
expressed more highly in females in the FC and CB, as well as in the heart and lung. We 
did not find any major sex differences in gene expression in the bladder, liver, lung or 
pancreas, apart from genes located on the sex chromosomes and those that are involved 
in sex hormone production. This can be contradictory to that which has been found in 
mouse studies where thousands of genes have been found to be sex-biased [66, 67]. This 
may reflect an evolutionary difference between the species. Apart from the brain, we 
found the largest number of sex-biased gene expression differences in the heart, kidney, 
colon and thyroid (Table 3-2). Thyroid hormones are known to regulate sex hormone-
binding globulin (SHBG) production, which transports androgens and estrogens through 
the bloodstream [68]. In the thyroid, 133 autosomal genes were sex-biased, 75% of which 
were expressed more highly in males. Genes that encode for growth factors and 
signalling molecules were highly expressed in the thyroid of males, such as CCL28, a 
growth factor in hematopoietic stem cells [69], CMTM4, a chemokine that regulates the 
cell cycle [70], and GH1, a gene that encodes for growth hormone [71]. These findings 
suggest a functional role for the thyroid in influencing sexually dimorphic traits such as 
metabolism, as well as sex differences in thyroid hormone secretion [72]. There is also 
evidence to suggest that thyroid hormones significantly influence testosterone levels [73]. 
 
To determine if the differentially expressed genes between sexes were regulated by sex 
hormones, we quantified the number of genes that contained either AREs or EREs. For 
AREs we downloaded the coordinates of AR binding sites from the JASPAR database 
[31, 32] and for EREs we used a list of previously reported ERα targets [35]. In total we 
identified 3014 different genes that were expressed more highly in either sex in at least 
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one tissue. Of the 3014 genes, 875 contained AREs, 239 contained EREs and 86 
contained both. On average 32% of autosomal genes that were sex biased in tissues 
contained AREs or EREs. Therefore, across all tissues analysed approximately two-thirds 
of autosomal genes did not contain either AREs or EREs. 489 genes contained AREs 
within gene bodies such as introns and exons, 216 genes contained AREs upstream and 
within the promoters and 170 genes contained AREs located downstream of the gene. 
The precise locations of EREs were unknown as we were using a list of previously 
defined ERα targets. GO enrichment for genes that contained both AREs and EREs in 
each individual tissue did not produce any significant enrichment, most likely due to the 
lists of genes being too small. We therefore found it advantageous to combine the list of 
genes across different tissues since the list of genes in each tissue were too small to 
produce any significant results. The genes that contained either or both AREs or EREs 
and were expressed more highly in females were enriched for GO terms relating to 
response to wounding and inflammatory response. For example, we found genes related 
to interleukin signalling and inflammatory processes to be expressed more highly in 
females such as TNFAIP6, IL10RB, and IFNA2 in the DLPFC, HC and AnCg, 
respectively. On the other hand genes containing either or both AREs or EREs that were 
expressed more highly in males were enriched for GO terms relating to mitochondrion 
and generation of precursor metabolites and energy. As already mentioned, we found a 
variety of ATPase’s to be expressed more highly in males in the AnCg, NC, DLPFC, CB, 
thyroid, colon and kidney such as ATP5G1, ATP6V1B2, ATP6V0B, ATP6V1C1 and 
ATP6V1A. These results indicate that sex chromosome genes and sex hormones are key 
regulators of sex-biased gene expression across a range of tissues. However, our data also 
suggest a significant number of genes that have sex-biased expression may potentially be 
independent of direct influence by sex chromosomes or sex hormones. 
3.4.5 Sex-biased epigenetic modifications 
 
Genes that are involved in the regulation of transcription and histone modifications also 
showed sex differences. In the colon, genes expressed more highly in males included 
those that encode for histones (H3F3A, H3F3AP4, H3F3AP6 and H3F3BP1) and 
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ribosomal proteins (RPS3A, RPS3AP26, RPS3AP6, RPL13A, RPL4, RPL4P4, 
RPL13AP5, RPS3AP5, RPS3AP47, RPL7A, RPL7AP6, RPL23AP74, RPL4P5, 
RPL3P4, RPL13AP20 and RPL13AP25). These genes were also expressed more highly 
in males in other tissues such as the brain, heart and kidney. It is worth mentioning that 
we also found other members of the RPL gene family to be more highly expressed in 
females in other tissues (Supplementary Table 3-1, 3-2 and 3-3). We also found sex bias 
in some genes that encode for enzymes that regulate histone modifications. For example, 
SET, a gene that inhibits nucleosome and histone H4 acetylation [74] was expressed 
more highly in males in the DLPFC, SMYD3, a histone methyltransferase [75], PRMT2, 
PRMT5 and PRMT8 (histone arginine methyltransferases [76]) were more highly 
expressed in males in the AnCg and DLPFC (Supplementary Table 3-1, 3-2 and 3-3). 
Together these findings suggest that sex differences in tissue-specific gene expression 
extend from sex hormones and into genes that regulate gene expression and translation. 
Furthermore, our findings of sex bias in genes that encode for histones and histone 
modifying enzymes in most tissues suggest the possibility that sex-specific epigenetic 
modifications act on transcription that may result in phenotypic sex differences. 
3.4.6 X-linked sex-biased gene expression  
 
As expected, a majority of X-linked, sex-biased genes were expressed more highly in 
females (Figure 3-4), with the exception of those in the AnCg in which 75% were more 
abundantly expressed in males. The mechanism by which genes on the single copy X 
chromosome in males could be expressed more highly than in females with two copies is 
obviously likely to be associated with XCI but another mechanism is likely to be active 
and requires investigation. Although we do report Y chromosome genes in our analysis 
(Table 3-2, Supplementary Table 3-1), we do not consider these genes as differentially 
expressed between sexes, since females do not have a Y chromosome. We do, however, 
consider the reported Y chromosome genes as detectable in the analysed tissues and act 
as a positive control and these genes may have potential roles in the male phenotype in 
these tissues. Many X-linked genes that were expressed more highly in females have 
been previously reported to escape XCI [77]. Not surprisingly, we consistently found 
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XIST and JPX (genes that orchestrate XCI [78, 79]) to be expressed more highly in 
females and interestingly, many sex-biased X-linked genes that are known to regulate 
gene expression have been defined previously [80]. For example, we found KDM6A 
(Figure 3-5), a gene that regulates chromatin modifications, to be expressed more highly 
in females in the liver, lung, DLPFC, NC, AMY, FC, bladder and CB. In addition, forest 
plots (Figure 3-5) demonstrate consistency between individual data sets of KDM6A 
expression showing higher expression in females across different tissues. Furthermore, 
we also found KDM5C to be expressed more highly in females in the lung, FC, bladder 
and CB. Genes that are involved in post transcriptional processes and more highly 
expressed in females in the liver, thyroid, FC and CB, include ZRSR2, DDX3X which 
are involved in alternative splicing. In addition, we also found translation regulators 
EIF1AX and RPS4X, to be expressed more highly in females in the lung, pancreas, HC 
and colon.  
Across all tissues, we found a total of 86 different genes on the X chromosome to be 
more highly expressed in males in at least one tissue. 22 of the 86 X chromosome genes 
more highly expressed in males have homologous counterparts on the Y chromosome and 
are located within pseudoautosomal region 1 (PAR1) [81], which may explain the 
differences in expression. However, not all X chromosome genes that were expressed 
more highly in males were within PAR1 or had homologous Y chromosome counterparts, 
such as SMARCA2, an ATPase and chromatin re-modeller [82]. These findings suggest 
that X-linked sex-biased genes may potentially regulate autosomal gene expression such 







Figure 3-4: X-linked sex-biased gene expression. 
The total number of genes located on the X chromosome that were expressed more highly in females (pink) and males (blue) 




Figure 3-5: Forest plots of the standardised mean difference of KDM6A expression. 
Showing higher expression in females in the liver (A), lung (B), CB (C) and DLPFC (D). Each blue box is representative of the study 




3.4.7 Enriched transcription factors  
 
We next investigated which transcription factors (TFs) were enriched in the sex-biased 
genes by running a TF binding site (TFBS) enrichment analysis using oPOSSUM-3 and 
the JASPAR core motifs [31, 36]. Both the Sry-related HMG box (SOX) and the 
Forkhead-box (FOX) family of TFs were enriched within 10kb of the transcription start 
site (TSS) of sex-biased genes across all tissues (Supplementary Table 3-5). The SOX 
TFs are vital for sex determination [83] and the FOX TFs are essential for embryonic 
development and also have roles in regulating the immune system [84-86]. Sex 
chromosome derived TFs such as ZFX and SRY were also enriched within 10kb of the 
TSS. We also found the androgen receptor (AR) as an enriched TF within the AMY, CB, 
FC, bladder, and lung. In addition, HNF1A and HNF1B were enriched in genes 
upregulated in both males and females within all tissues apart from the NC and DLPFC. 
HNF1A and HNF1B are homeobox TFs that are required for expression of specific liver 
genes [87]. These findings reveal TFs that may have important roles in regulating 
sexually dimorphic gene expression such as HNF1A and HNF1B, which as mentioned 
earlier have only previously been shown to be required for expression of specific liver 
genes [87]. However, the genes that encode for the majority of the TFs that were enriched 
within sex-biased genes were not themselves differentially expressed between the sexes. 
Although in this study we focus on gene expression, TFs undergo more processing post 
transcription and therefore their protein abundance within tissues may differ between 
sexes.  
3.4.8 Sex differences in other tissues  
 
In this study we have analysed sex-biased gene expression in 15 human tissues. However, 
we must acknowledge other studies that have also analysed sex-biased gene expression. 
One of the largest studies that has analysed sex-biased gene expression is the Genotype-
Tissue Expression (GTEx) project [88]. The GTEx project has used RNA-seq to analyse 
gene expression in a variety of different human tissues which would give a broader 
comparison of gene expression differences between tissues. In comparison to GTEx [88] 
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we have analysed sex-biased gene expression in 5 of the same human tissues which is 
represented as a Venn diagram (Supplementary Figure 3-1). We found an overlap of sex 
chromosome genes as being sex-biased between this study and GTEx. However, there 
were many genes that we found to be sex-biased that were not in GTEx [88]. A possible 
explanation for the difference between studies is that in GTEx only samples from175 
individuals were used [88] as opposed to over 2500 in this study which provides much 
greater statistical power compared to GTEx [88]. In addition, GTEx also used RNA-seq 
and were therefore able to quantify the expression of genes for which no probes were 
available in the microarrays used in this study.  
3.4.9 Bias of male samples   
 
To prevent any biases in our analyses we have performed differential gene expression in 
tissues from all publicly available data to our knowledge. However, since most studies 
neglect to account for samples sex [7, 8], we unfortunately had a ratio of 2.1:1 males to 
females on average across all tissues analysed. Therefore, this in itself may create some 
biases in our analyses. Across all data sets (Table 3-1) the ratio of males to females was 
skewed towards males apart from one data set containing thyroid samples (GSE33630), 
where the ratio was 2.5 females for every male.  
To determine if the ratio of males to females affects the differential expression analyses 
we conducted a 10-fold cross validation of the differential gene expression analyses in 
the tissue where the ratio of males to females was the greatest. The AMY gene expression 
data had a ratio of 4.5 males to every female. In this analysis we randomly removed male 
samples from the analysis to make the number of each sex the same and then assessed 
which genes were differentially expressed between males and females. We performed 
this analysis 10 times and then compared which genes were consistently identified as sex-
biased to our original analysis where we did not sub-set any male samples. In the analysis 
with the sex chromosomes included we found the sex chromosome genes (XIST, 
RPS4Y1, DDX3Y, KDM5D, USP9Y, EIF1AY and TTTY15) consistently classified as 
sex-biased in the 10-fold cross validation. However, in the original analysis we identified 
4 autosomal genes to be sex-biased and upregulated in females (Supplementary Table 3-
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1). However, these 4 autosomal genes were not found to be sex-biased in the 10-fold 
cross validation. By performing the 10 fold cross validation, we removed samples which 
would have decreased our statistical power and therefore increased the magnitude of the 
adjusted p-value which is what occurred. Therefore caution should be taken when 
interpreting the results of genes that were found to be sex-biased with an adjusted p-value 
close to 0.05 and in tissues where there is a large ratio of males to females. However, this 
analysis does provide reassurance that the sex chromosome genes that were found to be 
sex-biased in the original analysis were not greatly affected by the bias in male samples.  
3.4.10 Strengths and limitations  
 
While our analyses reveal many sex differences in gene expression within a variety of 
tissues, there are several limitations to this study. Firstly, most tissues (where age was 
provided) were from individuals who were post reproductive age (average age = 47 
years) which may not have captured the true extent of sex-biased gene expression that 
would otherwise be evident during early adulthood when sex hormones are at their peak 
production. Thus, using data from older individuals limited our ability to assess sex-
biased gene expression in individuals of reproductive age. We also report a number of 
genes previously associated with diseases and disorders that were differentially expressed 
between sexes. RNA expression differences do not necessarily cause phenotypic 
variation, as there are multiple levels of gene and protein regulation that can occur post 
transcription. Next-generation sequencing, as opposed to microarrays used in this study, 
would allow a more complete assessment of sex-dependent gene expression differences 
but there is currently more samples that have been analysed using microarrays and 
therefore more statistical power can be achieved. Furthermore, on average, 64% of genes 
differentially expressed between sexes in each tissue had a magnitude log2FC < 1. Most 
genes that were found to be sex-biased do not have large log2FC apart from genes 
located on the sex chromosomes. In addition, most genes that were found to be sex-
biased across all tissues had a magnitude log2FC < 1.5 (Supplementary Table 3-7). 
Therefore, future studies would need to be adequately powered to replicate our findings. 
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Despite these limitations, to our knowledge this is the largest analysis of sex differences 
in gene expression across a range of human tissues. 
Despite the large amount of genomic data that was available for this study it was 
unfortunate not to consider clinical and lifestyle factors such as age, smoking status, 
sample heterogeneity and body mass index (BMI) which may potentially have an effect 
on gene expression. We were unable to correct for these potential confounding factors 
because, as detailed in Supplementary Table 3-6, most studies provide little or no clinical 
information about the samples. Furthermore, only 32% of all the samples analysed in this 
study were from females which may potentially create a bias for genes to be more highly 
expressed in males. However, by acknowledging this limitation we draw attention to the 
bias towards using only males in biomedical research. We therefore urge future research 
in all fields of biomedical science to use an equal sex ratio in study design.  
3.5 Conclusions  
 
Our analyses have revealed substantial differences in the transcriptional landscape 
between sexes across a range of human organs and tissues and highlight possible 
mechanisms by which gene expression may contribute to sexually dimorphic traits. 
Improved understanding of these is fundamental to understanding diseases with different 
prevalence between the sexes. Our data show that sex differences in gene expression vary 
widely across different tissues. We identified a consistent trend for genes known to 
regulate the immune system to be more highly expressed in females and those involved in 
energy production and growth were more highly expressed in males. These may be the 
result of different evolutionary pressures between the sexes. The brain demonstrates the 
largest differences in sex-biased gene expression with several sex-biased genes associated 
with specific brain disorders, providing insight into possible mechanisms for the 
association of sex-specific prevalence of certain brain disorders.  
 
Our findings also indicate that many sex biased genes within tissues are independent of 
sex chromosome genes or sex hormones. Approximately 32% of autosomal genes in each 
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tissue contained an ARE or ERE, which suggests there are other mechanisms that 
underpin sex differences in gene expression. One potential mechanism is through 
epigenetic factors, such as chromatin modelling which has been suggested to have sex 
specific functional roles [89].  
 
Finally, our data demonstrate why it is important to consider sex as a biological 
confounder in biomedical studies. Future studies should incorporate sex differences in 
their analyses which will help to provide new insights in health and disease. The sex-
biased genes identified in this study provide a basis for determining the mechanism by 
which sexual dimorphism occurs and potential causal pathways for sexually biased 
disease susceptibility. More importantly however, they provide potential targets for novel 
sex specific treatments. 
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For Supplementary Table 3-1, 3-2, 3-3, 3-4, and 3-5 please refer to the electronic 
supporting information. 
Supplementary Table 3-1: Differential gene expression analysis between males and 
females in each tissue, including the sex chromosomes. 
A list of differentially expressed genes between sexes in each tissue with all the 
chromosomes included in the analysis. A fold change > 0 indicates the gene is expressed 




Supplementary Table 3-2: Differential gene expression analysis results with genes on 
the Y chromosome removed from the analysis. 
A list of sex-biased genes with the Y chromosome genes removed from the analysis. A 
fold change > 0 indicates the gene is expressed more highly in males and a fold change < 
0 indicates the gene is expressed more highly in females. 
Supplementary Table 3-3: Differential gene expression analysis results with genes on 
the X and Y chromosomes removed from the analysis. 
A list of sex-biased genes with the sex chromosome genes removed from the analysis. A 
fold change > 0 indicates the gene is expressed more highly in males and a fold change < 
0 indicates the gene is expressed more highly in females. 
Supplementary Table 3-4: Gene ontology results. 
This table lists all the GO terms that were found to be enriched within each tissue. Only 
significant GO terms were found for the NC, AnCg and HC. 
Supplementary Table 3-5: Transcription factors that were found to contain enriched 
motifs with 10kb of the transcription start site of sex-biased genes in each tissue. 







Supplementary Table 3-6: Clinical and lifestyle factors supplied by each data set. 
A table representing which data set supplied sample information such as age, ethnicity, sex, smoking status and disease status. 
GEO Accession  Organ/Tissue Age Ethnicity Smoking BMI RIN Sex Batches Diseases Contact Country 
GSE10072 Lung Yes NS Yes NS NS Yes NA Cancer USA 
GSE11512 Brain Yes NS NS NS NS Yes NA NA Germany 
GSE13507 Bladder NS NS NS NS NS NS NA Cancer South Korea 
GSE15471 Pancreas NS NS NS NS NS NS NA Cancer Romania 
GSE18995 Liver NS NS NS NS NS NS NA NA South Korea 
GSE23649 Liver NS NS NS NS NS NS NA NA Spain 
GSE26887 Heart Yes NS NS NS NS Yes NA Diabetes  Italy 
GSE33630 Thyroid  NS NS NS NS NS NS NS Cancer Brussels 
GSE36192 Brain NS NS NS NS NS NS Yes NA Bethesda 
GSE38941 Liver NS NS NS NS NS NS NA HBV USA 
GSE41328 Colon NS NS NS NS NS NS NA Cancer USA 
GSE43974 Kidney NS NS NS NS NS NS NA NA Netherlands 
GSE44456 Brain  Yes NS Yes NS NS Yes Yes Cirrhosis USA 
GSE45642 Brain NS NS NS NS NS NS Yes NA USA 
GSE50892 Kidney Yes Yes NS NS NS NS NA Cirrhosis USA 
GSE51024 Lung NS NS NS NS NS NS NA Cancer USA 
GSE54572 Brain NS NS NS NS NS NS NA NA USA 
GSE55231 Heart Yes NS NS NS NS Yes NA NA Netherlands 
GSE57338 Heart Yes NS NS NS NS Yes NA Heart Failure USA 
GSE61276 Liver NS NS NS NS NS NS Yes Cancer Estonia 
GSE65144 Thyroid  NS NS NS NS NS NS NA Cancer USA 
GSE8671 Colon NS NS NS NS NS NS NA Cancer Switzerland 




Supplementary Table 3-7: Total number of sex-biased genes at different log¬2¬FC cut-offs.  
A table listing the total number of genes that were found to be sex-biased in each tissue at different log2FC cut-offs. This analysis was 
performed with the sex chromosomes included.  
 Magnitude Log2FC cut-offs 
Tissue No Cut off FC > 0.5 FC > 1 FC > 1.5 FC > 2 
Bladder 16 13 10 7 6 
Brain (Nucleus Accumbens) 264 55 9 4 4 
Brain (Amygdala) 17 12 6 4 3 
Brain (Cerebellum) 98 32 20 12 8 
Brain (Anterior Cingulate Cortex) 1818 1281 54 10 0 
Brain (Dorsolateral Prefrontal Cortex) 198 98 7 4 3 
Brain (Frontal Cortex) 45 45 45 45 45 
Brain (Hippocampus) 205 168 43 12 7 
Colon 218 218 175 125 106 
Heart 375 251 31 7 2 
Kidney 224 59 4 4 3 
Liver 32 29 12 5 2 
Lung 36 33 19 9 4 
Pancreas 22 19 13 11 10 
Thyroid 163 162 85 45 27 






Supplementary Figure 3-1: Venn diagrams representing the overlap of defined sex-biased genes between this study and a previous 
study. 




Supplementary File 3-1: Detailed methodology. A description of the precise methods 
used involved in data collection, data processing, normalisation, batch correction and 
differential expression. 
Overview  
In this additional file we supply more detail on the precise methods used to conduct our 
gene expression meta-analysis.  
Data collection 
Initially, we searched the Gene Expression Omnibus (GEO) [1] and ArrayExpress [2] for 
microarray data sets containing human tissues from healthy individuals. We identified 22 
microarray data sets containing 15 different human tissues from 9 different organs. 
Unfortunately, we were unable to consider lifestyle and clinical factors such as smoking, 
body mass index (BMI), age and ethnicity since most data sets did not supply any of this 
information (Supplementary Table 3-6). We accept not being able to correct for these 
factors is a limitation of our study. However, despite the enormous generosity of the 
researchers who had made their data publicly available we think researchers should be 
encouraged to collect and supply clinical data with future genomic data sets. Despite a 
lack of clinical and lifestyle data on individual samples we were able to select samples 
from data sets where the individual did not have any cancerous tissue in their body. For 
example, in the data set GSE61276, there were liver tissue samples from fetuses, adult 
liver tissues from individuals who had met accidental death and liver tissue from 
individuals who had malignant tumours. Therefore, we selected only adult liver tissue 
samples from individuals who had met accidental death. Although the precise details of 
death and other clinical details of each individual in GSE61276 is unknown to the public, 
by removing samples from individuals who had malignancies reduced the potential for 
confounders in our differential expression analyses. In addition and as stated in our 
manuscript we chose data sets that had more than 10 samples for better sample sex 





Data processing and normalisation 
The 22 microarray data sets used in this study used either an Affymetrix or Illumina 
platform and the pre-processing and normalisation for each platform was tailored by 
using a variety of Bioconductor packages (http://bioconductor.org/). For studies that used 
Affymetrix platforms, we firstly downloaded the individual .CEL files from GEO and 
used simpleaffy [3] to generate a matrix of normalised expression values for each 
individual data sets. In studies that had used Illumina platforms, we used beadarray [4] 
which too generated a matrix of normalised expression values for data sets using Illumina 
platforms.  
 
As detailed in Supplementary Table 3-6, 4 of the 22 data sets contained data obtained in 
batches. To correct for these batch effects in these three individual data sets we used the 
Combat function in the SVA package [5].  
Differential expression analyses 
Differential expression analysis between males and females was performed 
independently in each tissue. Depending on the number of data sets used in each tissue 
we used either one of two methods to identify sex-biased genes. 
For tissues such as the bladder, where there was only one available data set we used the 
Empirical Bayes method that is described within the limma package [6]. For tissues such 
as the heart, where we had more than one data set containing the tissue we used 
metaGEM package (https://spiral.imperial.ac.uk/handle/10044/1/4217) and used the 
inverse–variance method as previously described [7]. We chose the metaGEM approach 
with tissues with more than one data set since the data set have used different microarray 
platforms. In other words, since each microarray platform has used different probes to 
annotate for gene expression, their expression values cannot be grouped together. 
Furthermore, using this approach allows for correction of the data set size using Hedges’ 
g. Using this approach allows the use of more samples that have been analysed on 




One of the limitations of using these two approaches is that the magnitude difference in 
gene expression between males and females is not necessarily interchangeable. To 
overcome this limitation, one approach would be to use a single platform to measure gene 
expression such as RNA sequencing. However, there are currently many more publicly 
available samples that have been analysed by microarrays than by RNA-seq. We 
therefore focused on using microarrays in this study to maximise the statistical power of 
our analyses. 
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RNAs using deeply sequenced RNA-seq from first trimester, term and 
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Abstract  
The placenta is the most poorly understood organ within the human body, however its critical role in pregnancy is 
unquestionable. Most studies that have focused on human placental gene expression have done so at term (≥ 37 weeks’ 
gestation). This makes it difficult to infer gene expression characteristics of the placenta during its development. Moreover, 
placental expression studies have previously mainly focused on protein-coding genes and known annotated transcripts that 
have previously been identified. Due to the lack of high-throughput sequencing data carried out on the placenta compared to 
other tissues, there are still undiscovered “novel” transcripts that may play a crucial role in placental development, and in turn, 
have an immediate and life-long impact on the health of both mother and baby. In this study, we performed RNA sequencing 
(RNA-seq) on placental tissue samples from first trimester (n=30), uncomplicated term (n=22) and preeclamptic pregnancies 
(n=18) to characterise gene expression across gestation and in preeclampsia pathology. Unsupervised clustering revealed 
distinctively different transcriptomes across gestation time points, with genes expressed during first trimester being enriched 
for cancer related genes and cell growth, whereas placentas from uncomplicated term pregnancies were enriched for genes 
relating to inflammation processes. In addition, placentas from preeclamptic pregnancies were enriched for genes relating to 
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angiogenesis compared to those from uncomplicated term pregnancies. We also performed a de novo transcript analysis which 
identified 23 large intergenic non-coding RNAs (lincRNAs). The specific splice variants of these transcripts have not 
previously been annotated in any non-coding RNA databases. By comparing these transcripts with RNA-seq data from the 
NIH Epigenomics Roadmap, we were able to conclude these lincRNAs were placental tissue specific. Moreover, we compared 
these transcripts to novel lncRNAs in the FANTOM5 project and found 9 to overlap. However, these 9 transcripts were found 
to have splice variants variations specific to the placenta. Furthermore, 4 were found to be exclusively expressed during first 
trimester and 1 at term, 14 were differentially expressed across gestation, and 13 in placentas from preeclamptic pregnancies 
compared to those from uncomplicated term pregnancies. These analyses suggest these transcripts may potentially have roles 
in placental development and in preeclampsia. The identification of novel placental specific transcripts highlights the need for 
further research to completely characterise the placental gene expression profile and that unannotated genes within the placenta 
may potentially become targets of future research into pregnancy complications.  
4.1 Introduction 
 
The placenta remains the most poorly understood organ in the human body [1]. Although it has a short existence, it carries the 
task of providing protection from the maternal immune system, proper development to the growing fetus and the exchange of 
nutrients, gases and wastes. Impaired implantation and early placental morphogenesis during the early stages of development 
can lead to an increased risk of pregnancy complications such as preeclampsia (PE), preterm birth (PTB), fetal growth 
restriction (FGR) and miscarriage [2].  Many studies have established a disruption of normal placental gene expression in 
pregnancy complications [3-7]. However, these studies have been focused predominantly on placentas from term pregnancies.  
Genome wide transcriptome analysis of the first trimester placenta has only been conducted by microarray studies [8, 9]. These 
have focused on differential gene expression analyses between gestational time points [8, 9]. It is worth mentioning that 
differential gene expression (36 genes) has been detected in placentas (10-12 weeks’ gestation) from pregnant women who 
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were destined to develop PE compared to normal pregnancies [8]. Unfortunately, due to low sample sizes (4 PE, 8 controls), it  
is unlikely that the true extent of differentially expressed genes was captured. Furthermore, studies using RNA sequencing 
(RNA-seq) of placental tissue have also been limited to pregnancies at term or in late third trimester [3, 4, 10-12]. In addition, 
there are no reports that examine gene expression differences between first trimester and term pregnancies using a higher order 
systems level perspective such as a co-expression analysis. Moreover, RNA-seq studies have not sequenced deeply enough to 
detect many non-coding RNAs. For example, a recent RNA-seq study on placental tissue sequenced to an average depth of 
22.3 million reads per sample [3]. However, other projects such as that from the FANTOM5 consortium have sequenced to a 
depth of approximately 200 million reads per sample in other human tissues, but not in the placenta [13]. Sequencing depth is 
important as deep sequencing is required to detect the expression of lowly expressed genes.  
In this study, we used RNA sequencing (RNA-seq) to assemble the transcriptome of 30 first trimester, 22 term and 18 
preeclamptic placentas. Our analyses identify distinct transcriptomes in placentas from first trimester, term and preeclamptic 
pregnancies. Furthermore, we have also identified novel large intergenic non-coding RNAs (lincRNA) specific to the human 
placenta.  
4.2 Methods 
4.2.1 Ethics statement 
 
Written, informed consent was obtained from all patients prior to collection of placental tissue. First trimester placental t issue 
was collected from women undergoing elective terminations of pregnancy at the Women’s and Children’s Hospital North 
Adelaide, whereas term placental tissue samples were collected after delivery at the Lyell McEwin Hospital, South Australia. 
Collection of first trimester placental tissue was approved by the Women’s and Children’s Health Network Human Research 
Ethics Committee (REC2249/2/13) and the University of Adelaide Human Research Ethics Committee (H-137-2006). 
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Collection of term placental tissue was approved by the Queen Elizabeth Hospital and Lyell McEwin Hospital Human 
Research Ethics Committee (REC 1712/5/2008 and HREC/12/TQEHLMH/16). 
4.2.2 RNA extraction and sequencing  
 
First trimester placental villous tissue was collected from women who were undergoing elective termination (6-11 weeks’ 
gestation). Placental villous tissue from both uncomplicated term and preeclamptic pregnancies were from either elective 
caesareans or vaginal deliveries (37-42 weeks’ gestation). Placental villous tissues were incubated in RNAlater solution 
(Invitrogen) at 4˚C for 24 h prior to being stored at -80˚C. RNA was extracted from each placental villous tissue using TRIzol 
following the manufacturer’s protocols. Sequencing libraries were prepared using Illumina TruSeq Stranded Total RNA 
Sample Preparation kits and all the ribosomal RNA was depleted using Ribo-Zero Gold. Sequencing was performed on the 
Illumina Hi-Seq 2500 using a 100bp pair-end protocol at the Queensland Brain Institute and at the Australian Cancer Genomic 
Facility in Adelaide.  
4.2.3 Differential expression and co-expression analyses 
 
Sequence adapters were trimmed from the fastq files using AdapterRemoval [14]. The trimmed RNA-seq reads were aligned to 
the human genome (UCSC hg38) using Bowtie 2 v2.1.0 and TopHat v2.0.9 [15]. Aligned read counts for each gene were 
determined using HTSeq v0.6.0 [16] with UCSC hg38 annotation. All differential expression analyses were performed using 
edgeR [17] and genes were considered significantly different if the false discovery rate (FDR) < 0.05. WGCNA was performed 
on all placental tissue samples with all expressed genes using the standard method as previously described [18, 19].  




For de novo transcript discovery, we used cufflinks v2.1.1. We selected the top 1% of highly expressed transcripts identified 
by cufflinks for further validation to reduce the possibility of falsely predicted transcripts. To determine if these transcripts 
have been previously annotated we compared the transcripts to three additional long non-coding RNA (lncRNA) databases 
(NONCODE [20], LNCipedia [21] and Gencode 25 [22]) using cuffcompare v2.1.1. As an additional in silico validation we 
used CPAT [23] to determine the coding potential of the novel transcripts. We also compared our analysis to the most recent 
FANTOM5 cap analysis [13] which contains data for novel lncRNAs. Overlap between FANTOM5 data and potential novel 
transcripts found in this study was compared using intersectBed function in BEDTools [24].  
4.2.5 Gene Ontology   
 
Genes that were upregulated in a group and gene lists for each module were tested for GO enrichment using DAVID [25]. The 
genes were compared to all human genes with the DAVID database. 
4.3 Results  
4.3.1 RNA-Seq data set  
 
We performed RNA-seq (Illumina Hi-Seq 2500) on a total of 70 placentas from first trimester (n=30), uncomplicated term (n=22) and preeclamptic 
pregnancies (n=18) (Table 4-1). On average, 40.3 million 100-base pair, paired-end reads were aligned to the human genome (UCSC, hg38) with an 
alignment rate of 91.2%. This is approximately double the sequencing depth of a recent RNA-seq study on placental tissue [3]. This gives this study increased 
sensitivity to detect the expression of non-coding RNAs. The NIH Epigenomics Roadmap RNA-seq data generated on average between 30-50 million reads per 
sample [26] which is comparable to this study. This enables comparison of gene expression profiles between placenta and other human tissues. Furthermore, 
this also makes it a well suited comparison to determine the expression profiles of any potential novel transcripts found in this study. Genes with an expression 
of < 1 count per million (CPM) were removed from the analysis leaving a total of 16,481 genes from UCSC hg38 annotation. No statically significant 
differences were found in gestational age of delivery, birth length or birth weight between the uncomplicated term and preeclamptic pregnancy groups. 
 
Table 4-1: Clinical characteristics of the participants in the study.  
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  First Trimester Uncomplicated Term Preeclampsia 
N 30 22 18 
Maternal Age (years) NA 23 23 
Average Gestation at collection (weeks)  
(mean, range) 
8.4 (6-11) 40.5 (37-42) 38.6 (37-42) 
Fetal Sex (F/M) 15/15 11/11 9/9 
Birth Weight (g) 
(mean ± SD)  
NA 3573 ± 377  3005 ± 647 
Birth Length (cm) 
(mean ± SD) 
NA 50 ± 2 47 ± 3  
NA =not available 
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4.3.2 Clinical comparisons 
 
In order to address potential confounding clinical variables we performed differential 
expression analyses between different clinical outcomes. Unfortunately, clinical details of 
women who were undergoing elective terminations were unavailable for this study. 
Therefore clinical comparisons were performed using placentas from term pregnancies 
where clinical details were ethically obtained. Previous studies have identified large sex 
differences in gene expression in human tissues [27] including the placenta [28]. In this 
study, we had a ratio of 1:1 males to females in all groups. This was done on purpose to 
reduce to any potential sex differences. We performed differential expression analyses 
between sexes in each group and only detected differentially expressed X and Y 
chromosome genes. Here we do not consider the Y chromosome genes as differentially 
expressed but included them in our analysis to determine if our analyses were correct. We 
found all differentially expressed Y chromosome genes to be upregulated in placentas 
from male fetuses. In comparison to a meta-analysis study which contained 303 samples 
from microarray studies [28], we did not detect large sex differences on autosomes. The 
only genes found to be differentially expressed between sexes were on the sex 
chromosomes such as UTY, a gene found on the Y chromosome. We also found XIST, 
KDM5C, which are on the X chromosome and were found to be upregulated in placentas 
from females in agreement with our previous study [28].  However, as suggested in a 
previous study [3], the lack of observable sex differences in gene expression was most 
likely the result of low sample sizes.  
 
In our uncomplicated term pregnancy group, we tested for differential expression 
between the delivery modes (vaginal/caesarean section). During a vaginal birth the 
placenta can be hypoxic for a long period of time due to uterine contractions and time to 
delivery after detachment from the uterus which can result in gene expression changes 
compared to elective caesarean delivery [29]. However, we detected no significant 
differentially expressed genes between groups even at a relaxed threshold (FDR < 0.1). 
We also tested for gestational age differences in the first trimester group by splitting the 
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samples into either early (6-8 weeks, n=19) or late (10-11 weeks, n=10) gestation, 
however we detected no significantly differentially expressed genes between the groups. 
Rapid placental development and growth occurs during these weeks of gestation and 
what occurs early on in gestation may have implications later on in pregnancy. A 
limitation of this study is that the outcome of pregnancy for placentas collected during 
first trimester is unknown. This therefore may be a confounding factor within our 
analyses and may contribute to why no gene expression differences were observed 
between early and late first trimester. Our data suggest that clinical confounding factors 
such as fetal sex, mode of delivery and gestation differences during first trimester do not 
have a significant effect on gene expression. 
4.3.3 Placental gene expression across gestation 
 
Differential expression analyses were conducted between all three gestation and outcome 
groups in order to determine differences across gestation and to determine the extent of 
disrupted placental gene expression in PE. Since maternal age was available for the first 
trimester group we were unable to account for this in our analyses. This is a limitation of 
the study as this group may have been potential difference in age between the other 
groups. We firstly conducted our differential gene expression analysis between placentas 
from first trimester and uncomplicated term pregnancies. We detected differential 
expression of 7240 genes (FDR < 0.01) between first trimester and term using UCSC 





Figure 4-1: Differential placental gene expression of genes that encode for circulating maternal factors. 
A. A volcano plot showing genes which were upregulated during first trimester (red dots) or at term (blue dots) in the placenta. B. 
Differential placental gene expression that encode for circulating maternal factors.  
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Since the placenta secretes factors such as proteins and hormones into the maternal 
bloodstream, we took a closer look at genes that encode proteins and hormones that are 
known to circulate in maternal blood to determine if their expression levels correlate with 
what is observed in the maternal blood. We found genes that encode for subunits for 
proteins such the beta subunit of luteinizing hormone (LH) and β-human chorionic 
gonadotrophin (β-hCG) which were LHB and CGB respectively. These genes were found 
to be more highly expressed during first trimester (Figure 4-1). This matches what is 
known to occur in the maternal blood where levels of β-hCG are known to decline across 
gestation [30]. Furthermore, we found placental lactogen (CSH1) and pregnancy 
associated plasma protein A (PAPPA) to be more highly expressed in placentas from 
uncomplicated term pregnancies compared to first trimester (Figure 4-1). Circulating 
levels of CSH1 [31] and PAPPA [32] in maternal blood are known to increase during 
gestation. Therefore, our placental gene expression data matches the published protein 
levels found in maternal blood. This provided confidence in the validity of our analyses.  
 
The first trimester placental gene expression profile was distinctly different compared to the 
uncomplicated term and PE groups (Figure 4-2A). We detected a total of 7240 differentially 
expressed genes (FDR < 0.01) between first trimester (3481 upregulated) and term (3759 
upregulated) but chose to focus on a subset of 703 genes (FDR < 0.01) with magnitude log2FC > 
2 (Figure 4-2B), for downstream analyses such as GO term enrichment. We found 321 and 382 
of these genes to be more highly expressed in placentas during first trimester and uncomplicated 
term pregnancies, respectively, compared to placentas from preeclamptic pregnancies. Genes 
upregulated in first trimester were enriched for GO terms such as mitosis (GO:0007067) and M 
phase (GO:0000279) similar to a cancer-like expression profile which has previously been 
shown [33]. For example, we found KIFC1, a kinesin motor protein which is associated with 
cancer [34, 35], to be upregulated in placentas from first trimester compared to uncomplicated 
term pregnancies (Supplementary Table 4-1).  Conversely, genes upregulated at term were 
enriched for GO terms involved in inflammation such as the inflammatory response 
(GO:0006954) and response to wounding (GO:0009611). Some of these genes included IDO2 
(Figure 4-2B, Supplementary Table 4-1) a gene associated with a pro-inflammatory response 
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[36, 37] which was found to be upregulated in placentas from term uncomplicated pregnancies 
compared to first trimester placenta. This analysis is consistent with the first trimester placenta 
being highly proliferative. However, it does suggest that term placentas are associated with a 
pro-inflammatory response. The pro-inflammatory profile from uncomplicated term pregnancies 
may be the result of the fact that these placentas have undergone stress during labour. This stress 
would result in an increase in hypoxia which may cause an increase in expression of genes 
relating to inflammatory processes. The uncomplicated term group was a mix of placentas from 
both labour and non-laboured pregnancies and which may have implications for this analysis. 
However, as detail prior in the previous section no differences were found in gene expression 






Figure 4-2: Differential gene expression analyses. 
A. Principal component analysis of placental transcriptome. First trimester samples are represented by red circles, term uncomplicated 
samples by green triangles and preeclamptic samples with blue squares. B. Venn diagram showing the top significantly differentially 
expressed genes from the different placenta group comparisons.
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4.3.4 Disruption of placental gene expression in preeclamptic pregnancies 
 
Preeclampsia is a pregnancy complication characterised by high maternal blood pressure 
(> 140/90 mmHg) and proteinuria (24 hour, >0.3g) [38-40]. Previous studies have found 
that placental gene expression is disrupted in PE compared to uncomplicated term 
pregnancies [3, 4, 7]. However, no study to date has compared global placental gene 
expression between first trimester and preeclamptic pregnancies. Since the first trimester 
placenta grows and differentiates in a hypoxic environment until maternal blood flow is 
established to it beginning at 10-12 weeks’ gestation and the PE placenta is thought to be 
hypoxic, it may be that the PE placenta is more similar to the first trimester placenta than 
to that from uncomplicated pregnancies. Furthermore, inadequate spiral artery modelling 
can result in inconsistent oxygen levels which can induce oxidative stress in PE.  
 
 
We also compared placentas from PE and term uncomplicated pregnancies and found 
4074 genes to be differentially expressed (FDR < 0.01) (Supplementary Table 4-3). We 
found 2267 and 1807 of these genes to be upregulated in placentas from uncomplicated 
term pregnancies and preeclamptic pregnancies, respectively. Some of these genes 
included a micro RNA precursor transcript (miRNA-7393-2) (Figure 4-2B) which 
suggests a disruption in ncRNA genes in PE. Overall we found genes upregulated in 
uncomplicated term compared to PE placentas to be enriched for genes relating to 
nucleotide binding (GO:0000166) and ATP binding (GO:0005524). These GO terms are 
consistent with the pathology of PE where an increase of oxidative stress can disrupt 
energy production.  
 
We found 8780 genes (FDR < 0.01) to be differentially expressed between first trimester 
(5106 upregulated) and PE (3674 upregulated) (Supplementary Table 4-2). Again, we 
chose to focus on a subset of 737 genes (FDR < 0.01, magnitude log2FC > 2) (Figure 4-
2B). 524 of the 737 genes overlapped with the analysis between first trimester and 
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uncomplicated term. This suggests a strong difference in placental gene expression across 
gestation which is maintained irrespective of the later gestation diagnosis of preeclampsia 
or uncomplicated pregnancy. More interestingly, 195 genes were found not to overlap 
with the previous comparison and were therefore unique to the first trimester and PE 
comparison (Figure 4-2B). These genes which have been subtracted from the other two 
analyses can be used to determine the true extent of gene expression differences between 
first trimester and PE.  A closer inspection of these genes found that they were related to 
GO terms such as collagen trimer (GO:0005581) and extracellular region (GO:0005576). 
This suggests that there is a difference in genes relating to the cell surface which may be 
highlighting a difference in the gestational time points of the two groups. 
 
Upregulated transcripts in PE placentas were enriched for genes relating to 
mitochondrion (GO:0005739) and generation of precursor metabolites and energy 
(GO:0006091). This suggests there may be a disruption of placental cellular energetics in 
PE. Defects in implantation and placental morphogenesis in early gestation are known to 
increase the risk of preeclampsia and other pregnancy complications [41, 42]. Impaired 
implantation and early placental development may restrict nutrient transfer and placental 
energetics later thereby disrupting placental gene expression. An increase in oxidative 
stress in PE may also explain the upregulation of genes relating to energy production 
processes. PE can develop due to a perfused placenta which can result in an increase of 
factors such as abnormal gene expression. Therefore the upregulation of genes relating to 
mitochondria and energy in PE, may be the result of a perfused placenta. 
4.3.5 Long non-coding RNA expression in the placenta 
 
To date, other studies that have focused on global placental gene expression have done so 
on protein coding genes. However, it is important to acknowledge that there are 
potentially thousands of non-coding RNAs which may be vitally important for proper 
placental development. To date, no such study has performed a de novo transcript 
analysis on placental tissue. This has been due to the lack of RNA-seq studies on 
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placental tissue. Therefore, there is a lack of knowledge surrounding placental lncRNAs 
which may have functions in regulating placental gene expression. 
Here in this study we analysed lncRNA expression in all 3 groups. We used the 
NONCODE [20] data base to analyse expression, which contains genomic data for 
144,157 transcripts. Unfortunately, it does not contain annotated functions for all 
transcripts since this data base has also performed a de novo transcript analysis using 
RNA-seq data. We found 34,717 transcripts to be expressed in the placenta and used 
these genes to perform differential expression analyses. We found 952 transcripts to be 
differentially expressed (FDR < 0.01, magnitude log2FC > 2) between placentas from 
first trimester (447 upregulated) and uncomplicated term (505 upregulated) pregnancies 
(Supplementary Table 4-4). Since there is little knowledge of functions of these 
transcripts in the literature, we accessed the supplied GO terms relating to each transcript 
from the NONCODE data base [20]. The potential functions of these transcripts are 
consistent with the protein coding and more well annotated genes identified above. For 
example, a transcript on chromosome 14 (NONHSAG015923.1) which was upregulated 
in first trimester (Supplementary Table 4-4) compared to term, is associated with GO 
terms such as positive regulation of cell proliferation (GO:0008284). Another transcript 
on chromosome 1 (NONHSAG003845.2) was more highly expressed in placenta from 
uncomplicated term pregnancies compared to first trimester (Supplementary Table 4-4) 
and is associated with the inflammatory response (GO:0006954). Our analysis shows that 
the expression profiles of lncRNA across gestation have similar functions to the protein 
coding genes. Therefore, these transcripts may have roles in regulating placental gene 
expression and development. They may be key regulators of proliferation during first 
trimester and involved in inflammatory processes later on in gestation.  
We also analysed lncRNA expression in placentas from preeclamptic pregnancies. We 
identified 1154 transcripts to be differentially expressed between first trimester (519 
upregulated) and PE (635 upregulated) (Supplementary Table 4-5). Interestingly, 466 of 
these transcripts were also found to be differentially expressed between the first trimester 
and uncomplicated term placentas suggesting that there is a strong difference in 
expression of non-coding RNAs across gestation. This is also consistent with the protein 
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coding and well annotated genes identified above, in that a large number of genes are 
differentially expressed across gestation irrespective of pregnancy outcome. However, we 
also found 688 transcripts differentially expressed between PE and first trimester but not 
with the uncomplicated term group. One of these genes, NONHSAG002977.2, is a 
transcript on chromosome 1 that was found to be more highly expressed in placentas 
from first trimester when compared to preeclamptic placentas (Supplementary Table 4-5). 
However, this transcript was not differentially expressed between first trimester and 
uncomplicated term placenta. This gene is associated with blood vessel remodelling 
(GO:0001974), an essential placental developmental process that proceeds across 
gestation [43] suggesting this gene may have an important role in regulating blood vessel 
development throughout gestation. This analysis highlights how proliferative the placenta 
is during first trimester. Proper spiral artery remodelling is essential for placental 
development and for successful pregnancy outcome. It is therefore not surprising to find 
lncRNAs associated with blood vessel development to be more highly expressed during 
first trimester. However, since it is downregulated in PE when compared to first trimester 
it may suggest impaired blood vessel remodelling in PE. We also compared placentas 
from uncomplicated term and preeclamptic pregnancies and found 248 transcripts to be 
differentially expressed (Supplementary Table 4-6). Of these 248 transcripts 141 were 
found to be uniquely associated with the uncomplicated and PE comparison. 
Furthermore, we found other transcripts including NONHSAG078935.1 and 
NONHSAG093772.1 which are on chromosomes 2 and 6, respectively, also relating to 
blood vessel development to be downregulated in preeclamptic placentas (Supplementary 
Table 4-6). This analysis suggests that there may be poor placental blood vessel 
development in placenta from preeclamptic pregnancies that may be associated with or 
potentially mediated by lncRNAs. 
4.3.6 Identification of novel transcripts specific to the placenta 
 
Since the placental transcriptome is not well characterised, we performed a de novo 
transcript analysis using all 70 samples from our RNA-seq data set. To reduce false 
positives, we selected the most highly expressed predicted novel transcripts (2767 
transcripts) and compared these to three additional non-coding RNA databases 
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(NONCODE [20], LNCipedia [21] and Gencode v25 [22]). Thereby, we identified 26 
transcripts that were not annotated in any of the non-coding RNA databases. We also 
performed an in silico validation of the coding potential of the novel transcripts using 
CPAT. Three of the transcripts were classified as coding and were removed from further 
downstream analyses, which left 23 remaining novel non-coding RNAs (Supplementary 
Table 4-7). These 23 novel non-coding RNAs were all >200nt and were within intergenic 
regions of the genome and therefore would be classified as large intergenic non-coding 
RNAs (lincRNAs).  
 
We further analysed and made use of publicly available RNA-seq data to determine if the 
novel lincRNAs were specific to the placenta. We used RNA-seq data generated from the 
NIH Epigenomics Roadmap Project [26] to determine if the novel lincRNAs were 
expressed in other human tissues or cells. Using the same methods for alignment and 
generation of read counts (refer to methods) we analysed data from 198 RNA-seq 
samples from the NIH Epigenomics Roadmap Project. We did not find expression of any 
of the novel lincRNAs in any other normal human tissue or cell. This analysis suggest 
these transcripts are specific to the human placenta. 
 
We combined the 23 novel lincRNAs with our RNA-seq analysis and conducted 
differential expression analysis to determine if their expression levels alter across 
gestation and/or in PE. 14 novel lincRNAs were differentially expressed between first 
trimester and term. In addition, four of the novel lincRNAs were only expressed during 
first trimester. Moreover, we found one novel lincRNA to be expressed at term but not in 
first trimester. Some of these transcripts were also found to be in potential clusters 
(Figure 4-3). For example, Figure 4-3 shows a potential cluster of novel lincRNAs on 
chromosome 9 which were exclusively expressed during first trimester. A zoomed view 
of this novel lincRNA (Figure 4-3A) shows it is a bi-exonic placental transcript which 
spans 20,501bp which is expressed during first trimester (Figure 4-3B). In addition, we 
confirmed expression of these novel transcripts by qPCR in an independent set of 
placentas (Figure 4-3C). This extra validation verifies that the novel transcripts found in 
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this study do exist and can be detected in other placentas from pregnancies outside of the 





Figure 4-3: A cluster of novel large intergenic non-coding RNAs specific to first trimester placentas on chromosome 9 identified by 
RNA sequencing. 
A. A region of focus on chromosome 9 containing first trimester specific novel large intergenic non-coding RNAs. A bi-exonic 
transcript which is exclusively expressed in first trimester shown by B. RNA sequencing and confirmed by C. qPCR. HPRT is used as 
a reference gene.  
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Since we found a large difference in lncRNA expression in placentas from PE 
pregnancies, we also performed differential expression analyses of the novel lincRNAs in 
placentas from preeclamptic pregnancies. We found 14 of the novel lincRNAs to be 
differentially expressed between placentas from first trimester and PE. Interestingly, 
these 14 novel lincRNAs were also differentially expressed between the first trimester 
and uncomplicated term placenta. This suggests the expression profiles of these 14 novel 
lincRNAs are potentially maintained across gestation irrespective of pregnancy outcome. 
We also found 13 novel lincRNAs to be differentially expressed between placentas from 
uncomplicated term and preeclamptic pregnancies. This suggests there is a disruption of 
their gene expression profiles in PE.  
4.3.7 FANTOM5 comparison  
 
The FANTOM5 project is a consortium that has focused on the identification of novel 
lncRNAs from a diverse range of cell types [13]. This project used RNA-seq to a depth of 
approximately 200 million reads per sample, which is 5 times deeper than the sequencing 
used in this project. Therefore, this is a valuable resource to determine if any of the 
potential novel lincRNAs found in this study are truly placenta specific. Since 
FANTOM5 only contains genomic data for hg19 annotation, for this comparison only, 
we converted the coordinates in our study from hg38 to hg19. Using BEDTools we found 
overlapping genomic coordinates for 9 of the potential 23 novel lincRNAs found in this 
study (Supplementary Table 4-8). Therefore, these 9 lincRNAs that were found to 
overlap in some form may be expressed in other human tissues. Since they were not 
shown to be expressed in any other human tissues in the NIH Epigenomics Roadmap it 
suggests that these lincRNAs are lowly expressed. The NIH Epigenomics Roadmap 
RNA-seq data sequenced to a depth between 30-50 million reads per sample [26], which 
is within the range of that performed in this study. This suggests these 9 lincRNAs that 
overlapped with the FANTOM5 data may be expressed in tissues other than the placenta 
but at a much lower level. This shows the importance of sequencing sufficiently deeply to 




Moreover, as shown in Supplementary Table 4-8, none of the splice variants of the 9 
overlapping lincRNAs were found in the FANTOM5 data. This suggests that these 
transcript splice variants are placenta specific but other splice variants of these genes are 
transcribed in other human tissues. Unfortunately, since these lincRNAs are novel and 
there is currently no functional annotation of these transcripts, it is difficult to draw 
conclusions regarding their role in the placenta. In addition, the overlap between novel 
transcripts in this study and FANTOM5 did not contain the full transcript. For example, 
Figure 4-4 shows the overlap between XLOC_004232 and the first exon of a novel 
lncRNA identified by FANTOM5. However, as shown in Figure 4-4, it is only the 3’ end 
of XLOC_004232 that overlaps with that found in FANTOM5 and the rest of the 
transcript was unique to this study. This was the case with most of the overlaps between 
this study and FANTOM5 (Supplementary Table 4-8) in that it was only a small fraction 
of the transcripts that overlapped. This highlights the novelty of the transcripts identified 





Figure 4-4: Overlap of novel lncRNAs between FANTOM5 and this study. 
The 3’ end of XLOC_004232, a mono-exonic lincRNA found in this study was found to overlap with the first exon of a novel lncRNA 
found in FANTOM5. Note these coordinates have been converted to hg19.
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4.3.8 Characterisation of novel large intergenic non-coding RNAs and co-
expression of lincRNA with other protein-coding genes  
 
Many of the novel lincRNAs identified in this study were either differentially expressed 
across gestation or had an altered expression in placentas from preeclamptic compared to 
uncomplicated pregnancy. Therefore, these transcripts are likely to have unique roles in 
placental development, so we decided to characterise the lincRNAs by in silico analyses 
to provide insight into their biological roles. We firstly determined if the novel lincRNA 
locations overlap with any known disease associated single nucleotide polymorphisms 
(SNPs). We compared the National Human Genome Research Institute (NHGRI) 
Catalogue of disease associated SNPs from Genome-Wide Association Studies (GWAS) 
[44] to the locations of the novel lincRNAs. However, none of these overlapped with any 
of the novel lincRNA locations. We then used GREAT, which is an online tool that 
returns GO terms based on the genomic location and neighbouring genes. However, this 
resulted in no enrichment (FDR < 0.05) for GO terms for any of the 23 lincRNAs. 
Previous studies have commonly used correlation based techniques to determine the 
function of lncRNAs such as co-expression based methods [45-47]. In this study, we used 
a weighted gene co-expression network analysis (WGCNA) [18, 19] which identifies 
modules of genes with similar expression patterns. This method can be a useful strategy 
to identify novel transcripts with a high module membership and to provide insight into 
their possible biological function. Using expression data from all 70 placentas, we 
identified a total of 18 modules (Figure 4-5A). We summarised the overall expression of 
each sample then calculating the first principle component of gene expression in each 
module. GO term enrichment was also performed on each module which simplified 
analyses by summarising genes into GO terms. We found many co-expression modules to 
be differentially expressed across gestation (Figure 4-5B). However, these modules 
mostly contained genes that were found to be differentially expressed in the earlier 
comparisons. For example, modules containing genes relating to mitosis (GO:0007067) 
were found to be differentially expressed between placentas from first trimester and 
uncomplicated term pregnancies. Overall, co-expression analysis reiterated the 
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differential expression analyses. However, the goal of co-expression analysis here was to 





Figure 4-5: Co-expression analysis of the placental transcriptome. 
A. Dendrogram of placental gene expression. Each line represents an individual gene expressed in the placenta and these have been 
grouped into modules. Modules are represented as non-grey colours below the dendrogram. B. Heatmap of the mean eigengene 




Unfortunately, 22 of the 23 novel lincRNAs did not share co-expression patterns with 
other expressed placenta protein-coding genes and therefore were not classified into any of 
the modules. However, one novel lincRNA located on the p-arm of chromosome 7 was 
classified into a module that was enriched for GO terms relating to homophilic cell 
adhesion via plasma membrane adhesion molecules (GO:0007156) and angiogenesis 
(GO:0001525). The transcript was also found to be upregulated in placentas from 
uncomplicated term pregnancies compared to first trimester (Figure 4-5C).  This transcript 




Here we have characterised the expression profiles of both protein- and non-coding genes 
in placentas that were from either first trimester pregnancies or those that had reached term 
and were uncomplicated or preeclamptic pregnancies. We are the first to use RNA-seq on 
first trimester placentas, which have been difficult to sample for experimental and ethical 
reasons. Thus, our study has identified placenta specific novel lincRNAs which likely have 
potential roles in placental development.  
 
We compared placental gene expression between first trimester and uncomplicated term 
pregnancies and found placental gene expression consistent with reported protein levels in 
the maternal circulation. For example, genes within the LHB-CGB cluster on chromosome 
19 were expressed more highly during first trimester compared to term. CGB genes encode 
for βhCG a protein essential for establishment of pregnancy and used as a diagnostic 
marker of pregnancy [30]. β-hCG is found at its highest levels during first trimester [30] 
consistent with placental RNA-seq data showing genes in the LHB-CGB cluster to be 
expressed more highly during first trimester. This was also the case with other genes such 
as that encoding placental lactogen (CSH1). Placental lactogen is a growth hormone gene 
family member in the growth hormone locus on chromosome 17 and is required for 
maternal metabolic adaptation to pregnancy and glucose tolerance to meet fetal energy 
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demand [48]. Maternal blood levels of placental lactogen steadily increase throughout 
gestation, which again matched with our observable gene expression data.  
 
Our differential gene expression analysis indicates that, the first trimester placental 
transcriptome harbours many hallmarks of cancer due to the high number of genes relating 
to proliferation processes compared to term placenta. Not only did we identify genes 
upregulated in first trimester to be enriched for GO terms relating to mitosis, but also many 
genes associated with cancer. For example, INHA, a gene derived from placental 
trophoblast which is a member of the TGF-β superfamily [49, 50] and a marker of ovarian 
cancer [51] was upregulated during first trimester compared to term placenta 
(Supplementary Table 4-1). This analysis suggests that a first trimester placenta is an organ 
of high proliferation which is required for rapid growth for developing fetus. Using genes 
that are commonly seen upregulated in a cancer simply shows the high levels of cell 
growth during the first trimester of pregnancy. 
 
We also performed differential expression analysis on placentas from preeclamptic 
pregnancies and found 524 differentially expressed genes between first trimester and either 
uncomplicated term or preeclamptic pregnancies when compared to (Figure 4-2B). This 
large proportion of genes whose expression is maintained irrespective of pregnancy 
outcome, suggests strong differences in expression profiles across gestation. Some of these 
genes included CGB5 (Figure 4-2B, Supplementary Table 4-1, 4-2) which as discussed 
above is part of the LHB-CGB cluster and is expressed more highly during first trimester. 
More interestingly, we found 195 genes (Figure 4-2B) the expression of which was not 
maintained between comparisons. GO term analysis of these genes suggested a disruption 
in genes involved in cell adhesion in placentas from preeclamptic pregnancies. We also 
performed differential expression analysis between placentas from either uncomplicated 
term or preeclamptic pregnancies. GO term analysis of these genes suggested a disruption 
of energy metabolism pathways in PE. Since impaired implantation and placental 
trophoblast invasion of the maternal vasculature is associated with PE disruption of 
expression of genes relating to cell adhesion may potentially provide insight into the 
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molecular mechanisms associated with PE [41, 42, 52, 53]. Furthermore, since the 
preeclamptic placenta may not necessarily be obtaining sufficient oxygen and 
micronutrients from maternal blood, this may lead to disruptions in energy metabolism. In 
other words, the expression profiles of the preeclamptic placenta shown herein may reflect 
a placenta that did not undergo proper implantation and morphogenesis during the early 
stages of development.  
 
This study was also the first, to our knowledge, to characterise global lncRNA expression 
profiles of placentas from first trimester, uncomplicated term or preeclamptic pregnancies. 
The transcriptome of placentas in this study included the expression profiles of 34,717 
lncRNAs. Our differential expression analyses showed that those differentially expressed 
between placenta from first trimester and uncomplicated term pregnancies had similar 
patterns of expression to those of protein coding genes. For example, we found lncRNAs 
relating to enhanced cell proliferation (Supplementary Table 4-4) were more highly 
expressed during first trimester. This reiterates the notion that the transcriptome of the first 
trimester placenta resembles that of a highly proliferative cancer. Compared to first 
trimester placenta, we found lncRNAs that were more highly expressed in placentas from 
uncomplicated term pregnancies to be associated with the inflammatory response. This too 
reiterates the notion that a placenta at term is undergoing an inflammatory response. This 
also suggests that lncRNAs associate with important cellular and molecular processes in 
the placenta across gestation. However, unlike protein coding genes, the functions of 
lncRNAs are yet to be characterised. Therefore, there may be a variety of yet to be 
determined roles that these lncRNAs play in the placenta. These lncRNAs could be 
potentially characterised by performing targeted experiments such as knocking them out 
individually. This would allow determination if they are biologically important in the 
context of a placenta. Furthermore, by analysing what is dysregulated once knocked out 
would determine important and associated molecular pathways. In addition, this study has 
used placental villous tissue, a heterogeneous sample which contains multiple cell types. 
This is a limitation of the study as it is unknown what specific cell types express the 
lncRNAs. Future experiments would firstly have to characterise the expression profiles of 
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different placental cell types to determine which cell types are expressing specific 
lncRNAs. This would allow for better characterisation of the lncRNA when performing 
knock out experiments.  
 
We also undertook lncRNA expression analysis using placentas from preeclamptic 
pregnancies. Over 40% of the lncRNAs found to be differentially expressed between 
placentas from first trimester and preeclamptic pregnancies were also differentially 
expressed between first trimester and placenta from uncomplicated pregnancies. Despite a 
different pregnancy outcome at term these data suggest a strong difference in expression 
profiles across gestation. However, this also shows that 60% of the lncRNAs were not 
maintained across comparisons. We had a closer look at these transcripts and found 
enrichment for GO terms relating to blood vessel development. These lncRNAs 
specifically were downregulated in placentas from preeclamptic pregnancies compared to 
first trimester placenta suggesting disrupted expression of lncRNAs related to blood vessel 
development in preeclampsia. For example, NONHSAG002977.2 is a transcript known to 
be associated with blood vessel remodelling and was downregulated in PE compared to 
first trimester. Furthermore, this transcript was enriched for the GO term titled ‘blood 
vessel endothelial cell proliferation involved in sprouting angiogenesis’. This suggests that 
this transcript may be important in regulating angiogenesis and possibly spiral artery 
remodelling. To the best of our knowledge, due to the lack of literature and data 
surrounding these lncRNAs, this was the only transcript known relating blood vessel 
remodelling to be differentially expressed. Therefore, future work should focus on 
characterising other lncRNAs as they may important roles in PE. Spiral artery remodelling 
is an important process in placental development when insufficient can increase risk of PE 
[52, 53]. The lncRNAs found to be downregulated herein may underpin some of the 
mechanisms involved in spiral artery remodelling during placental development and when 
disrupted they may be associated with poor spiral artery remodelling resulting in PE. This 




In addition, to conducting differential expression analyses we performed a de novo 
transcript analysis which identified 23 previously unannotated transcripts specific to 
placental tissue. Four of these transcripts were only expressed during first trimester while 1 
was found to be expressed in placentas at term. The remaining 18 transcripts had similar 
placental expression across gestation and in both uncomplicated and preeclamptic 
pregnancies. RNA-seq data from the NIH Epigenomics Roadmap from 198 human tissue 
samples indicated that these transcripts were placenta specific. However, 9 of the 23 
transcripts found in this study were shown to overlap with those identified by the 
FANTOM5 project. However, as shown in Figure 4-4 and Supplementary Table 4-8, the 
overlap occurred in only a small fraction of the transcripts in this study. Despite 
FANTOM5 sequencing 5 times deeper than that performed in this study, the full length 
transcripts were not found suggesting the transcript variants identified in this study are 
exclusively expressed in placental tissue.  Furthermore, 14 were found to be differentially 
expressed in placenta from first trimester and uncomplicated term pregnancies. In addition, 
13 were differentially expressed between placentas from preeclamptic and uncomplicated 
term pregnancies. Due to their specificity to the placenta and expression changes across 
gestation and in PE, these novel lincRNAs may have a functional role in placental 
development. In silico analyses on their biological function was limited due to the lack of 
available data regarding their genomic positions. For example, we found no disease 
associated SNPs to overlap with genomic regions of the lincRNAs. In addition, GO term 
analyses based on their surrounding genes returned no significant enrichment terms. The 
lack of data about their biological function is partly due to their location. This is one of the 
limitations regarding complex genomic work as undertaken in this study. Although new 
technology has enabled the identification of these transcripts, further work is required to 
determine their biological roles and whether or not they have important roles in placental 
development or PE. Despite not finding much information on their biological function for 
most of the novel lincRNAs, we did find one that is possibly related to cell adhesion and 
angiogenesis. Co-expression analysis suggests one of the transcripts located on 
chromosome 7 to be involved in genes relating to GO terms such as angiogenesis 
(GO:0001525). Furthermore, this transcript was also upregulated in placenta from 
uncomplicated term pregnancies compared to during first trimester. This may suggest that 
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this transcript is involved in angiogenesis pathways which are essential for proper fetal 
growth and development. However, the precise mechanisms of action for this transcript 
remain to be elucidated.  
 
The RNA-seq protocol used in this study returned on average 40.3 million reads per 
sample, which was sufficient to identify 23 previously unannotated transcripts. Some of 
these transcripts, such as in Figure 4-3, appear to be within clusters. RNA-seq is becoming 
increasingly more sensitive and able to sequence to a greater depth so future RNA-seq 
studies on placental tissue will be able to determine if these clusters of novel transcripts are 
in fact clusters or potentially long transcripts. Hence, this study highlights that continued 
research in this area is needed. The identification of the novel lincRNAs has potentially 
only scratched the surface of unannotated transcripts within placental tissue. Using RNA-
seq to sequence to a greater depth is likely to reveal more transcripts. This may also 
uncover transcripts that may become targets in future therapeutic development in 
pregnancy complication research.  
4.5 Conclusion 
 
This study is the first to use RNA-seq on first trimester placental tissue and to characterise 
lncRNA expression. It has identified unique transcriptomes in placenta from first trimester, 
term and PE pregnancies. Consequently, we now have a comprehensive list of 
differentially expressed genes between the three comparisons of placental tissue analysed 
in this study. Furthermore, our analyses of the placental expression profiles of lncRNAs 
from first trimester, uncomplicated term and preeclamptic pregnancies has revealed a 
downregulation of lncRNAs associated with blood vessel development in PE. Apart from 
analysing known gene expression, this study went a step further to identify previously 
unannotated transcripts. In total, we identified 23 novel lincRNAs in placental tissue. 
Using publicly available data from the NIH Epigenomics Roadmap were specific to 
placental tissue, although comparison with FANTOM5 data suggests some may be very 
lowly expressed in other tissues. Furthermore, due to the differential expression of these 
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transcripts between pregnancy group comparisons, these novel transcripts may have 
potential roles in placental development or the onset of PE.  
 
This study has uncovered new placenta specific transcripts which has identified new 
targets for placental development research. Future work is required to determine their exact 
biological roles which may be associated with normal and aberrant placental development. 
Moreover, RNA-seq analysis to a greater depth is required to potentially identify more 
novel transcripts which may have biological functions in a successful pregnancy outcome. 
4.6 Supporting Information 
 
For Supplementary Table 4-1, 4-2, 4-3, 4-4, 4-5, 4-6, 4-7 and 4-8 please refer to the 
electronic supporting information. 
Supplementary Table 4-1: Genes differentially expressed between first trimester and 
term placentas. 
Supplementary Table 4-2: Genes differentially expressed between first trimester and 
preeclamptic placentas. 
Supplementary Table 4-3: Genes differentially expressed between term and preeclamptic 
placentas. 
Supplementary Table 4-4: Long non-coding RNAs differentially expressed in the 
placenta between first trimester and uncomplicated term pregnancies.  
Supplementary Table 4-5: Long non-coding RNAs differentially expressed in the 
placenta between first trimester and preeclamptic pregnancies. 
Supplementary Table 4-6: Long non-coding RNAs differentially expressed in the 
placenta between uncomplicated term and preeclamptic pregnancies. 
Supplementary Table 4-7: Genomic information of all variations of the 23 novel large 
intergenic non-coding RNAs. 
Supplementary Table 4-8: Overlap between novel lncRNAs found in FANTOM5 and 
this study. 
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Abstract  
Aim: To determine whether dynamic DNA methylation changes in the human placenta 
can be used to predict gestational age. 
Materials & Methods: Publically available placental DNA methylation data from 12 
studies, together with our own data set, using Illumina Infinium Human Methylation 
BeadChip arrays.  
Results & Conclusion: We developed an accurate tool for predicting gestational age of 
placentas using 62 CpG sites. There was a higher predicted gestational age for placentas 
from early onset preeclampsia cases, but not term preeclampsia, compared to their 
chronological age. Therefore, early onset preeclampsia is associated with placental aging. 
Gestational age acceleration prediction from DNA methylation array data may provide 
insight into the molecular mechanisms of pregnancy disorders. 
5.1 Introduction  
 
DNA methylation is a heritable epigenetic process that can regulate important genetic 
mechanisms and processes such as gene expression, X chromosome inactivation (XCI) 
[1], cellular identity [2] and genomic imprinting [3].  DNA methylation is the covalent 
attachment of a methyl group to a cytosine ring by a DNA methyl transferase (DNMT) 
[4]. In this article we focus on cytosine-5 DNA methylation within CpG dinucleotides as 
opposed to other methylated cytosines such as CHG and CHH. Recently, DNA 
methylation levels for 353 CpG sites have been used to measure the epigenetic age, 
defined as the predicted age by DNA methylation, of a variety of human tissues, which 
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has a high correlation (r = 0.92) with the actual age [5]. Moreover, another study found 
that accelerated aging [5], defined as the difference between the estimated epigenetic age 
and the actual known age, is associated with maternal characteristics in pregnancy such 
as smoking, weight, BMI, selenium and cholesterol in peripheral blood [6]. The placenta 
is unique compared to other tissues, with the exception of cancer tissues [7, 8] and a 
human fetal fibroblast cell line (IMR90) [9] in that it has been shown that it has low 
levels of genome wide CpG methylation [10, 11]. Despite this, overall placental genome 
CpG methylation has been observed to increase during gestation [12]. However, precisely 
what DNA methylation changes occur during gestation and how these changes relate to 
pregnancy success is unknown. 
 
Poor placental function, due to impaired placentation has been proposed to be a cause of 
preeclampsia (PE) [13], which is characterised by high maternal blood pressure and 
proteinuria [14]. Adversities during pregnancy may cause epigenetic changes and altered 
fetal development outcomes [15], which may be orchestrated by the placenta [16]. 
Differential DNA methylation in the placenta has been shown to occur in pregnancy 
complications [17] including PE [18-21], gestational diabetes mellitus (GDM) [18, 22, 
23] and intrauterine growth restriction (IUGR) [24].  DNA methylation is critical for 
optimal placental and fetal development. For example, genomic imprinting regulates 
expression of IGF2 and H19 which are both required for proper placental development. 
Hypomethylation within the imprinting control region of IGF2 has been shown to be 
associated with reduced fetal growth [25, 26] whereas loss of imprinting of H19 has been 
reported to be associated with PE and with small for gestational age (SGA) infants [27].  
 
Previous studies have reported altered placental gene expression in human pregnancy 
complications including PE [28-32], GDM [31] and fetal growth restriction [28, 33]. 
However, little is known whether changes in DNA methylation and gene expression 
overlap in the placenta.  The relationship between global placental gene expression and 
DNA methylation is conflicting as one study has reported a general trend between the 
increase in DNA methylation and decrease in gene expression levels during gestation 
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[12], whereas another study using matched samples has reported no overlap between 
gene expression and DNA methylation changes between placentas from PE and 
uncomplicated pregnancies [21]. In addition, genes within partially methylated domains 
(PMDs) in the term placenta have been reported to be repressed [10].  
 
In this study, we assembled a large data set of publically available placental tissue DNA 
methylation data that has been measured using the Illumina Infinium HumanMethylation 
arrays. We sought to determine the precise changes in DNA methylation that occur in the 
placenta across gestation and determined whether DNA methylation data can be used to 
predict the gestational age of a placenta. Finally, we investigated what happens to the 
predicted gestational age in placentas from preeclamptic pregnancies. In this study, we 
hypothesised that the gestational age of the placenta can be estimated by its DNA 
methylation levels and that pregnancy complications such as PE would be characterised 
by accelerated placental aging. Our computational analysis of DNA methylation data 
reveal accurate predictions of the gestational age of the placenta. Furthermore, our 
findings of gestational age acceleration in early onset preeclamptic placentas suggest a 
novel method to assess biological aging in the placenta. Moreover, gestational age 
prediction of the placenta may identify novel mechanisms in pregnancy complications, 
such as those associated with placental aging. 
5.2 Materials and methods 
5.2.1 Quantification of the DNA methylation levels 
 
Quantification of the DNA methylation level of each CpG site that is annotated in either 
the Illumina 27k or 450k was performed using standard techniques. The publicly 
available human placental data sets (Table 5-1) were obtained from the Gene Expression 
Omnibus (GEO) using the GEOquery Bioconductor package. Briefly, DNA methylation 
levels of each CpG site from each data set was quantified by the β value, which is the 
ratio of the methylated and unmethylated alleles. The β value is calculated by taking the 
ratio of the two fluorescent signals (methylated and unmethylated signals) in studies that 
provided the two fluorescent signals.  
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Table 5-1: A description of the DNA methylation data sets containing placental tissue used in this study. 
GEO 
Accession   
Data set summary Platform No. of placental tissue 
samples 
Gestational age range 
(weeks) 
GSE31781 Placental tissue samples from three gestational age 
time points. 
27k 18 first trimester, 
10 second trimester, 
14 term 
8-42 
GSE36642 Cord blood and placentas from monozygotic (MZ) 
and dizygotic (DZ) twins. 
27k 28 third trimester 32-38 
GSE36829 Placental tissue from term pregnancies. 27k 48 term  37-42 
GSE59274 Placental tissue samples from women with PE or 
uncomplicated pregnancies. 
27k 24 uncomplicated, 
24 PE 
28-41 
GSE46573 Epigenome-wide association study  450k 2 term  NA 
GSE52576 Genome wide human imprinting analysis of 
different healthy human tissue. 
450k 4 term  NA 
GSE54399 Whole cord blood and placental tissue from normal 
pregnancies. 
450k 24 uncomplicated NA 
GSE57767 Placental tissue samples from normal term, preterm 
PE and term PE women. 
450k 14 uncomplicated,  
12 preterm PE,  
19 term PE 
NA 
GSE44667 Placental tissue from women with EOPET and 
gestational age matched controls. 
450k 20 third trimester, 
20 PE 
25-37 
GSE66210 First trimester chorionic villous samples from 
normal and trisomy pregnancies. 
450k 12 normal,  
12 trisomy 21, 
12 trisomy 18, 
6 trisomy 13 
NA 
GSE73375 Placental tissue samples from preeclamptic and 
normotensive women. 
450k 17 uncomplicated,  
19 PE 
NA 
GSE74738 Placental tissue from uncomplicated pregnancies. 450k 28 term 36-42 
This study Placental tissue from uncomplicated elective 
caesarean pregnancies. 
27k 22 term 35-40 
DZ: dizygotic, EOPET: early onset preeclampsia, MZ: monozygotc, NA: Not available, PE: preeclampsia, 27k: Illumina Infinium 
HumanMethylation27, 450k: Illumina Infinium HumanMethylation450 
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5.2.2 Differential methylation analysis  
 
Differential methylation analysis was performed using the 450k data sets for which we 
had data for 469,017 probes. Normalisation was performed using the BMIQ method [34], 
which corrects for the probe design bias in the Illumina Infinium HumanMethylation450 
BeadChip followed by quantile normalisation.  Since the data were from multiple data 
sets, batch effects were corrected using the Combat function in the ChAMP Bioconductor 
package which corrects for biases as a result of batch effects [35, 36].  Multidimensional 
scaling plots of the 1000 most variable probes of the data were used to check for outliers. 
Sample sex was identified using the minfi package in which the median value of the β 
values for probes that mapped uniquely for the X and Y chromosome, respectively, were 
determined [37]. Differentially methylated CpG sites were identified using empirical 
Bayesian variance method in limma which was used to test for differential methylation 
differences [38]. The Bumphunter Bioconductor package was used to identify 
differentially methylated regions by running 1000 permutations of the data [39]. We 
selected data sets (GSE44667, GSE46573, GSE52576, GSE54399, GSE57767 and 
GSE73375) that had used the Illumina Infinium HumanMethylation450 BeadChip array 
to assess sex differences in placental DNA methylation and differential methylation 
between PE and uncomplicated pregnancies (Table 5-1). In total, we had placental DNA 
methylation data for 70 preeclamptic and 62 uncomplicated pregnancies.  
5.2.3 Gestational age prediction  
 
We selected data sets for placental tissue samples that were publically available and 
which contained individual gestational age information and were from healthy singleton 
pregnancies (GSE31781, GSE36829, GSE59274, GSE44667 and GSE74738) (Table 5-
1). We also combined these data sets with our own data set for 22 term placentas from 
uncomplicated pregnancies. Probes that were present in both the 27k and 450k array were 
kept and probes that were annotated to the sex chromosomes were removed. Every 
sample in the training data set contained β values for 18,437 probes. Normalisation was 
performed as described by Horvath [5], using a modified version of the Beta MIxture 
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Quantile dilation (BMIQ) [34] method. This modified version of BMIQ rescales the 
Infinium II probes to the mean β value of each probe in the largest data set (GSE36829) 
prior to quantile normalisation. Using the R package glmnet [40], we regressed 
gestational age with the 18,437 probes. The elastic net regression or the alpha parameter 
of glmnet was 0.5 and the minimum lambda value based on the training data was 
0.6807.The elastic net model automatically selected 62 CpG sites, such that given the 
level of methylation of the 62 CpG sites the gestational age of a placenta can be 
calculated. 
5.2.4 Gestational age acceleration heritability  
 
To determine the heritability of gestational age acceleration, which is defined as the 
difference between the chronological and predicted gestational age of a placenta we used 
Falconer’s formula (H2 = 2(cor(MZ)-cor(DZ))). Falconer’s formula was used to 
determine the broad sense heritability which is the proportion of variance of gestational 
age acceleration as a result of genetic factors. The broad sense heritability was 
determined by using a data set (GSE36642) that contained monozygotic and dizygotic 
twins of the same sex. Firstly, the predicted gestational age of the twin placentas were 
determined as described above. The twin data set was split into either monozygotic or 
dizygotic twins and for each twin pair the gestational age acceleration was calculated. For 
each twin pair, each sibling was randomly selected as either twin 1 or twin 2 and the 
pearson correlation of gestational age acceleration was determined in both monozygotic 
and dizygotic twins. The correlation of both monozygotic and dizygotic twins were 
inputted into Falconer’s formula to determine the broad sense heritability.  
5.2.5 Annotation of CpG sites  
 
Annotation of all the CpG sites within the analysis of this study for the Illumina Infinium 
HumanMethylation27 and HumanMethylation450 BeadChip was performed using two 
annotation Bioconductor packages [41, 42].  
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5.3 Results  
5.3.1 Differential methylation in placentas from preeclamptic pregnancies 
 
We first searched the GEO [43] for DNA methylation data sets containing placental 
tissue that were measured on either the Illumina Infinium HumanMethylation27 
BeadChip or Infinium HumanMethylation450 BeadChip. In total, we identified 387 
placental tissue samples from 12 different data sets (Table 5-1). We selected only 
placentas assessed using the Illumina DNA methylation arrays, the most commonly used 
platform to quantify DNA methylation in the placenta. Here, we used publically available 
placental DNA methylation data (Table 5-1) to assess differential methylation between 
placentas from PE and uncomplicated pregnancies. We selected only datasets that used 
the Infinium HumanMethylation450 BeadChip for differential methylation analysis since 
most studies involving placental samples from women with preeclampsia had used this 
platform (Table 5-1) and it contains the largest number of CpG sites available for 
analysis.  When comparing 70 placentas from preeclamptic pregnancies and 62 placentas 
from term uncomplicated pregnancies we found a total of 741 CpG sites (FDR < 0.01) 
were differentially methylated (Supplementary Table 5-1). We then tested for 
differentially methylated regions (DMRs) and identified 3 DMRs in placentas from 
preeclamptic pregnancies which overlapped the 5' region of MARC2, FAM3B and 
TP53TG1.  
5.3.2 Sex differences in DNA methylation  
 
To identify whether sex differences also occur in the placental DNA methylome, we 
identified a total of 2,898 differentially methylated CpG sites (FDR < 0.01) between 35 
male and 27 female placentas from uncomplicated singleton term pregnancies that had 
been analysed using the Infinium HumanMethylation450 BeadChip (Supplementary 
Table 5-2). Of the 2,898 CpG sites, 420 were located on autosomes, 2,464 on the X 
chromosome and 14 on the Y chromosome. Although we are reporting Y chromosome 
CpG sites, we do not consider these CpG sites as differentially methylated between sexes. 
In addition, upon removing the Y chromosome from our analysis we did not observe a 
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difference in the total number of differentially methylated X chromosome or autosomal 
CpG sites. We also identified a total of 396 DMRs between sexes (Supplementary Table 
5-3). All of these were located on the X chromosome with 311 and 85 being 
hypermethylated in females and males, respectively. The 85 hypermethylated DMRs on 
the X chromosome in males did not overlap with any reported sex biased genes [44], with 
the exception of XIST which is upregulated in females and is well-known for its role in 
XCI in female mammalian somatic cells [45].The most statistically significant 
differentially methylated autosomal CpG site as defined by the empirical Bayesian 
variance method in limma between sexes was hypermethylated in females and was within 
exon 1 of TLE1 which is a marker of synovial sarcoma [46]. Although TLE1 is expressed 
in the placenta, it has not been reported to be differentially expressed between fetal sexes 
in the placenta [44, 47]. 
5.3.3 Gestational age calculator training data set  
 
Although a multi-tissue age predictor using DNA methylation data has been previously 
developed [5], we set out to determine if DNA methylation can be used to predict the 
gestational age of the placenta. To develop our placental gestational age calculator, only 
placentas from healthy singleton pregnancies with individual gestational age information 
were included. Placental tissue samples from PE pregnancies were excluded from the 
training data set to reduce potential confounding factors caused by the disease. In total, 
we used 170 placental tissue samples that had individual gestational age information to 
generate the gestational age calculator. The 170 placental tissue samples were taken from 
five publically available data sets, along with our own generated data analysing 22 term 
placentas (Table 5-1). Four of the six data sets were obtained using the Infinium 
HumanMethylation27 BeadChip and the other two on the Infinium 
HumanMethylation450 BeadChip and the included datasets contained placental tissue 
samples that spanned 8-42 weeks gestation. We selected probes that were present in all 6 
data sets and removed probes that were found on sex chromosomes, leaving a total of 
18,437 probes (no missing data). We randomly assigned half of the 170 placental tissue 
samples to a training data set, leaving the other 85 samples for validation. 
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5.3.4 Identifying and validating the gestational age calculator 
 
Briefly, we firstly normalised the training data using the modified version of the Beta 
MIxture Quantile dilation (BMIQ) [5, 34]. The mean beta value of each probe in the 
largest data set (GSE3829) was used as the gold standard of the probes, similarly as 
previously described [5], in the normalisation step (Supplementary Table 5-4). A gold 
standard of the probes was used for normalisation since the data sets were from two 
different microarray platforms and it rescaled the probes that were present in both 
microarray platforms. After normalisation we regressed the chronological gestational age 
against the 18,437 CpG sites using an elastic net penalised regression model [40]. The 
model automatically selected 62 CpG sites (Supplementary Table 5-5) to predict the 
gestational age of a placenta. In the training data set we found an extremely high 
correlation (r = 0.99, p < 2.2e-16) between the chronological and the predicted gestation 
age (Figure 5-1A). In addition, the median absolute difference between the predicted and 
chronological gestational age in the training data set was found to be 0.23 weeks. We 
then tested these 62 CpG sites in the validation data set (Figure 5-1B) and also found a 
high correlation between the chronological and predicted gestational age (r = 0.95, p < 
2.2e-16). The median absolute difference in the validation data set was 1.47 weeks and 
the root mean square error was 2.3. The heatmap (Figure 5-1C) allows visualisation of 
the CpG sites and shows changes in DNA methylation across gestation. Furthermore, the 
lack of vertical lines in the heatmap suggests that the CpG sites are robust against data set 
effects. In order to further validate the 62 CpG sites, we predicted the gestational age of 
all remaining publically available placental tissue samples from uncomplicated 
pregnancies that did not have individual gestational age information (Supplementary 
Table 5-6). Although these remaining samples did not have individual gestational age 
information, we sought to determine if the predicted gestational age matched the labelled 
trimester of pregnancy for each sample. We found a concordance between the predicted 
gestational age and labelled trimester of pregnancy, which assured us that it is an accurate 
predictor of gestational age. Here in this study we refer to the predicted gestational age of 





Figure 5-1: The correlation between the chronological and DNA methylation gestational 
age of each placenta. 
(A) Training data set and the (B) validation data set. (C) A heatmap visualising the 
gradual changes in DNA methylation in each of the 62 CpG sites (rows) across gestation 
in all samples (columns). The samples have been ordered by increasing gestational age 
and the probes have been ordered by the increasing magnitude of correlation with 
gestational age. The Data Set heatmap represents the origin of each sample.  
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5.3.5 The 62 gestational clock CpG sites 
 
The 62 gestational clock CpG sites can be characterised into two groups depending on the 
direction of their correlation with gestational age. 27 CpG sites were found to positively 
correlate and become hypermethylated with increasing gestational age whereas, the other 
35 CpG sites negatively correlated and became hypomethylated with increasing 
gestational age.  
5.3.6 Gestational age acceleration in placentas from preeclamptic 
pregnancies 
 
Since differential DNA methylation occurs in placentas from PE compared to 
uncomplicated pregnancies [17], we investigated if accurate prediction of gestation age 
can also be achieved in placentas from PE pregnancies. Two data sets (GSE44667 and 
GSE59274) contained individual gestational age information for placental tissue samples 
from PE pregnancies (26 early onset PE and 18 late onset PE). We then compared the 
chronological gestational age with the DNAm GA (Figure 5-2) and found that placentas 
from early onset PE pregnancies (< 34 weeks gestation) had a higher DNAm GA 
compared to their chronological gestational age (p = 3.44e-6, two-tailed, paired t-test). 
However, late onset placentas from PE pregnancies (≥ 34 weeks gestation) did not show 
any significant difference between their chronological and DNAm GA (p = 0.38) 
indicating that late onset PE does not affect placental aging. From here on, we refer to the 
difference between chronological and DNAm GA as gestational age acceleration, similar 
to what has been defined previously [5]. One data set (GSE36642) contained placentas 
from monozygotic (MZ) and dizygotic (DZ) twins with individual gestational age 
information, allowing the determination of gestational age acceleration heritability by 
calculating the broad sense heritability using Falconer’s formula (H2 = 2(cor(MZ)-
cor(DZ))). We conducted our analysis on gestational age acceleration heritability on twin 
samples of the same sex. The broad sense heritability was used to determine the 
proportion of variance of gestational age acceleration as a result of genetic variation.  
Despite having a small sample size, we calculated the gestational age acceleration for 
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each sample and determined the broad sense heritability to be 57.2% in MZ and DZ twin 






Figure 5-2: Gestational age acceleration in early onset PE. 
Placentas from pregnancies complicated by early onset PE (A) show a higher DNA methylation gestational age (DNAm.GA) 
compared to their chronological gestational age (Chron.GA). (B) Placentas from late onset PE do not show any difference between the 
chronological and DNA methylation gestational age. Error bars are represented as standard deviations.  
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5.4 Discussion  
 
In this study, we investigated DNA methylation differences in the placenta across 
gestation and in different pregnancy outcomes. We found 34 genes that have been 
reported to be differentially expressed in placenta from PE compared to uncomplicated 
pregnancies [30] to contain at least one differentially methylated CpG site 
(Supplementary Table 5-1).  For example, there was a differentially methylated CpG site 
in the promoter of RAC1 (ras-related C3 botulinum toxin substrate 1) (Supplementary 
Table 5-1), a member of the RAS-superfamily [48], which has been found to be 
upregulated in placenta from preeclamptic pregnancies [30]. We also tested for DMRs in 
placentas from preeclamptic and uncomplicated pregnancies. We identified three DMRs 
which overlapped the 5' region of MARC2, FAM3B and TP53TG1. However, to our 
knowledge these genes have not been reported to be differentially expressed in placenta 
from women with preeclampsia. 
 
Sex differences in pregnancy outcomes have been reported, for example women bearing 
a male fetus are at a 20% higher risk of preterm birth (PTB) [49-51]. The fetus and 
placenta are genetically identical [52]. The placenta has been implicated in a number of 
pregnancy complications, including PTB [53]. Therefore it is reasonable to suggest that 
sex differences in outcomes may potentially be orchestrated by the placenta. Sex 
differences in placental gene expression have been previously reported [44, 47] and in 
comparison to the placental sex biased gene expression meta-analysis [44], 20 genes 
(located on the X chromosome and upregulated in females) were found to contain at least 
one CpG site or DMR that was hypermethylated in females. However, this may be the 
result of XCI in females.  
 
It is unclear why 85 X chromosome DMRs should be hypermethylated in males 
considering XCI occurs in females. Despite being hypermethylated in males, there are no 
reports of sex differences in expression of the genes in which these DMRs occur. 
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Potentially they may regulate other sex-specific differentially expressed RNAs including 
ncRNAs or affect TF binding. Further research is required to elucidate the precise 
mechanisms by which the 85 X chromosome hypermethylated DMRs in males act.  
 
 We therefore, found a lack of overlap with our differential DNA methylation analysis 
and two gene expression meta-analyses [30, 44]. These findings were consistent with a 
previous study in which changes in gene expression and DNA methylation did not 
overlap from matched placental samples from PE and uncomplicated pregnancies [21]. 
Furthermore, changes in DNA methylation within the promoters of genes does not 
always alter gene expression as reported for colon cancer [54]. We also found little 
overlap between genes that have previously been reported to be sex biased in the placenta 
[44] and our DNA methylation results. Interestingly, we did find 420 differentially 
methylated autosomal CpG sites and 85 X chromosome hypermethylated DMRs in 
males. However, due to the poor overlap with gene expression and the effect of XCI it is 
difficult to draw any conclusions on what the effect of the differences in DNA 
methylation that were observed had on gene expression. 
 
The lack of overlap between DNA methylation and reported gene expression changes 
have several limitations. Firstly, in comparison to the two gene expression meta-analyses, 
we analysed far fewer samples and therefore may not have been statistically powered to 
detect small differences. Secondly, the Illumina DNA Methylation BeadChip arrays only 
assess approximately 2% of the CpG sites in the human genome and do not assess other 
methylated cytosine sites such as CHG and CHH. Therefore, we may not have captured 
the true landscape of DNA methylation in the placenta. Finally, the comparison between 
DNA methylation and gene expression was not in the same samples and therefore there 
may have been too much biological variability to detect any overlap. Despite these 
limitations, our findings suggest CpG methylation in the placenta may not be a key 
regulator of gene expression and therefore may be more dependent on other epigenetic 
factors such as histone modifications, small RNA regulation or non-coding RNA 
changes. It has been reported that the placenta with the exception of the brain, has high 
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levels of non-CpG methylation compared to other human tissues [55] which may have a 
bigger influence on gene expression levels.  
In this study, we identified 62 CpG sites, which together can be used to determine the 
gestational age of a placenta. Several limitations of our study for predicting gestational 
age do require discussion. Firstly, the training data set consisted of placentas from 8-42 
weeks gestation with a bias of samples being from late third trimester. First and second 
trimester samples comprised only 11% and 9.5% of the training and validation data, 
respectively. This may have created some biases in the CpG sites chosen and may cause 
some inaccuracy in identifying the gestational age of placentas from first and second 
trimester. Secondly, in relation to gestational age acceleration heritability the twin data 
set only contained 14 twin pairs. Therefore we may have not captured the true extent of 
gestational age heritability within this study. Future studies with large sample sizes of 
twin pairs are required to determine the true extent of the heritability of gestational age 
acceleration. In addition to gestational age prediction, we used first and second trimester 
placentas from terminated pregnancies. One limitation is that some of these placentas 
may have been from women destined to develop a pregnancy complication which may 
have implications for our gestational age prediction. A possible approach to overcome 
this limitation is to use placental villi from chorionic villus sampling in ongoing 
pregnancies. Thereby, samples that were from complicated pregnancies could be 
excluded from the analysis. Unfortunately, to our knowledge there is no publically 
available DNA methylation data on such samples that we could use to test our gestational 
age prediction.  
 
Placentas from early onset preeclamptic pregnancies were found to have a higher DNAm 
GA compared to their chronological gestational age. Using a twin data set we were able 
to determine the broad sense heritability of gestational age acceleration to be 57.2%. This 
finding suggests environmental factors also have an influence together with genetic 
factors on gestational age acceleration.  Maternal lifestyle factors such as smoking [56, 
57] are known to alter DNA methylation levels in the placenta. Therefore, the maternal 
environment can affect the intrauterine environment, and thereby could influence 
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gestational age acceleration in the placenta. Furthermore, other lifestyle factors such as 
BMI have been found to increase the epigenetic age in certain tissues such as the liver 
[58]. It would therefore be important to investigate the effect of maternal lifestyle factors 
on gestational age acceleration as they may have implications for pregnancy success. 
Unfortunately these data are often not recorded for publically available data sets. This 
limitation also applies to the exact nature of the twin placentas included in the publically 
available data. For example, we do not know if the twin pregnancies had fused placentas 
or not. Although each individual twin is listed as having a separate placenta, it may be 
possible that some of the twin pregnancies had fused placentas and therefore the exact 
sampling sites could confound the data on heritability. Therefore, we suggest some 
caution with respect to the heritability of gestational age acceleration analysis as we do 
not have full clinical details for the publicly available twin data set (GSE36642).  
 
Using our gestational age tool, we also provide an estimation of the gestational age of all 
remaining publicly available placenta samples from uncomplicated pregnancies for which 
gestational age information is not recorded as a resource to the scientific community 
(Supplementary Table 5-6). It has also been reported that the placental transcriptome is 
clearly distinct in PE compared to other pregnancy complications [31]. It would therefore 
be of interest to determine if the placental gestational age acceleration observed in early 
onset PE pregnancies also occurs in other pregnancy complications. Likewise, the 
gestational age acceleration observed in placentas from early but not late onset PE 
highlights potential differences in the etiology of the two diseases. Furthermore, 
gestational age acceleration may potentially reveal potential mechanisms in the 
development of early-onset PE and other pregnancy complications. First trimester 
chorionic villus samples could potentially be used to determine when accelerated 
placental aging first occurs. This may provide insight into the mechanisms and the 
association of placental aging and pregnancy complications such as early onset PE. 
However, chorionic villus sampling is only used in some high risk pregnancies but has a 





In conclusion, we have identified 62 CpG sites that can be used to determine the DNAm 
GA of a placenta. Furthermore, we found evidence of placental aging in placentas from 
early onset preeclampsia. Future studies are required to determine if gestational age 
acceleration is unique to early onset preeclampsia or is common to other pregnancy 
complications. In addition, future research should also determine if gestational age 
acceleration or placental aging could be detected perhaps in maternal blood early in 
pregnancy in women who are destined to develop a pregnancy complication. Although, 
we found little overlap between DNA methylation and gene expression changes, further 
studies involving matched samples are required to confirm these findings.  
5.6 Supporting Information 
 
For Supplementary Table 5-1, 5-2, 5-3, 5-4, 5-5, and 5-6 please refer to the electronic 
supporting information. 
Supplementary Table 5-1: CpG sites that were detected to be differentially methylated 
between placentas from preeclampsia and uncomplicated pregnancies. 
The position and the gene that the CpG sites is associated with is supplied. Genes that 
have also been detected to be differentially expressed in placentas from preeclampsia and 
uncomplicated pregnancies [30] are highlighted in bold. 
Supplementary Table 5-2: CpG sites that were found to be detected to be differentially 
methylated between male and females placentas from uncomplicated pregnancies. 
Supplementary Table 5-3: Differentially methylated regions between male and females 
pregnancies from uncomplicated pregnancies. 
Regions with a p.value and/or fwer = 0 are values with p.value and/or fwer < 0.001. 
Bumphunter was unable to determine the exact number by running 1000 permutations on 
the data.  
Supplementary Table 5-4: The gold mean of each probe used in the normalisation step 
in determining the gestational age of a placenta. 
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The mean of methylation of each probe in the largest data set (GSE36829) was used 
along with the modified BMIQ normalisation step [5] to rescale and adjust probes with 
the two different chemistries as previously described [5]. 
Supplementary Table 5-5: The coefficient values and locations of the 62 CpG sites used 
to determine the gestational age of a placenta. 
Supplementary Table 5-6: The predicted gestational age of all remaining placenta 






Supplementary Figure 5-1: Twin data set (GSE36642) used to calculate the broad sense of heritability of accelerated gestational 
aging. 
Each point represents a twin pair from (A) monozygotic (MZ) and (B) dizygotic (DZ) placental tissue samples. There was a high 
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Abstract 
Genotyping-by-sequencing (GBS) is a practical and cost effective method for analysing 
large genomes from high diversity species. This method of sequencing, coupled with 
methylation-sensitive enzymes, is an effective tool to study DNA methylation in parts of 
the genome that are inaccessible in other sequencing techniques or are not annotated in 
microarrays technologies. Current software tools do not fulfil all experimental GBS assays 
such as those using methylation-sensitive restriction enzymes for determining differences 
in DNA methylation between samples. Here we present msgbsR, an R package that 
contains tools for the analysis of methylation-sensitive genotyping-by-sequencing 
(msGBS) experiments. msgbsR can be used to identify and quantify read counts at 
methylated sites directly from alignment files (BAM files). The package also enables 
verification of restriction enzyme cut sites with the correct recognition sequence of the 
individual enzyme. In addition, msgbsR allows the analysis of differential DNA 
methylation and facilitates the creation of genomic plots of cut site locations. msgbsR 
assesses DNA methylation based on read coverage (like RNAseq experiments) rather than 
methylation proportion, and is a useful tool in analysing differential methylation on large 
populations. The package is fully documented and available freely online as a 
Bioconductor package (https://bioconductor.org/packages/release/bioc/html/msgbsR.html). 
6.1 Introduction 
 
Genotyping-by-sequencing (GBS) is a cost effective next generation sequencing method to 
analyse high diversity in large genome species. Reducing genome complexity with 
restriction enzymes (REs) can be advantageous as it may reach parts of the genome 
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inaccessible to sequence capture approaches [1]. However, current GBS data analysis tools 
do not satisfy all experimental designs. For example, using methylation-sensitive REs in a 
GBS experiment, which is known as methylation-sensitive GBS (msGBS) [2] or 
methylation-sensitive restriction enzyme digestion followed by sequencing (MRE-seq) [3] 
is an effective way to identify differentially methylated sites that may not be annotated or 
accessible in other technologies, such as microarrays. Other GBS data analysis tools such 
as Stacks [4] and TASSEL [5] focus on association mapping and do not supply methods on 
identifying, annotating or testing for differential methylated sites from a msGBS 
experiment. 
 
The cost of NGS has declined dramatically in recent years due to the increased throughput 
of current sequencing machines such as Illumina HiSeq X Ten and NovaSeq platforms. As 
a consequence, it is now feasible to determine DNA methylation on a large population 
using msGBS making it advantageous compared to array and other sequencing techniques. 
For example, in humans the Illumina HumanMethylation450 BeadChip is a popular 
method for epigenome studies [6] but relies on prior knowledge of individual CpG sites 
that are contained on the array. This contrasts with msGBS which only relies on the action 
of restriction enzyme cut sites, and therefore offers an unbiased approach to annotating 
methylated sites as opposed to microarrays has the ability to annotate more methylated 
sites in the human genome. Furthermore, msGBS also offers an unbiased approach to 
annotating methylated sites as opposed to microarrays. Compared to other sequencing 
approaches designed to identify methylation such as whole-genome bisulfite sequencing 
(WGBS) or methylation-capture techniques, msGBS infers methylation via read coverage 
and does not require additional sample treatment to convert methylated cytosines (i.e. 
Sodium bisulfite treatment). Determining read coverage, as opposed to WGBS and array 
methods, enables a library preparation step that avoids treatment with sodium bisulfite, 
which damages and fragments input DNA [7].  
 
While msGBS protocols have a wide-variety of uses, current analysis approaches lack the 
ability to quantify methylation on a methylation-sensitive panel. Here in this paper, we 
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present msgbsR, an R package for the analysis of data obtained from msGBS experiments. 
Our pipeline allows researchers to conduct analyses of msGBS experiments, in order to 
identify differentially methylated sites. msgbsR includes tools such as reading the read 
counts from a sorted and indexed genome alignments or BAM file(s) directly into the R 
environment, checking that the cut sites match the RE sequence, identifying differential 
methylated sites, and seamless annotation using available reference genomes in the 
R/Bioconductor framework. To demonstrate the utility of the msGBS approach, and the 
msgbsR analysis package, we analysed a population of rats (control vs treatment) for 
differential DNA methylation (Rattus norvegicus), and two publicly available agricultural 
crop datasets from barley (Hordeum vulgare) and maize (Zea mays) to show the extensive 
potential applications in epigenetic research. 
6.2 Results  
6.2.1 Generating the table of read counts 
 
Using a reference genome, alignment of the sequencing data produced from an msGBS 
experiment results in reads that begin at RE cut sites. As a result reads will generally begin 
at a defined RE cut site, producing a pileup of reads at those genomic positions (Figure 6-
1A). Thus, it is possible to count the total number of reads that mapped to these RE cut site 
positions. The msgbsR analysis pipeline firstly starts with functions allowing the import 
and verification of raw read counts at the RE cut sites that were produced in a msGBS 
experiment by reading sorted and indexed BAM file(s) (Figure 6-1B). These sorted and 
indexed BAM files can be the output from an alignment tool such as Bowtie2 [8] and 
SAMtools [9]. The rawCounts function takes a list of sorted and indexed BAM files and 
imports the raw read counts into the R environment. The msgbsR package utilises other 
Bioconductor packages to ease data analysis, with rawCounts being directly applicable to 
the data format of a RangedSummarizedExperiment from the Bioconductor package 
SummarizedExperiment [10]. The resulted RangedSummarizedExperiment data object 
contains a table of read counts of potential cut site locations with their genomic 





Figure 6-1: A simplified schematic of methylation-sensitive genotyping-by-sequencing (msGBS) and the msgbsR pipeline. 
(A) An example of msGBS using the restriction enzyme, MspI, which cleaves DNA at the recognition sequence C^CGG if the internal 
cytosine is methylated. However, MspI does not cut at the recognition site if both cytosines are methylated or the external cytosine is 





The output of the rawCounts function uses the start position of all mapped reads in a 
BAM file. However, there may be incorrectly mapped reads that do not correspond to a 
specified RE recognition sequence. Incorrectly mapped reads can be filtered out of the 
analysis prior to any downstream analyses using the checkCuts function, which takes a 
GRanges data object that contains the positioning of the potential cut sites and the 
recognition sequence of the RE. The checkCuts function then uses a reference genome in 
the format of a BSgenome which is obtainable from Bioconductor. However, if a 
BSgenome is unavailable, a user-defined FASTA file can also be used to determine if the 
recognition sequence matches in the reference genome. checkCuts then returns a 
GRanges object with the correct positions of the cut sites while incorrectly mapped reads 
can then be filtered out of the RangedSummarizedExperiment.  
6.2.2 Package Validation 
 
We performed the msgbsR pipeline on our own msGBS data set. Our msGBS data set 
focused on the prostates tissue from the offspring of rats who were either fed a control (n 
= 26) or experiment high fat maternal diet (n = 18). This experiment focused on using the 
methylation sensitive RE, MspI, which cleaves at the recognition site C^CGG (Figure 6-
1A). Initially, after mapping there were a potential of 1,616,611 MspI, sites. However, 
after running checkCuts, this was reduced to 1,252,042 MspI sites. The incorrectly 
mapped reads were unique to an individual sample. In other words the same incorrect site 
did not occur in multiple samples. We therefore found it advantageous to have the 
function checkCuts, as it can remove incorrectly mapped reads which may have been 
introduced in an earlier step prior to running the msgbsR pipeline. By running the 
checkCuts function ensures there are no incorrect mapped reads within any downstream 
analyses. This is important as incorrect sites can impact downstream analyses such 
returning sites that are differentially methylated but are in fact false positives.  
 
We also used msgbsR on a publicly available msGBS experiment focusing on barley and 
maize (SRP004282.1) leaf samples [2]. This experiment used ApeKI, a methylation-
sensitive endonuclease that recognizes the 5 bp sequence GCWGC (W = A or T).  Firstly, 
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we mapped the barley and maize samples to their respective available reference genomes 
(see methods) and used the rawCounts function on the resulted sorted and indexed BAM 
files to determine count numbers. Initially, this resulted in a total of 4,081,975 and 
1,155,762 potential ApeKI sites for the maize and barley data set respectively. However, 
after running the checkCuts function this was reduced to 3,791,316 and 1,032,360 cut 
sites for the maize and barley data set respectively. This was potentially due to 
incorrectly mapped reads and ensured all downstream analyses were performed using 
sites that were correctly mapped. 
6.2.3 Visualisation  
 
msGBS experiments can produce varying numbers of cut sites and reads depending on 
the DNA methylation state and the efficiency of the library preparation step for each 
individual sample. A way to overcome false positives associated with differences in read 
numbers between samples is to remove samples that produced a low number of reads 
and/or cut sites. This can be done before performing differential methylation analysis 
using the plotCounts function incorporated in the msgbsR package. Figure 6-2A and 6-
2B were generated using the plotCounts function and show the total number of reads 
compared to the total number of cut sites produced for each individual sample from the 
publicly available data set described above [2]. We also performed this function on our 
own data set focusing on prostates from rat offspring from either a control or 
experimental high fat maternal diet. As shown in Figure 6-3A, there are potential outliers 
which can be removed prior to performing any differential methylation analyses. For 
example, there were 7 samples that produced < 1 million MspI cut sites and 4 samples 
that produced > 6 million reads. Ideally, msGBS sequencing should be performed 
multiple times to produce technical replicates enabling us to determine if outliers were 
introduced as a result during sequencing. For the purpose of this experiment, sequencing 
was performed once and we therefore removed these outliers prior to differential 






Figure 6-2: The output of the plotCounts function.  
The distribution of the library size compared to the total number of ApeKI cut sites produced for each sample from either the (A) 






Figure 6-3: The msgbsR pipeline on our rat prostate msGBS data. 
(A) Output of the plotCounts function showing the distribution of the total number of reads and 
cut sites per sample. Samples are coloured depending on their diet group. (B) A histogram of 
reads for a control sample showing a negative distribution. (C) A volcano plot showing 
differentially methylated sites (FDR < 0.01) between the control diet (blue dots) and the 
experimental diet (red dots). 
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6.2.4 Differential methylation analysis 
 
One of the advantages of msGBS experiments is the ability to sequence hundreds of 
samples from different groups or conditions, and thus increase statistical power in 
analyses. However, when experiments have numerous groups or conditions it can become 
time consuming to perform multiple analyses. The msgbsR package contains a function 
that automates normalisation and determines differentially methylated sites between 
groups. Since the data generated from a msGBS experiment is in the form of read counts, 
we can take advantage of tools typically used in RNA-seq analyses [11]. The diffMeth 
function uses edgeR [12] tools to automate splitting the data, perform normalisation and 
identify differentially methylated sites. We choose to use edgeR, since it works on the 
assumption that the read count data distribution is negative binomial. msGBS data is too 
negative binomially distributed (Figure 6-2B) which is represented in a random control 
sample from our own msGBS data. We performed differential methylation analysis using 
the diffMeth function, and found 31,768 sites to be differentially methylated (Figure 6-
2C). In other msGBS experiments there is generally more than one comparison. Thus, 
this function can quickly perform differential methylation analyses from an experiment 
where there is a large number of groups or conditions. 
6.3 Discussion 
 
The advancement of high throughput technologies has enabled varying sequencing 
techniques. However, there is a limited number of bioinformatics tools available for the 
analysis of all the available sequencing protocols. msGBS is a reduced representation of 
whole genome sequencing which can be used to study DNA methylation and parts of the 
genome that are normally inaccessible in other sequencing technologies [1]. However, 
there is a current lack of bioinformatics tools that are tailor made for the analysis of 
msGBS experiments within the literature. Here in this study we outline msgbsR, an R 
package which can be used in part of the pipeline in analysing msGBS experiments. Our 
package works by identifying methylated sites and read counts directly from sorted and 
indexed BAM files into the R environment and can verify if the reads have mapped 
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correctly to the recognition site of the RE by using a reference genome in the format of 
either a BSgenome or FASTA file. 
 
Reduced representation sequencing conducted in msGBS enable a larger number of 
samples to be sequenced, making this a more desireable methylation analysis platform 
compared to high-resolution protocols such WGBS. For example, in an agricultural 
setting it may be used to assess both genetic and epigenetic variation over mapping 
populations [13] or for assessing the epigenetic impact of breeding populations in new 
environments [14]. In a medical setting the DNA methylation data can be used to make 
group comparisons [15]. Furthermore, single nucleotide polymorphisms (SNPs) data can 
also be obtained from msGBS data, thereby making this approach essential for genome-
wide and epigenome-wide associations studies at the same time. msgbsR can also be used 
with non-methylation sensitive GBS to verify reads have been mapped correctly and to 
determine if there are any differences in read counts between groups, allowing it to be 
used in conjunction with other Bioconductor packages for assessing genetic variation, 
such as GWAStools [16]. 
Differential methylation can be performed using msgbsR which contains a wrapper 
function using edgeR [12]. We choose to make a wrapper function of edgeR since 
msGBS experiments typically contain samples from multiple groups. Performing 
differential methylation analyses can become time consuming especially when there are 
multiple comparisons to consider. Our wrapper function uses the recommend trimmed 
mean of M-values (TMM) normalisation method suggested by edgeR [17]. However, we 
do acknowledge users may wish to use other bioinformatics tools to perform differential 
methylation analyses. Users may want to perform other normalisation methods or use 
other downstream packages such as methylSig [18] a package designed to identify 
differentially methylated sites and regions. There are also other Bioconductor packages 
such as BiSeq [19] or DSS [20] which have been too can be used identify differentially 
methylated sites and regions. However, these tools have been primarily designed to work 
with whole genome bisulphite (WGBS) sequencing whereby methylation is determined 
through the proportion of methylated and un-methylated reads, and may not necessarily 
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fulfil the user requirements when working with msGBS data. The output of msgbsR after 
reading the sorted and indexed BAM file(s) is SummarizedExperiment, a data format 
which is compatible with other Bioconductor packages. Therefore, users can then use 
other packages within their own msGBS pipeline after msgbsR has read the data into the 
R environment.  
 
The msgbsR package contains a variety of functions to automate the data analysis of a 
msGBS experiment. The input and output of the functions used in the msgbsR package 
are compatible with Bioconductor packages such as BSgenomes, and edgeR [12]. 
Furthermore, msgbsR is fully documented, contains a tutorial data set and is freely 
available from Bioconductor.  
6.4 Methods 
6.4.1 Library preparation and sequencing of rat msGBS 
 
DNA was extracted from prostates and then digested with EcoRI and MspI using the 
MSAP technique [21, 22]. EcoRI is a restriction enzyme and recognises the sequence 
G^AATTC and is not methylation sensitive. Illumina sequencing primer adapters were 
ligated to the digested genomic DNA. Using a technique as previously described [23, 24], 
cycling was performed using a BioRad 100 thermocycler at 37˚C for 2 hours followed by 
enzyme inactivation for 20 min at 65˚C. Barcoded adapters were designed with an MspI 
overhang and a common Y adapter with an EcoRI overhang using the script by Thomas 
P. van Gurp (www.deenabio.com/services/gbs-adapters) and were ligated as previously 
described [23]. T4 ligase (200U) and T4 ligase buffer (NEB T4 DNA Ligase #M0202) 
along with 0.1 ρmol and 15 ρmol of the barcoded MspI adapter and EcoRI adapter 
respectively. The reaction mixture was incubated at 22˚C for 2 hours and then 65˚C for 
20 mins for enzyme inactivation. 5µL from each ligation reaction were pooled together 
and then divided into equal volumes for column clean-up using the PureLink PCR 
Purification Kit (Life Technologies). Samples were then pooled back together for a total 
of 60µL in molecular biology grade water. PCR reactions were performed in a 25µL 
volume with 10µL of digested DNA, 5µL of 5x NEB MasterMix, 2µL of 10µM Forward 
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and Reverse primers at 10µM. PCR cycle reactions (Solexa) were performed at 98˚C for 
30 seconds, followed by 16 cycles of 98˚C for 30 seconds, 62˚C for 20 seconds and 72C 
for 30 seconds and finally 72˚C for 5min. Size selection of fragments was performed 
using Ampure XP magnetic beads (Beckman). Fragments were captured and eluted into 
30µL of water. Samples were sequenced using an Illumina HiSeq 2500 (Illumina Inc., 
San Diego, CA, USA) at the Queensland Brain Institute (QBI).  
6.4.2 Publicly available data set 
 
The publicly available data set (SRP004282.1) used to demonstrate several functions of 
msgbsR was firstly obtained from the Sequence Read Archive (SRA) [25]. SRA files 
were then converted to FASTQ files using the SRA tool kit [26]. This study contained 
two data sets containing samples from either barley or maize leaves [2]. Both data sets 
were demultiplexed using specific barcodes provided within the study [2] and GBSX 
[27]. This resulted in each individual sample from each data set in a FASTQ format. 
6.4.3 Processing of sequencing data 
 
Alignment of reads was performed using bowtie2 v2.2.3 [8] to each respective reference 
genome. We used the latest barley reference genome (ASM32608v1) which was obtained 
from the plant Ensembl website (plants.ensembl.org/Hordeum_vulgare/). For maize, we 
used the Ensembl release (AGPv4) which we obtained from the Illumina iGenomes 
website. For the Rat data we used UCSC latest release (rn6) which was obtained from the 
Illumina iGenomes website. Alignment with bowtie2 resulted in BAM files which were 
then sorted and indexed using SAMtools v1.2 [9]. The sorted and indexed BAM files 
were then directly read into the R environment using the rawCounts function within the 
msgbsR package enabling downstream analyses with msgbsR. Since the offspring were 
from some of the same mothers, differential methylation was performed using the mother 
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7 A prognostic DNA methylation signature for pregnancy 
complications 
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Abstract   
DNA methylation is an epigenetic modification well known for regulating gene 
expression. DNA methylation changes provide good prognostic and diagnostic 
biomarkers for a range of health issues, as well as being used to determine an individual’s 
age and probability of cancer relapse. In this study, we focused on DNA methylation as a 
prognostic tool to identify women who subsequently develop a pregnancy complication.  
We assessed DNA methylation using a methylation-sensitive genotyping by sequencing 
(msGBS) assay using DNA extracted from circulating maternal leukocytes at 15 weeks’ 
gestation from women who went on to have an uncomplicated healthy pregnancy or 
developed gestational diabetes mellitus (GDM), preeclampsia (PE), preterm birth (PTB) 
or delivered a small for gestational age (SGA) baby. msGBS provided DNA methylation 
data for 2,610,160 sites from 402 women. Using a recursive feature-elimination method, 
we built binary classification models for each pregnancy complication using 
uncomplicated pregnancies as a reference group. In total, we identified 84 methylated 
sites that can distinguish women having either a GDM, PE, PTB or SGA pregnancy. We 
were also able to build other predictive models of other clinical characteristics such as 
maternal smoking and BMI. This study highlights the potential of DNA methylation from 
maternal blood as a non-invasive, prognostic tool in predicting pregnancy complications.  
7.1 Introduction 
 
Pregnancy complications such as gestational diabetes mellitus (GDM), preeclampsia 
(PE), preterm birth (PTB) and small for gestational age (SGA) are major causes of 
maternal and perinatal morbidity and mortality. Pregnancy complication rates vary 
worldwide, the most common, GDM, affects up to 20% of women worldwide [1]. PE is a 
154 
 
hypertensive disorder of pregnancy which occurs after 20 weeks’ gestation and affects 2-
10% of pregnancies worldwide [2]. PTB occurs when infants are born before 37 weeks’ 
gestation and affects up to 11% of pregnancies worldwide [3]. IUGR, defined as an infant 
born < 5th percentile of birth weights affects up to 3-7% pregnancies worldwide [4].  
Prediction of a pregnancy outcome prior to the onset of a complication would be 
clinically very useful to reduce or possibly prevent any maternal or perinatal morbidity or 
mortality. Previous prediction models have included the use of Doppler ultrasound 
approaches, maternal serum levels of beta human chorion gonadotrophin (β-hCG), 
inhibin A and pregnancy-associated plasma protein A (PAPPA), placental growth factor 
[5-11]. However, in other biomedical settings analysis of DNA methylation is proving to 
be an appropriate candidate for disease outcome prediction. In this study, we focused on 
the most widely studied epigenetic modification, 5’ methylcytosine DNA methylation, 
where DNA is methylated via the addition of a methyl group to a cytosine. DNA 
methylation is essential for development [12] and is influenced by both genetic [13] and 
environmental factors [14]. Epigenetic marks, including DNA methylation, can  
contribute to identification of complex phenotypes and diseases.  
DNA methylation has proven to be an effective biomarker for disease prediction and 
clinical characteristics. It has been used to predict age [15, 16], cardiovascular disease 
[17], cancer [18, 19], mortality [20] and other clinical characteristics such as obesity and 
smoking [21]. In a reproductive setting it has also been used to predict gestational age 
from cord blood [22] and placental tissue [23]. However, no study has used DNA 
methylation as a biomarker for the prediction of pregnancy complications. 
In this study, we used a methylation sensitive genotyping by sequencing (msGBS) 
approach to firstly assess DNA methylation in leukocytes isolated from maternal blood. 
Extracting leukocytes from the maternal blood, which are in a high abundance to be 
profiled properly, is a non-invasive method to profile pregnant women. The latter was 
obtained from women who participated in the Screening fOr Pregnancy Endpoints 
(SCOPE) study at 15 weeks’ gestation [24]. Using this DNA methylation data set we 
were able to build predictive models of pregnancy complications, including, GDM, PE, 
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PTB and SGA. Our approach has identified selected methylated sites that can predict 
pregnancy outcome and other clinical characteristics.  
7.2 Methods 
7.2.1 Pregnancy data set 
 
Ethics approval was obtained from the local ethics committee (REC 1712/5/2008) and all 
women provided written informed consent. Women in this study were recruited from the 
Lyell McEwin Hospital, South Australia. Women were recruited into the SCOPE study 
from November 2004 to February 2011 and were nulliparous and were having singleton 
pregnancies. In total, blood collected at 15 weeks’ gestation from 402 women was used in 
this study. Clinical outcomes and measurements of the participants (Table 7-1) were 
collected as part of the SCOPE study. Body mass index (BMI) was collected at 15 weeks 
gestation, the same time as the collection of the blood. GDM was defined using a 
Glucose Tolerance Test with a reading of 5.5 mM or higher when fasting or a 2 h level of 
8 mM or a random glucose level of > 11 mM. PE was defined as systolic blood pressure 
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg post 20 weeks’ gestation 
occurring at least twice 4 h apart with proteinuria (24 h urinary protein ≥ 300 mg). PTB 
was defined as birth occurring prior to 37 weeks’ gestation. SGA was defined as 





Table 7-1: Characteristics of participants used for the final DNA methylation data set after outliers were removed. 
Characteristics are represented as mean and standard deviation unless detailed otherwise. 




Small for Gestational 
Age 
N 178 31 54 48 74 
Maternal Age (years) 23.5 ± 5.2 28.5 ± 4.7 23.3 ± 4.2 24.1 ± 6.0  24.3 ± 5.7 
Gestational Age at delivery 
(weeks) 
40.1 ± 1.1 39.1 ± 1.1 38.9 ± 1.9 32.9 ± 4.5 40.0 ± 1.4 
Fetal Sex (F/M) 93/85 17/14 29/25 21/27 36/38 
Birth Weight (g) 3570 ± 387 3316 ± 444 3417 ± 536 2164 ± 851 2711 ± 356 
Birth Length (cm) 50.1 ± 1.8 48.8 ± 2.0 49.5 ± 2.5 42.1 ± 9.5 47.3 ± 2.1 





7.2.2 DNA isolation  
 
Buffy coats were isolated from EDTA blood samples by adding proteinase K (20µg/µL) 
and inverting, followed by the addition of 20% Sodium Dodecyl Sulphate (SDS).  The 
resuspended solution in TES solution was then incubated for 24 h at 37˚C followed by 
the addition of an equal volume of 3M NaCl and mixed vigorously. The solution was 
precipitated on ice and then centrifuged at 13,000 rpm for 10 mins. The supernatant was 
removed and combined with 2x the volume of 100% ethanol. The DNA was then 
precipitated and washed with 70% ethanol. The pellet of DNA was then dried and re-
dissolved in Tris-EDTA (TE) buffer. DNA was assessed and quantified on a Thermo 
Fisher Scientific NanoDropTM 1000 Spectrophotometer.  
7.2.3 Library Preparation and sequencing  
 
Using a modified methylation sensitive amplified polymorphisms (MSAP) technique [25, 
26], DNA was digested with EcoRI and MspI (Figure 7-1). MspI is a restriction enzyme 
which cleaves DNA at C^CGG, only when the internal cytosine is methylated. EcoRI is a 
restriction enzyme and recognises the sequence G^AATTC. Illumina sequencing primer 
adapters were ligated to the digested genomic DNA. Using a technique previously 
described [27, 28], reactions were performed in a 96 well plate (95 samples, 1 water as a 
control). Cycling was performed using a BioRad 100 thermocycler at 37˚C for 2 h 
followed by enzyme inactivation for 20 min at 65˚C. 96 barcoded adapters 
(Supplementary Table 7-1) were designed with an MspI overhang and a common Y 
adapter with an EcoRI overhang using the script by Thomas P. van Gurp 
(www.deenabio.com/services/gbs-adapters). A 40µL ligation reaction as described by 
[27], was carried out using the same 96 well plate. T4 ligase (200U) and T4 ligase buffer 
(NEB T4 DNA Ligase #M0202) along with 0.1 ρmol and 15 ρmol of the barcoded MspI 
adapter and EcoRI adapter respectively. The reaction mixture was incubated at 22˚C for 2 
h and then 65˚C for 20 mins for enzyme inactivation. 5µL from each ligation reaction 
were pooled together and then divided into equal volumes for column clean-up using the 
PureLink PCR Purification Kit (Life Technologies). Samples were re-pooled for a total of 
60µL in molecular biology grade water. PCR reactions were performed in a 25µL volume 
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with 10µL of digested DNA, 5µL of 5x NEB MasterMix, 2µL of 10µM Forward and 
Reverse primers at 10µM. PCR cycle reactions (Solexa) were performed at 98˚C for 30 s, 
followed by 16 cycles of 98˚C for 30 s, 62˚C for 20 s and 72˚C for 30 s and finally 72˚C 
for 5min. Size selection of fragments was performed using Ampure XP magnetic beads 
(Beckman). Fragments were captured and eluted into 30µL of water. Samples were 
sequenced using an Illumina HiSeq 2500 (Illumina Inc., San Diego, CA, USA) at the 
Queensland Brain Institute (QBI). To achieve a high sequencing depth and coverage, 






Figure 7-1: Library preparation of msGBS prior to sequencing and analysis.
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7.2.4 Processing raw sequencing data 
 
Samples were demultiplexed using specific barcodes for each sample using GBSX [29]. 
Paired end samples were merged together using BBMerge [30] with a minimum overlap 
of 25bp. Reads were aligned to the human reference genome (UCSC hg38) using bowtie2 
v2.2.3 [31]. The MspI cut sites generated from this experiment were located and 
confirmed using the msgbsR package [32]. The MspI cut sites were annotated using a 
gff3 file of the human genome which was obtained from Ensembl [33]. 
7.2.5 Single nucleotide polymorphism overlap 
 
Since single nucleotide polymorphisms (SNPs) can disrupt the recognition site by 
altering the sequence, we determined the overlap of MspI cut sites produced compared to 
common SNPs within the human population using dbSNP (SNP147) [34]. This database 
contains approximately 150 million SNPs that are present within at least 1% of the 
human population [34]. Overlap of SNPs with MspI cut sites was performed using the R 
package GenomicFeatures [35].  
7.2.6 Principal component linear discriminant analysis plots and feature 
selection 
 
Principal component linear discriminant analysis (PC-LDA) plots were generated by 
firstly performing a linear discriminate analysis on all MspI cut sites using the FIEmspro 
R package [36]. We performed feature selection to reduce the total number of MspI cut 
sites in order to identify markers of clinical outcomes and characteristics. Feature 
selection was performed using the FIEmspro R package where the total number of MspI 
cut sites selected was equal to 1% of the total number of samples for each comparison, 
thereby selecting the most important sites and reducing overfitting. We then used these 





7.2.7 Building predictive models of categorical clinical outcomes and 
characteristics  
 
In order to develop predictive models we firstly divided the data into a training and 
testing data set to build and train our models (Figure 7-2). 70% of the samples, with each 
specific pregnancy outcome and from the uncomplicated term group, were randomly 
assigned to a training data set, with the other remaining samples being assigned to a 
testing data set. In order to identify which MspI cut sites can be used to predict clinical 
outcomes and characteristics, we used a recursive feature elimination (RFE) method 
implemented in the caret R package [37].  The RFE method firstly fits a model with all 
predictors (MspI cut sites), then after multiple iterations returns the model with the best 
performance and the minimum number of predictors required. We also performed the 
RFE method using a repeated cross validation and with different functions including 
linear discriminant analysis, random forests, naïve Bayes and bagged trees. We then 
selected the best performing function, which we defined with the highest accuracy in the 
testing data set after 10-fold cross validation. This resulted in a model with the minimum 
MspI cut sites required to predict a clinical outcome or characteristic. The ROCR R 
package [38] was used to calculate area under the curve (AUC) values for receiver 









Figure 7-2: Flow diagram of model construction to identify biomarkers of pregnancy 
outcome and other clinical characteristics or outcomes.
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7.2.8 Building predictive models of continuous characteristics  
 
In order to build models that can assess a continuous characteristic such as maternal age, 
we used the glmnet R package [39]. The data was firstly divided into training (70%) and 
testing (30%) data sets and using an elastic net regression method, the normalised and 
batch corrected methylation data was regressed against a continuous characteristic. The 
elastic net regression model automatically selects the minimum number of sites that are 
required to accurately predict an outcome. These sites were then used in the testing data 
set to assess a model’s performance.  
7.2.9 Functional Annotation 
 
Functional annotation was conducted using the closest gene to a cut site which was then 
used to identify enriched Gene Ontology (GO) terms. Annotation was performed using 
the hg38 reference genome obtained from Ensembl [40]. GO enrichment was conducted 
using all human genes in the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.8 [41] and g:Profiler [42].  
7.3 Results and Discussion 
7.3.1 DNA methylation data set 
 
On average, 1,418,372 reads were aligned to the human reference genome per sample 
with an average alignment rate of 82.6%. The resulting table of read counts contained a 
total of 2,610,160 MspI cut sites across all the autosomal chromosomes and the X 
chromosome (Supplementary Figure 7-1). We removed outliers that generated >20 
million reads (1 sample) and <100,000 and >600,000 cut sites (13 samples). Ideally, these 
samples would then have to be sequenced again. This resulted in a DNA methylation data 
set of 388 samples (Uncomplicated = 178, GDM = 31, PE = 54, PTB = 48, SGA = 74, 
Multiple Complications = 3), which was used for downstream analyses. On average, 
303,052 methylated sites were produced per sample. The average (mean) distance from 
the start site of a gene was 500,511 bp and the total number of sites per chromosome are 
supplied in Supplementary Table 7-2. 
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7.3.2 Removal of potential SNP-driven differences 
 
SNPs can often disrupt restriction enzyme recognition sites, so we set out to remove 
MspI cut sites which overlapped with a SNP that was present in at least 1% of the 
population. We obtained the full database of common SNPs (see methods) within the 
human population and determined the overlap with the MspI cut sites generated in our 
DNA methylation dataset. In total, 32% of all MspI cut sites overlapped with a common 
SNP. These were all removed from the data. We then constructed models to predict 
pregnancy complications and other clinical characteristics using this methylation data set. 
7.3.3 DNA methylation at 15 weeks’ gestation is a biomarker of subsequent 
pregnancy outcome 
 
After the removal of confounding SNP sites, we initially built predictive models of 
pregnancy complications using all remaining MspI cut sites generated from all 
chromosomes. However, due to high variability of DNA methylation in X chromosome 
inactivation [43-45], we found it advantageous to remove the X chromosome sites from 
the analysis. This is because X inactivation is not consistent within each sample and is 
random. This left a total of 1,665,641 MspI cut sites on autosomal chromosomes to build 
predictive models of pregnancy complications. 
PC-LDA revealed pregnancy outcome can be separated by DNA methylation (Figure 7-
3A). This analysis suggests that there are selected methylated sites that are responsible 
for distinct clustering. As described in the methods, we applied a machine learning 
method to identify sites which are able to distinguish defined pregnancy complications 
and build predictive models of future pregnancy complications. Samples from the 
uncomplicated pregnancy group comprised the reference group and binary classification 
models were built for each pregnancy complication. Hierarchical clustering (Figure 7-3B) 
indicates that GDM, PE and PTB are distinctively different in comparison to the 
uncomplicated group. It also suggests that the SGA group is the most similar to the 
uncomplicated group. This was most likely due to SGA being defined as babies born 
<10th customised centile. Some of these babies may have been growth restricted and 
others constitutionally small but normal. The GDM, PE and PTB may be distinctively 
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different from the SGA and uncomplicated group due to unknown factors influencing 
their methylation profiles. Potential factors could have included maternal characteristics 
such as smoking which is known to impact fetal growth [46-48]. These pregnancy 
complications are influenced by a combination of genetic and environmental factors. 
These factors can also impact on methylation profiles which may potentially distinguish 






Figure 7-3: Separation of pregnancy outcomes by DNA methylation 
A. PC-LDA plot of the three discriminant functions highlighting differences in DNA methylation patterns between pregnancy 
outcomes. B. Hierarchical clustering based on PC-LDA of pregnancy outcome. Small for gestational age (SGA) and the 
uncomplicated group are similar based on DNA methylation, whereas gestational diabetes mellitus (GDM), preeclampsia (PE) and 
preterm birth (PTB) are distinctively different.
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Our 10-fold cross validation on the testing data set returned an excellent AUC ≥ 0.9 for our 
GDM and PTB in ROC analyses (Figure 7-4, Table 7-2). A good AUC for our PE and SGA 
models (Figure 7-4, Table 7-2) and a moderate sensitivity and high specificity rates across all of 
our models (Table 7-2) were achieved. Our GDM model required a total of 20 sites, whereas the 
PE, PTB required 21 sites each and the SGA model required 24 sites (Table 7-2, Figure 7-5). 
Although, not marginally different in the total number of sites in each model, the more separated 
group, GDM, did require the least number of sites. Potentially, the more distinct groups from the 
reference or uncomplicated group required fewer sites for accurate prediction. Two chosen MspI 
sites (chr11:43579222 and chr18:76001386) were common to both the GDM and SGA models 
(Figure 7-5). These sites were 27bp and 6732bp upstream, respectively, from the start site of two 
long intergenic non-coding RNAs (lincRNA) (Supplementary Table 7-3). These markers may 
have been chosen by the model as they are markers of uncomplicated term pregnancies. This 
would explain why there is an overlap of markers between the two models despite the two 
pregnancy complications clustering separately in hierarchical clustering (Figure 7-3). However, 
the focus of this study was to identify biomarkers and therefore any association with particular 
genes is outside the scope of this study. The models were also built independently of clinical 
characteristics such as smoking and BMI. This was to determine if such biomarkers can be found 
that are strong enough to predict the pregnancy outcome regardless of clinical characteristics. 
Furthermore, it is difficult to determine or incorporate clinical characteristics into the pregnancy 
outcome models since there some of the groups had a low percentage of these characteristics 
(Table 7-1). For example, 9.6% and 5.6% of GDM and PE samples were smokers, respectively. 
Due to a low sample size of smokers and statistical power in these groups, characteristics such as 




Figure 7-4: Receiver operating characteristic curves showing the false positive rate (100-
Specificity) against the true positive rate (Sensitivity). 
A. Gestational Diabetes Mellitus (GDM) B. Preeclampsia (PE) C. Preterm Birth (PTB) 






Table 7-2: Accuracy measures and number of MspI cut sites required for each pregnancy complication model. 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) are represented as mean and standard 
deviation. 
AUC: area under the curve, NPV: negative predictive value, PPV: positive predictive value. 
 GDM PE PTB SGA 
 Training Testing Training Testing Training Testing Training Testing 
Sensitivity 0.54 ± 0.13 0.49 ± 0.15 0.66 ± 0.05 0.66 ± 0.11 0.73 ± 0.06 0.61 ± 0.12 0.81 ± 0.05 0.55 ± 0.07 
Specificity 0.98 ± 0.01 0.94 ± 0.05 0.95 ± 0.01 0.92 ± 0.03 0.96 ± 0.02 0.93 ± 0.05 0.95 ± 0.02 0.86 ± 0.04 
PPV 0.84 ± 0.07 0.68 ± 0.23 0.80 ± 0.04 0.70 ± 0.10 0.83 ± 0.08 0.72 ± 0.17 0.88 ± 0.03 0.62 ± 0.08 
NPV 0.92 ± 0.02 0.91 ± 0.02 0.91 ± 0.01 0.91 ± 0.03 0.93 ± 0.02 0.90 ± 0.03 0.92 ± 0.02 0.82 ± 0.02 
AUC 0.98 0.97 0.94 0.89 0.95 0.96 0.92 0.81 












7.3.4 What is known about the pregnancy outcome biomarkers? 
 
In total, 84 MspI sites across all autosomal chromosomes were identified as biomarkers 
for the four pregnancy complications studied (Figure 7-6, Supplementary Table 7-3). 26 
of the 84 sites were annotated to be within genomic locations of unknown biological 
function. The remaining sites were within (< 80kbp) known genomic features such as 
genes, exons, introns, 5´ untranslated regions (5´ UTR) and 3´ untranslated regions (3´ 
UTR). However, these sites can be a large distance from these genomic features 
(Supplementary Table 7-3). For example, one site was 79,030bp from the start of an exon 
(Supplementary Table 7-3). A GO enrichment for the sites to the closest genes returned 
no significant terms for any of the models. However, the aim of this study was to identify 
biomarkers and since there is no associated gene expression data we are unable to 




Figure 7-6: A circos plot showing the positions of the MspI cut sites identified as 




7.3.5 Intrauterine growth restriction (IUGR) 
 
In the binary classifier model for SGA we achieved AUC value of 0.81. Whereas the 
other models achieved much higher AUC values (> 0.89). The SGA model may 
potentially have not achieved as good an AUC value as the other models since some 
participants may have been classified as SGA, but are actually well nourished and are just 
genetically small. Therefore, some of the SGA participants may be genetically small but 
are not growth restricted. We then constructed another model using a more stringent cut 
off for SGA, using the participants who either had an uncomplicated pregnancy or had an 
infant that was < 5th centile, which was classified as IUGR. This model consisted of 37 
IUGR participants (Supplementary Figure 7-2A) and achieved an improved AUC value 
of 0.85 (Supplementary Figure 7-2B, Supplementary Table 7-4). This also resulted in the 
IUGR group being distinctively different to the uncomplicated group. Interestingly, the 
IUGR and SGA models both contained 3 of the same chosen MspI cut sites 
(Supplementary Table 7-5). This suggests there may be similarities in methylation 
profiles in SGA and IUGR. However, IUGR is a subset of SGA and the overlapping sites 
may potentially be statistically stronger in distinguishing the separation between 
comparisons. As described above the classification for SGA and IUGR differs by birth 
weight centile threshold. Therefore, some of the individuals that were classified in the 
SGA group were also IUGR individuals. The IUGR model may have achieved better 
performance compared to the SGA model since these fetuses may have been under 
nourished creating a distinct methylation profile.  
7.3.6 Comparing the DNA methylation models to existing pregnancy 
complication models  
 
There have been previous attempts at building predictive models for pregnancy 
complications. Our sensitivity, specificity and AUC were either comparable or better than 
those reported in other studies for GDM [49] (AUC = 0.91), PE [50-54] (AUC = 0.89, 
0.66, 76, 76, 0.97, respectively), PTB [55] (0.75) and SGA [56] (0.77) prediction. 
However, these studies did not use DNA methylation but focused on using serum 
concentrations of proteins. Serum levels of proteins are known to have high variability 
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[57, 58], which may have implications for biomarker design. Unlike protein levels, 
epigenetic marks including DNA methylation are relatively stable [59]. This makes 
methylated sites excellent candidates for biomarker prediction. Future studies should 
focus on incorporating DNA methylation into models for disease prediction. Due to 
epigenetic stability and low variability they can be used for more accurate prediction. 
Moreover, the declining cost of high throughput sequencing would increase the 
practicality of incorporating DNA methylation data into other disease prediction models. 
7.3.7 Biomarkers of smoking  
 
Cigarette smoking during pregnancy increases the risk of adverse outcomes for the 
developing fetus [60]. Many women who smoke quit once they find out they are 
pregnant. However, some continue to smoke throughout pregnancy. At 15 weeks’ 
gestation we were able to identify distinct MspI sites in women who had quit and those 
who continued smoking compared to those who did not smoke. We built models on the 
basis of self-reported information about maternal smoking status. Women who were non-
smokers were used as a reference group (n = 220) to build predictive models for women 
who had quit smoking (n = 59) or continued to smoke (n = 103). We built these models 
regardless of pregnancy outcome. Women who were either non-smokers, had quit 
smoking or continued smoking at 15 weeks’ gestation were able to be distinguished by 
DNA methylation profiles (Supplementary Figure 7-3A). We achieved highly accurate 
models for both quit smoking and continued smoking (Supplementary Table 7-4, 
Supplementary Figure 7-3B). DNA methylation has been previously used as a biomarker 
of smoking [21] and our study, reinforces the notion that smoking can influence DNA 
methylation patterns. It also illustrates that despite quitting smoking during early 
pregnancy there can be an everlasting epigenetic effect in maternal blood and presumably 
other tissues that may impact pregnancy outcome and long term health. However, we 
have previously reported that women who quit smoking before 15 weeks’ had similar 





7.3.8 Discrepancies in DNA methylation of women from different BMI 
categories 
 
Obesity during pregnancy is associated with GDM and hypertension [61]. Furthermore, 
differential methylation is associated with differences in BMI [62, 63]. In this study, we 
also determined if models could be built using DNA methylation to predict BMI in 
pregnant women. These models were built using a normal BMI range (20-25) as a 
reference group and were trained to predict underweight (BMI <20), overweight (BMI 
25-29.9) and obese (BMI ≥30) individuals. A PC-LDA revealed that these different BMI 
categories can be separated by DNA methylation (Supplementary Figure 7-4A). We 
achieved a high separation and accurate prediction (Supplementary Figure 7-4B, 
Supplementary Table 7-4) for underweight individuals (sensitivity = 0.96 ± 0.03, 
specificity = 0.58 ± 0.12, AUC = 0.95). We also achieved moderately accurate prediction 
for both overweight (sensitivity = 0.87 ± 0.05, specificity = 0.77 ± 0.07, AUC = 0.87) and 
obese individuals (sensitivity = 0.82 ± 0.08, specificity = 0.69 ± 0.06, AUC = 0.85). The 
BMI, along with the smoking and pregnancy outcome predictors are among the high 
performing models that were generated within this study.  This analysis suggests that 
underweight individuals have more distinct methylation patterns than overweight and 
obese individuals compared to a normal BMI. Potentially, being underweight may also 
mean that these individuals are micronutrient deficient compared to the overweight and 
obese individuals. Therefore, the methylation profiles may also be capturing other factors 
such as micronutrient status in underweight individuals which may explain the distinct 
methylation profile. In addition, although BMI can be easily measured, this analysis 
shows that there are distinct methylation profiles. This suggests that BMI can exert 
profound effects on DNA methylation patterns. Therefore, this may uncover molecular 
mechanisms associated with BMI, which could assist in explaining the effects of BMI.   
7.3.9 Circulating factors in maternal blood associated with DNA 
methylation  
 
Folate is part of the one carbon metabolism pathway which is essential for the production 
of methyl groups for DNA methylation [64]. We set out to determine if DNA methylation 
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can be used to determine the folate status of an individual. We initially attempted, using 
an elastic net regression method, to predict serum folate however this had poor 
performance, potentially due to a low spread of the data (±10nM). We therefore found it 
advantageous to categorise the data. Serum folate status was categorised into two groups 
using the median (34.4nM) as a threshold. We were able to identify 21 sites 
(Supplementary Table 7-4, 7-8) that can moderately predict high serum folate from low 
levels (Supplementary Figure 7-5A, 7-5B). One of the disadvantages of categorising the 
data is that samples close to the median can be incorrectly predicted. There is evidence of 
this in the PC-LDA plot (Supplementary Figure 7-5A) where samples of high and low 
serum folate are overlapping. We also set out to determine if level of methylation 
between the two serum folate groups differed. We determined the mean level of DNA 
methylation using all the MspI sites (Supplementary Figure 7-6A) or the selected sites 
within the model (Supplementary Figure 7-6B). We found no difference between the 
groups when using all the MspI sites, however, we found a significantly higher level of 
DNA methylation in the low folate serum group when using the selected sites within the 
model. This may provide the rationale for why these sites were distinguished between the 
two groups.  
 
Despite folate being well known for its role in the production of methyl groups a lower 
level of methylation was found in the higher folate status group. This is interesting as it 
may seem contradictory that having a high folate status is associated with low 
methylation levels. However, it is important not to forget that this assay only measures 
methylation at MspI sites and therefore the true extent of methylation has not been 
accurately quantified. Other sequencing methods such as whole genome bisulphite 
sequencing would capture the true extent of methylation. Since the true extent of the level 
of methylation in these samples has not be accurately quantified it is difficult to draw 
conclusion regarding the level of methylation and folate status.  
 




Previous studies have used DNA methylation to determine an individual’s age [15, 65]. 
We too set out to determine if maternal age can be determined using our DNA 
methylation data set using an elastic net penalised regression method as previously 
described [15, 39] (see methods). Unfortunately, we were unable to build an accurate 
predictive model of maternal age. The model failed to predict the maternal age in the 
testing data set (r =0.0), which may have been in part due to the narrow age range in these 
pregnant women (Table 7-1). This was surprising since models using DNA methylation 
have been previously developed to determine age [15, 65]. However, these studies have 
used microarray technology to build predictive models. Although, this study captured 
2,610,160 methylated sites, the sites required to predict age in other studies may not be 
present in our methylation data set. We therefore downloaded the positions of all sites in 
the Illumina Infinium HumanMethylation450 BeadChip from Illumina which have been 
used in other studies to predict age [15, 65]. We compared these sites to those generated 
in our study using msGBS. We found that none of the sties used in the microarray 
technology were present in our DNA methylation data set. This could potentially be a 
reason why we were unable to generate a model that can predict maternal age. In 
addition, this also makes it difficult to compare epigenome wide association studies 
(EWAS) since most studies use Illumina array technology. This suggests that determining 
age is site specific and that the sites captured in the current study may only be useful for 
prediction of certain characteristics.  
Although this study has been successful in identifying sites that can be used to predict 
pregnancy complications, smoking status and BMI categories, we were unable to build 
predictive models for many other clinical outcomes and characteristics. For example, we 
were unable to determine maternal characteristics such as blood pressure (diastolic and 
systolic), height, micronutrient status and supplement use. These factors may not have 
been able to be predicted due to low sample sizes for these characteristics. We were also 
unable to determine other fetal characteristics such as sex, birth length, birth weight and 
final gestation. These fetal characteristics may potentially not have any influence on 
maternal blood factors such as DNA methylation. Factors within the cord blood are likely 
to be better indicators of fetal characteristics than maternal blood. However, it is 
estimated that there are approximately 28 million CpG sites in the human genome [66]. 
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This study was able to capture 2.7 million methylated sites and therefore there may 
potentially be other sites more suitable for prediction of these characteristics.  
7.3.11 Strengths and limitations 
 
Conducting msGBS has its strengths and limitations. In comparison to other DNA 
methylation assays such as microarrays, it provides an unbiased approach to selection of 
methylated cytosine sites. Also compared to DNA methylation sequencing based 
techniques it is cost effective [67] and allows up 96 samples to be run at once. Although 
in this study we sequenced each sample three times, therefore a total of 32 samples could 
be run at once. A limitation of msGBS is that it is restricted to selected recognition sites. 
In this experiment, the restriction enzyme MspI was used, which has a recognition 
sequence of CCGG. DNA methylation was analysed at CCGG sites and other sites were 
not analysed. This potentially would have left other methylated sites out of the analysis 
that would be more suitable predictors. However, msGBS can be performed again, but 
with other methylation sensitive restriction enzymes, thereby covering more sites of the 
genome.  
One of the challenges in building predictive models using DNA methylation data is 
working with the high complexity of potentially millions of variables. Due to the high 
number of variables of DNA methylation data sets, computational time can become 
overwhelming [68]. Since DNA methylation data sets suffer from high dimensionality it 
can be advantageous to perform feature selection [68]. This is one of the advantages of 
our method as by performing feature selection prior to building the models using the RFE 
method resulted in reduced computational time. This allowed us to build other predictive 
models in other clinical characteristics such as smoking and BMI. However, performing 
feature selection does have its pitfalls. A limitation is that it can result in overfitting 
which is a common problem where a model is trained on few data points. This results in 
poor performance of the testing data set. However, as shown in this study our predictive 
models perform very well on the testing data set. To ensure the robustness of our models 
it is also essential to validate our models on an independent data set to determine if any 
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potential overfitting of the data has occurred. Future studies are required to test our DNA 
methylation prognostic models to determine their true performance. 
 
In this study, we have analysed the methylation profiles in the maternal blood from five 
distinct pregnancy outcomes (GDM, PE, PTB, SGA and Uncomplicated pregnancies). 
Although this study has shown that DNA methylation can be used to identify women 
having different pregnancy outcomes, it still needs to be developed more before it can be 
used clinically. As mentioned this study analysed five distinct pregnancy outcomes, 
however there are more different types of pregnancy outcomes. For example, PE can be 
divided into early onset (< 34 weeks’ gestation) or late onset (≥ 34 weeks’ gestation). 
This study only analysed pregnancies from late onset PE. It has been shown that there are 
differences in placental DNA methylation profiles between early and late onset PE 
pregnancies [69-71]. Therefore, DNA methylation profiles may be distinctively different 
in the maternal blood. Ideally, for a clinical application, models would have be 
constructed against a broader range of pregnancy outcomes. However, the aim of this 
study was to determine if DNA methylation can be used to identify different pregnancy 
outcomes.  
 
Currently, DNA methylation as a biomarker has mostly dominated in cancer related 
applications [59]. However, this study shows that DNA methylation can be used in other 
fields of research such as a reproductive setting. Here in this study, we have developed 
prognostic models using the level of methylation at selected sites. These DNA 
methylation prediction models could potentially have a role in a clinical setting. They 
could identify high risk individuals such that early prevention can be administered 
thereby reducing or eliminating any risk of a pregnancy complication. We were also able 
to develop accurate prediction models for other clinical characteristics such as BMI and 
smoking. DNA methylation can be a valuable tool to determine such characteristics 





In this study, we have identified DNA methylation signatures of pregnancy 
complications. Using DNA methylation we were able to build predictive models of 
pregnancy outcomes and other clinical characteristics of pregnant women at 15 weeks’ 
gestation, a long time before the diseases become symptomatic. Future work is required 
to replicate our results and test our models in an independent cohort. This analysis 
highlights the possibility of using DNA methylation as a prognostic tool for pregnancy 
complications. 
7.5 Supporting Information 
 
For Supplementary Table 7-1, 7-2, 7-3, 7-4, 7-5, 7-6, 7-7 and 7-8 please refer to the 
electronic supporting information. 
Supplementary Table 7-1: Barcode adapter sequences used for msGBS. 
Supplementary Table 7-2: Total number of methylated MspI sites captured on each 
chromosome. 
Supplementary Table 7-3: Locations of pregnancy outcome biomarkers and the closest 
genomic feature. 
Supplementary Table 7-4: Accuracy measures and number of MspI cut sites required 
predictive models. 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) 
are represented as mean and standard deviation. 
Supplementary Table 7-5: Locations of biomarkers for the intrauterine growth 
restriction (IUGR) model. 
Supplementary Table 7-6: Locations of biomarkers for women who had quit smoking 
or continued smoking at 15 weeks’ gestation. 










Supplementary Figure 7-1: Total number of reads per sample compared to the total number of cut sites generated per sample. 









Supplementary Figure 7-2: Identifying biomarkers of intrauterine growth restriction (IUGR). 
A. Principal component linear discriminant analysis (PC-LDA) of pregnancy outcome. B. ROC curve of intrauterine growth 






Supplementary Figure 7-3: Identifying biomarkers for women who had quit smoking and continued smoking at 15 weeks’ gestation. 
A. Principal component linear discriminant analysis (PC-LDA) of non-smokers, women who had quit smoking and women who 




Supplementary Figure 7-4: Identifying biomarkers of different body mass index (BMI) 
categories.  
A. Principal component linear discriminant analysis (PC-LDA) of individuals of different 








Supplementary Figure 7-5: Biomarkers of serum folate status. 
A. Principal component linear discriminant analysis (PC-LDA) of individuals with high or low serum folate levels. B. ROC 





Supplementary Figure 7-6: Average level of DNA methylation between the low and high serum folate groups. 
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8 Discussion  
8.1 General Discussion   
 
The work presented in this thesis has focused on identifying molecular markers for the 
identification of phenotypic traits. These molecular markers have primarily been the 
expression of genes and DNA methylation that were assessed by either large scale meta-
analyses of genomic data or using next generation sequencing technology. This thesis has 
identified a significant number of sexually dimorphic candidate genes and cytosine-
phosphate-guanine (CpG) sites that can predict the gestational age of a placenta. These 
candidate sex-biased genes and gestational age predictor sites were identified by taking full 
advantage of publicly available genomic data, a significant resource for health-specific 
data analyses. Additionally, this thesis has also used RNA sequencing technology to 
identify novel large intergenic non-coding RNAs (lincRNAs) in placental tissue. Next 
generation sequencing was also used to identify methylated cytosine sites in DNA from 
maternal peripheral leukocytes sampled early in gestation that predict later pregnancy 
complications. Overall, this thesis demonstrates the potential for using large genomic data 
sets and next generation sequencing applications to identify gene targets and biomarkers 
related to placental function and pregnancy outcome. 
8.2 Overall Significance   
8.2.1 Tissue specific sex-biased gene expression  
 
The sex biased gene expression research presented in Chapter 3 uncovers new candidates 
for sexual dimorphism. Classically, sex biased gene expression was thought to only occur 
at sex chromosomes [1]. However, these results indicate that autosomal genes can also 
demonstrate sex differences in expression. This was the first study to utilise large genomic 
data to assess sex differences in gene expression across multiple human tissues. This study 
also shows that sex-biased gene expression is tissue specific. Furthermore, it has 
demonstrated sex-biased gene expression occurs in specific brain tissues. Therefore our 
data may provide novel sex specific targets for disease treatments and better understanding 
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of sex differences in disease prevalence and prognosis. Furthermore, this may have 
implications for clinical trials which have predominantly used male participants. In 
addition, when it comes to treatments for diseases our data suggest that different treatments 
for males and females should be explored. This is warranted because the large sex 
differences in gene expression may impact how drugs act and are metabolised. Thus, the 
research presented here in chapter 3 has implications in a range of biomedical clinical 
fields.  
8.2.2 Novel placental specific transcripts 
 
Previous work has uncovered approximately 50,000 previously unannotated long non-
coding RNAs (lncRNAs) across a range of human tissues [2]. However, there has been no 
previous assessment of placental tissue for unannotated lncRNAs. The research presented 
in chapter 4 in this thesis fills this gap. Here, RNA-seq was used on placental tissue from 
first trimester, uncomplicated term and preeclamptic pregnancies. The data were used to 
perform a de novo transcript analysis which identified 23 large intergenic non-coding 
RNAs (lincRNAs). These, once previously unannotated transcripts, may potentially have 
roles in placental development as some were gestation specific and differentially expressed 
in group comparisons. Furthermore, these lincRNAs have now provided new targets for 
investigation of placental development and pregnancy complications. They may potentially 
have roles in regulating specific placental gene expression which is required for a 
successful uncomplicated pregnancy. However, more research is required to determine 
their functional roles in placental development and pregnancy complications. Nonetheless, 
this research highlights how little is known about gene expression in the placenta. Tools 
such as RNA-seq, have the potential to identify new transcripts in the placenta which may 
be important in placental development and identify new mechanisms in the development of 
pregnancy complications. 
8.2.3 DNA methylation as a biomarker 
 
DNA methylation has been proven to be an effective biomarker in a range of biomedical 
applications. However, this thesis has, for the first time, demonstrated the potential of 
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DNA methylation as a biomarker in pregnancy. The placenta undergoes dynamic changes 
across gestation. Although the placenta has low methylation levels compared to other 
human tissues, there are observable changes in DNA methylation across gestation. As 
detailed in Chapter 5, we developed a computational method which uses levels of DNA 
methylation at 62 specific sites to predict the gestational age of a placenta. The predicted 
gestational age can be interpreted as the biological age of a placenta. When used in 
placentas from early onset preeclampsia (EOPE), the predicted gestational age was greater 
than the chronological gestational age, which is the age at sampling or delivery. This 
suggests accelerated molecular aging indicating aberrant placental development and likely 
function. This tool can be used in other pregnancy complications to determine if 
accelerated placental aging is specific to EOPE. Furthermore, it also provides novel insight 
into the molecular mechanisms involved in PE. 
DNA methylation, due to its high stability, has a strong potential as a biomarker. Besides 
gestational age prediction in the placenta, DNA methylation can also be used for predicting 
potential disease. As detailed in Chapter 7, we developed a computational tool that uses 
DNA methylation to predict pregnancy complications. We assessed DNA methylation 
from peripheral leukocytes isolated from maternal blood at 15 weeks’ gestation. This has 
potential as a non-invasive tool in a clinical setting to identify women who will later 
develop a pregnancy complication, well before symptoms develop. Clinically, it may 
identify women at risk and enable early interventions to either prevent or reduce the 
severity of pregnancy complications. Models were built for each specific pregnancy 
complication using uncomplicated pregnancies as a reference group. The majority of sites 
chosen were specific to each pregnancy complication. This suggests that the onset of each 
pregnancy complication has a unique mechanism. Furthermore, predictive models were 
also built that distinguish clinical characteristics including maternal smoking and BMI. 
8.3 Contributions to the field  
8.3.1 Sex-biased gene expression data base 
 
Many fields of biological research have historically neglected to account for sex 
differences [3, 4]. Therefore, there is a lack of sex-biased gene expression data available in 
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human tissues. In general, research is conducted mostly on male subjects, due to the 
assumption of female hormonal cycles being a confounding factor [3, 4]. Failing to 
account for sex differences can potentially have long lasting effects to the health and well-
being of women. Some sex differences in disease prevalence and prognosis may originate 
from dimorphic gene expression, many of which are autosomal and not related to sex 
hormone profiles. The sex-biased gene expression meta-analysis has resulted in a wealth of 
data and therefore is potentially important for future research into sex differences in health 
and disease. The sex-biased genes identified in this thesis can be used as a basis to 
determine potential mechanisms by which sexual dimorphism occurs in disease 
susceptibility. In addition, it has also identified targets for sex specific treatments.  
8.3.2 Placental gene expression 
 
The work presented here comprises a comprehensive analysis of placental gene expression 
during first trimester and in either uncomplicated term or preeclamptic pregnancies. We 
have identified 7240 differentially expressed genes between placentas from first trimester 
and uncomplicated term pregnancies. These are two important time points during gestation 
and the gene lists contain genes that are essential for placental development. Furthermore, 
8780 differentially expressed genes were found between placentas from first trimester and 
preeclamptic pregnancies. These are important analyses as they show differences that 
occur in PE compared to uncomplicated pregnancies across gestation.  
 
The identification of previously unannotated lncRNAs has uncovered potential targets for 
disease treatment [2]. Previously, the placenta has been left out of published analyses. 
However, one focus of this thesis is the identification of novel lincRNAs in placenta and 
placenta specific transcripts. Future research using very deep sequencing is required to 
identify other novel transcripts that may be specific to the placenta. Furthermore, our 
analyses suggest there is still more to learn about placental gene expression. Additional 
research is needed to determine the role of the identified novel lincRNAs in this thesis. 
Since some were specific to either first trimester or term placental tissue, this suggests they 
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may have a critical role in placental development. Therefore, these lincRNAs may become 
furture targets to prevent or treat specific pregnancy complications. 
8.3.3 Bioinformatics software 
 
Next generation sequencing creates a wealth of complex data that is challenging to analyse. 
In this study, data from a methylation sensitive-genotyping by sequencing (msGBS) 
experiment was analysed. Although bioinformatic tools such as Tassel [5] and Stacks [6] 
exist which can analyse GBS data, these tools cannot be used to analyse the methylation 
part of the experiment. The new R package presented in this thesis enables analysis of 
DNA methylation from a msGBS experiment. The R package automates the generation of 
a table of read counts after alignment. It can also verify the recognition sites generated by 
the restriction enzyme. This R package fills in the missing link from data generation to 
downstream analyses. It has also enabled downstream analyses such as differential 
methylation.  
8.3.4 Novel computational prediction tools for DNA methylation 
 
DNA methylation has been proven to be an effective biomarker in many fields of 
biological research such as age [7, 8] and cancer [9, 10]. In this thesis, I have developed 
several computational tools to investigate the level and distribution of DNA methylation in 
human samples. The first is a computational method to predict the gestational age of a 
placenta. This method used DNA methylation data generated from the Illumina BeadChip 
Arrays, a commonly used tool to quantify DNA methylation. The predicted gestational age 
or DNA methylation gestational age (DNAm GA) can be seen as the biological age of a 
placenta. This gives the ability to assess the biological age of a placenta in pregnancy 
complications. As discussed in this thesis, placentas from early onset preeclampsia 
pregnancies aged at a faster rate than those from uncomplicated pregnancies. Therefore, 
this tool provides a way of assessing accelerated aging in the placenta. It can also be used 
to provide insight into placental aging and its relationship with pregnancy complications.  
The work presented in Chapter 7 provides a possible prognostic tool for the prediction of 
pregnancy complications early in gestation. Many studies have focused on developing such 
198 
 
predictive tools. However, the work presented here is the first to use solely DNA 
methylation. Furthermore, this study has shown other clinical characteristics such as 
smoking and BMI can be identified by DNA methylation. The work presented here 
highlights the potential of using DNA methylation in a clinical setting. In addition, it has 
the potential application of one day identifying women at high risk for a pregnancy 
complication thereby, allowing early prevention methods to be implemented.  
8.4 Strengths and Limitations  
8.4.1 Phenotypic data 
 
One of the disadvantages of using publicly available genomic data is the common lack of 
phenotypic data. This is because most studies either do not collect relevant information or 
the authors choose not to supply it when submitting their data to a publicly available data 
base. This has implications for future research which relies on publicly available data. 
Some research requires large sample sizes which can only be made possible with publicly 
available data. Unfortunately, since this data often does not contain all the relevant clinical 
information it may not all be very useful. Factors such as sample sex can influence gene 
expression such as shown in chapter 3. Knowing such information can assist in performing 
better and more detailed analyses. 
 
 The work presented in Chapter 3 focusing on sex-biased gene expression firstly had to 
overcome data sets lacking sex information. However, this was overcome using a 
Bioconductor package (massiR) which is able to determine sample sex. Although, it was 
not possible to determine other factors which may alter gene expression levels such as 
smoking, BMI, ethnicity and age as these were not supplied. Therefore, one of the 
limitations in this thesis, regarding the meta-analyses is not being able to block for 
phenotypic differences. Future publicly available data that is submitted online should 
supply more detailed phenotypic data which would enable more detailed comparisons and 
analyses, and enable researchers to test more complex scientific hypotheses which require 




8.4.2 Sequencing data 
 
One of the challenges of working with sequencing data is the computational time. This 
thesis has had a focus on DNA methylation, a type of data where there can be millions of 
sites. DNA methylation data, along with many other types of genomic data, suffer from 
high dimensionality [11]. In other words there can be too much data for models to 
effectively select the best markers. Furthermore, building models using genomic data can 
be even more challenging since selecting the best predictor can take a long time with 
scarce computing resources. To overcome these challenges the research presented in this 
thesis has used the latest in machine learning applications to determine the best predictors 
for each model. For example, in Chapter 7, a feature selection method was used to reduce 
possible sites from approximately 2 million to within a few hundred, depending on the 
conditions of the model. This enabled the analysis to be performed in a relatively short 
time frame. This is also why so many different clinical characteristics were also analysed 
in this study. However, one of the pitfalls of performing such techniques as feature 
selection is overfitting. This occurs when a model is designed with too few data variables 
[12, 13]. However, mindful of this limitation, the statistics such as the sensitivity and 
specificity of each model were tested in both training and testing datasets with 10fold cross 
validation. Since we did not see a large drop in performance from training to testing data, it 
suggests overfitting was kept to a minimum.  
8.5 Future directions 
 
Recently, more studies have focused on using genomics to determine phenotypic traits. 
This field of research offers new opportunities to develop new models that may be able to 
predict or diagnose a wide range of diseases. Generally, it was thought the bulk of sex-
biased gene expression occurred on the sex chromosomes. However, as shown in this 
thesis, this is not the case and sex-biased gene expression occurs on every autosome. 
Furthermore, as detailed in Chapter 3, many of the genes found to be sex-biased are also 
associated with many diseases. Future work should investigate if these genes have a role in 
the sexual dimorphism that occurs in many diseases. This could potentially lead the way to 
develop sex-specific treatments.  
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Although the transcriptomes in many human organs are well characterised, this thesis has 
shown that there is still relatively little known about placental gene expression. This tissue 
is important for the health of the developing feuts in utero, and therefore tissue is difficult 
to obtain until after delivery. RNA-seq has uncovered previously unannotated transcripts, 
furthering our knowledge of placental gene expression. However, the work presented here 
in this thesis has not identified all transcripts in the placenta. For example, there are 
potentially hundreds of small non-coding RNAs that have important roles in the placenta. 
Future research should focus on identifying and characterising these unannotated 
transcripts. Experiments such as sequencing to a greater depth may identify hundreds of 
other non-coding RNAs. In addition, future laboratory work such as cell and animal knock-
out experiments are required to characterise the functions of these non-coding RNAs in 
vitro and in vivo. These transcripts may have important roles in placental development and 
disruption of their expression may lead to the development of pregnancy complications. 
As shown in Chapter 5, the gestational age of a placenta can be determined by DNA 
methylation levels at 62 CpG sites. This work can be used in pregnancy complications to 
determine if placental aging occurs which may provide insight into how the disease occurs. 
However, predicting a disease such as pregnancy complication early on prior to disease 
onset has clinical application. This would enable early prevention measures to be taken and 
possibly prevention of the disease. A non-invasive measurement is ideal to reduce 
morbidity and potentially mortality. Here in this thesis, DNA methylation from leukocytes 
of the maternal blood was used to develop a prognostic model to predict pregnancy 
complications. As detailed in Chapter 7, great success was achieved using DNA 
methylation to predict pregnancy complications. This work has a lot to offer as a non-
invasive tool in a clinical setting. However, much more research is required prior to being 
used a prognostic tool. For example, the models developed here in this thesis will need to 
be validated in other cohorts. In addition, further work is required to determine why the 
biomarkers identified in this study are associated with these pregnancy complications. 
Overall, the work here in this thesis has shown that genomics has a lot to offer in 
understanding phenotypic differences in pregnancy. Much more work is required to further 
validate the models developed here in independent cohorts. Furthermore, sequencing 
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technology has allowed us to identify regions of the genome which were previously 
unannotated by microarray technology.  
8.6 Conclusion  
 
In this thesis the work presented has shown several aspects of gene regulation differences 
and the placental transcriptome. In addition, it has also demonstrated the use of DNA 
methylation as a biomarker of placental health and pregnancy outcome. Overall, this thesis 
has shown the use of genomics in the field of reproductive research. We have also 
demonstrated the importance of accounting for sex differences in biomedical research. The 
work presented here has provided a foundation for further placental research and 
biomarker discovery in prediction pf pregnancy complications. Finally the work presented 
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